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ABSTRACT 
 
Christopher James Backlund: Nitric Oxide-Release Vehicles as Oral Disease Therapeutics 
(Under the direction of Mark Schoenfisch) 
 
 
 Oral diseases (e.g., dental caries and periodontal disease) are caused by dental plaque 
biofilms.  Due to the central role of nitric oxide (NO) in the immune response to bacterial infection, 
the delivery of exogenous NO as an antibacterial to combat dental biofilms is of interest.  Herein, 
the synthesis of NO-release vehicles, followed by the evaluation of their chemical and physical 
properties in relation to their in vitro microbiological performance is described.    
 Hybrid silica nanoparticles exhibiting a range of NO-release totals and kinetics were 
synthesized by varying the aminosilane precursor identity and composition.  The greatest NO 
storage obtained was ~1 µmol/mg silica nanoparticle.  To study the effects of NO-release kinetics 
on bacterial killing, NO-release half-lives were also tuned (~30 and ~120 min), independent of 
both particle size (~150 nm) and NO-release totals (~0.2 µmol/mg). 
 Macromolecular nitric oxide-release vehicles (i.e., silica and dendrimers) proved more 
efficient than a small molecule NO donor (i.e., PROLI/NO) at delivering NO to oral pathogens, 
requiring lower NO doses to kill bacteria.  Periodontopathogens were significantly more 
susceptible to NO treatment than cariogenic bacteria, suggesting a differential sensitivity to NO.  
At the concentrations required to kill periodontopathogens, NO-releasing silica and dendrimers 
were mildly toxic (>60% cell viabilities) to human gingival fibroblasts (HGF-1), and were 
significantly less toxic than clinical concentrations of chlorhexidine (0.12 and 0.20% w/w).   
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The kinetic-dependent killing of cariogenic and periodontopathogenic bacteria with NO-
releasing silica nanoparticles was evaluated.  Particles with slower NO-release kinetics (half-life 
~120 min) demonstrated the greatest efficacy against periodontopathogens at pH 7.4.  They were 
also least cytotoxic to HGF-1 cells, supporting the use of extended NO-release from silica-based 
materials for killing periodontopathogens.  In contrast, cariogenic Streptococcus mutans was more 
susceptible to rapid NO release at lower pH (6.4).   
 The anti-biofilm activity of NO-releasing alkyl chain-modified poly(amidoamine) 
dendrimers was evaluated against S. mutans as a function of alkyl chain length, pH, and NO-
release kinetics.  Longer alkyl chains (i.e., hexyl, octyl, and dodecyl) were more bactericidal than 
shorter alkyl chains (i.e., propyl and butyl) at pH 7.4 due to greater membrane disruption.  At lower 
pH, bactericidal efficacy was enhanced due to greater dendrimer-bacteria association, increased 
membrane damage (longer chains), and faster NO-release kinetics (shorter chains).  The long alkyl 
chain dendrimers were toxic to mammalian cells, but less toxic with NO release.  The efficient 
anti-biofilm activity and reduced cytotoxicity for NO-releasing long alkyl chain-modified 
dendrimers supports their future development as dental caries therapeutics.          
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Chapter 1: Treating Dental Plaque to Mitigate Oral Diseases 
 
 Since the days of Louis Pasteur, bacteria have been studied in single species, nutrient-rich 
batch cultures in vitro to generate data for in vivo applications.1  However, infectious microbes do 
not typically exist in this pure, planktonic (i.e., free-floating) state in nature, but instead adhere to 
surfaces and ultimately organize into multispecies biofilms for survival in less than ideal (nutrient-
deficient) conditions.1-3  Although studying planktonic bacteria cultures according to classical 
germ theory has proved beneficial for identifying pathogens and developing antibiotics, the 
prevalence and virulence of infections caused by bacterial biofilms, particularly for oral diseases 
including dental caries, demands immediate attention.1-6  In this chapter, dental plaque biofilms 
and associated oral diseases (i.e., dental caries and periodontitis) will be discussed, followed by 
existing treatment schemes, the current research into eradicating dental biofilms, and finally the 
design of nitric oxide (NO)-releasing therapeutics for the management of oral health.       
 
1.1 Dental Plaque Biofilms 
The human oral cavity is inhabited by a diverse collection of >700 microorganisms, with 
an estimated increase into the thousands coinciding with advances in mass sequencing and 
identification techniques.7-9  Oral bacteria colonize a variety of surfaces in the mouth, including 
teeth, mucosal surfaces, and artificial structures (i.e., implants) as dental plaque.  Dental plaque is 
a complex microbial community comprised of numerous bacteria embedded within an 
extracellular matrix of polymers characterized by high structural heterogeneity, complex   
2 
 
interspecies interactions, protection from host defenses, and enhanced resistance to 
antimicrobials.10  Although dental research spans a period of >100 years, investigating plaque as 
a microbial community functioning within a biofilm rather than planktonic cultures is a fairly new 
practice.9  Dental plaque biofilms are dynamic, multifarious, and variable from person to person 
dependent on both external factors (i.e., pH, oxygen, bacterial co-adhesion and nutrients) and host 
genetics rendering them even more difficult to treat.  While certain commensal bacteria may 
support host defenses against infection, the accumulation of dental pathogens leads to illnesses 
such as dental caries and periodontal disease.  The ailments caused by plaque biofilms are a major 
component of the $104.8 billion spent on dental care in 2010, representing a dramatic increase 
over the past 10 years, with an expected 5% increase through 2021.11           
     
1.1.1 Dental plaque biofilm formation 
Despite plaque exhibiting a high degree of variation from person to person, the general 
process by which these oral biofilms form is universal, consisting of a highly ordered sequence of 
events in which bacteria adhere to a surface with ensuing co-aggregation of microbes and biofilm 
proliferation.8  These key steps can be grouped loosely into attachment, colonization, and biofilm 
development.8  
As shown in Figure 1.1,8 the formation of oral biofilms is initiated by bacterial attachment 
to a surface.  Moments after a thorough cleaning, a proteinaceous pellicle comprised of salivary 
proline-rich proteins, amylase, peroxidase, and mucin forms on surfaces.12  This film interacts with 
bacteria via weak, long-range physiochemical interactions causing a net attraction to the surface 
that results in reversible attachment to the pellicle.  However, a subset of bacteria will adhere to 
the pellicle via stronger, close-range irreversible interactions as they bind to complementary host  
3 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Key stages implicated in the formation of mature dental plaque biofilms.  Processes 
are referred to as: A) attachment B) colonization and C) biofilm development.  Figure adapted 
from Hojo et al.8  
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molecules present in the pellicle (e.g., bacterial glucotransferases binding with amylase).12  
Differences in pellicle composition govern the subsequent microbial interactions with this surface 
and thus dictate the bacterial composition of this layer of dental plaque.  In general, oral 
streptococci species (e.g., Streptococcus gordonii and Streptococcus sanguinis) are considered 
initial colonizers as they can strongly bind with proline-rich proteins and glycoproteins that are 
abundantly present in the protein pellicle.8   
Following initial attachment, bacterial co-aggregation and colonization occurs and plays a 
pivotal role in the development, structure, diversity, and functional organization of the biofilm.  
Planktonic cells unable to colonize the tooth pellicle directly can bind to bacteria already present 
on the film through various, yet specific, cell-to-cell interactions.8  Co-aggregation of microbes to 
both surface streptococci and non-native cells permits late colonizers (particularly Gram-negative 
anaerobes) to be included within the developing biofilm.4  For example, Fusobacterium nucleatum 
can interact with both streptococci species as well as Gram-negative anaerobes, serving as a link 
between the early and late colonizers of dental plaque.8,13     Sequential bacterial binding of this 
nature promotes the formation of diverse, multispecies biofilms with unique morphologies that 
incorporate otherwise non-adherent cells into the biofilm matrix.  Once integrated, the close 
proximity to oxygen-consuming aerobic cells allows for the survival of obligate anaerobes.  Once 
a multispecies consortium of bacteria have anchored themselves to the tooth surface, active 
metabolism and cell division contribute to the formation of a mature biofilm.   
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1.1.2  Protective mechanisms of plaque biofilms 
The persistent growth of numerous bacteria species, along with continued polymer 
production, creates a robust and thriving biofilm community embedded within a fortified 
exopolymer matrix.  The benefits to constituent bacteria within the mature biofilm extend beyond 
physical protection from external factors such as oxygen (for obligate anaerobes), the host immune 
response, and antibiotics.  The intimate interaction between cells allows for more efficient cellular 
metabolism, genetic exchange, and cellular signaling to ensure bacterial survival and success of 
the biofilm.8  For example, oral bacteria can obtain nutrients for survival from endogenous 
substrates in saliva and gingival crevicular fluid (GCF) or exogenous sources such as sugars and 
food debris.  However, their metabolism involves the concerted action of many bacterial species 
working together in metabolic communication.  This process can involve bacteria breaking down 
larger compounds into biologically active substrates for other cells or metabolites from one 
bacteria functioning as nutrients for another.8,13  This symbiotic metabolism has been observed for 
Streptococcus and Veillonella species, where lactates secreted from Gram-positive streptococci 
serve as energy sources for veillonellae and thus, these species are commonly detected together in 
the oral cavity.14,15  In fact, veillonellae are unable to colonize tooth surfaces without streptococci 
present.14   
Another example of bacterial symbiosis in dental plaque includes the production of growth-
stimulating quinones for bacterial survival.  Quinones are utilized as electron acceptors in bacterial 
metabolism, thus promoting bacterial growth, but are not produced endogenously.8  Bacteria in the 
oral cavity can capture quinones produced by neighboring bacteria in order to survive in the mouth 
without an endogenous source, allowing for colonization of the oral cavity by species that would 
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typically be excluded.  For example, veillonellae produce menaquinone (vitamin K2) which 
facilitates the growth of adjacent bacterial species such as Porphyromonas.8 
Besides benefiting metabolically from close spatial proximity to one another, oral bacteria 
communicate with each other via cell signaling known as quorum sensing.  Quorum sensing 
regulates gene expression for survival under stress conditions and is often observed in cases of 
high cell density, such as in dental plaque biofilms.8  These chemical signaling pathways are vital 
to the survival of the biofilm and regulate many cellular functions including acid tolerance, 
virulence, and biofilm formation.  Two primary signaling molecules involved in quorum sensing 
are autoinducer-2 (AI-2) and competence-stimulating peptide (CSP).8   The synthesis of AI-2 is 
directly linked to the preservation of oral bacteria (e.g., Porphyromonas gingivalis) as it protects 
against environmental stresses such as temperature, hydrogen peroxide, and pH.8,16  Indeed, 
streptococci AI-2 (luxS) knockouts are characterized by an impaired ability to form biofilms with 
other species (e.g., P. gingivalis) once adhered to the tooth supporting the role of communication 
via AI-2 in successful dental plaque formation.17  Similarly, CSP is produced by many oral 
streptococci species.  It has been proposed that S. mutans produces CSP in acidic environments to 
warn other bacteria about the potential lethal threat of low pH and thus serves to protect other non-
acidophilic species within the biofilm.8,10  Collectively, communication through quorum sensing 
allows bacteria to coordinate their behaviors with other species to ensure microbial survival and 
preservation of the biofilm. 
In addition to symbiosis and the protective effects of quorum sensing, bacteria residing 
within dental plaque biofilms possess enhanced resistance to antibiotics.3  This phenomenon is due 
in part to the exopolymer matrix encompassing the bacteria, which acts as a physical barrier and 
limits drug diffusion into the biofilm.  However, this mechanism alone does not account for the 
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drastic increase in drug concentration needed to eradicate plaque biofilms versus planktonic 
cultures.  Plaque can function as a “genotypic reservoir,” facilitating the sharing of genes between 
bacteria to further enhance antimicrobial resistance across species in the biofilm.  Indeed, CSP-
facilitated gene transfer for antibiotic resistant genes can play a significant role in propagating 
resistance among biofilm bacteria species.8,10  On a physical level, the phenotypic differences and 
heterogeneity of environment cause a decrease in efficacy of classic antimicrobials against dental 
biofilms.3  When bacteria are attached to a surface, the drug target may be modified or even 
nonexistent, rendering the drug less effective.  Furthermore, bacteria in nutrient-depleted 
environments (e.g., biofilms) can exhibit reduced or altered metabolism, which can greatly reduce 
drug efficacy.3  In addition, the local environmental conditions (e.g., decreased oxygen and lower 
pH) within the biofilm may be unfavorable for the optimal action of a drug.  Finally, biofilm 
retention of drug-degrading enzymes can protect resident flora.  For example, β-lactamase 
produced by oral bacteria and present in gingival crevicular fluid can degrade β-lactam drugs like 
penicillin.18  Additionally, the penicillin-sensitive Streptococcus pneumoniae can be protected 
from antibiotics by β-lactamase producing Moraxella catarrhalis and thus may still cause infection 
despite no inherent antibiotic resistance.19        
 
1.2 Plaque Biofilm-Related Diseases  
Once established, mature dental plaque biofilms are relatively stable over time in terms of 
their microbial composition and beneficial function within the mouth.20  In fact, healthy dental 
plaque, which consists primarily of Gram-positive cocci species and few Gram-negative bacteria, 
is important to the development and wellbeing of the host.4  The presence of dental biofilms 
consisting of “protective” bacteria is important to maintain health through “colonization 
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resistance,” where resident microbes outcompete foreign pathogens for nutrients and attachment 
sites.4,21,22  Furthermore, native bacteria can produce inhibitory metabolites or create unfavorable 
environments for colonization by exogenous pathogenic bacteria.4,23  While the importance of the 
resident microflora has been studied primarily in the gut, where germ-free animals are significantly 
more susceptible to disease than their healthy microflora-inhabited counterparts, this phenomena 
is important in the oral microbiome as well.20 
As with environmental conditions (e.g., temperature, oxygen, pH and nutrients) for 
bacterial growth, the microbial composition and critical point at which these biofilms become 
virulent are host dependent.9  Changes in environmental parameters are typically the driving force 
for oral disease, as they force the microbiome out of homeostasis with the host.  Other parameters, 
such as smoking, disease, and compromised immune systems, can also promote disease states 
within the oral cavity.4  Regardless of the contributing factors, the shift from health to disease is 
characterized by either the overpopulation of previously minor components of the biofilm or 
colonization by exogenous pathogens.  The progression from a health-associated oral microbiome 
to a disease state is common and costly.  Indeed, oral diseases in America have been coined a 
“silent epidemic” where 7.4% of total healthcare spending in 2006 was devoted to dental care, 
mainly due to dental caries and periodontal disease.11        
 
1.2.1 Dental caries 
 Also known as tooth decay, dental caries is one of the most costly and prevalent infectious 
diseases worldwide.  With 94% of the adult population (18 years or older) experiencing treated or 
untreated carious lesions,24 tooth decay is considered ubiquitous amongst civilized populations.25  
Dental caries is defined as the localized destruction of supragingival tooth enamel caused by acid 
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produced via bacterial fermentation of dietary sugars.25  Both the process leading to destruction as 
well as the lesions and cavities formed by the deterioration of enamel can be classified as caries.26  
Although the oral microbiome is diverse in microbial identity, a select few bacteria are 
overwhelmingly acidogenic and strongly correlated to the etiology of dental caries.  These 
cariogenic bacteria tend to be Gram-positive and belong to the lactobacilli or streptococci genus.  
A number of these bacteria have been studied as cariogenic bacteria linked to dental caries (Table 
1.1),27 but Streptococcus mutans is the main focus of research and considered the key etiological 
agent of dental caries.         
 Acidogenic microorganisms within the dental plaque biofilm (i.e., S mutans) metabolize 
dietary carbohydrates (e.g., glucose, fructose, sucrose) to produce lactic acid, which causes a local 
drop in pH.12  With the continuous production of acid, the local environment shifts to favor 
acidophilic bacteria and limits the survival of other microbes that cannot endure the harsh 
conditions.  This, in turn, promotes the colonization of the biofilm by greater numbers of 
acidogenic bacteria, thus fostering the cariogenic process leading to tooth decay.  Dental caries is 
a delicate balance between the constant demineralization and remineralization of the tooth surface 
with several factors, besides the presence of S. mutans, playing a role in demineralization of the 
enamel. 
Although elevated concentrations of S. mutans is a risk factor for dental caries, its presence 
alone does not necessitate the formation of cavities.  Instead, the process is extremely complex, 
occurs over a broad time frame, and is dependent on several host factors that are both innate and 
behavioral, complicating the prevention and treatment of the disease.  Biological risk factors 
include salivary flow, salivary composition, high numbers of cariogenic bacteria, and genetic  
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Table 1.1 Bacteria studied for their implication in dental caries.a  Table adapted from Silva et al.27 
  
Cariogenic Bacteriab 
Streptococcus mutans 
Streptococcus sanguinis 
Streptococcus gordonii 
Streptococcus sobrinus 
Streptococcus mitis 
Lactobacillus casei 
Lactobacillus acidophilus 
Lactobacillus fermenti 
 
aAs found in a review of literature pertaining to antimicrobials against dental pathogens. 
bListed in decreasing order of appearances in articles reviewed.  Streptococcus mutans was most 
prevalently studied bacteria amongst dental caries relevant pathogens.  
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factors.26  The behavioral aspects of the host contribute to risk as poor oral hygiene, diet (i.e., 
consuming large amounts of carbohydrates), and smoking can promote the formation of dental 
caries.26,28  In terms of diet, the frequency of sugar consumption more so than the total amount of 
sugar consumed has been shown to dictate the localized drop in pH leading to cavities.12   
 Also related to dietary behaviors, is salivary ion content which dictates the “critical pH” of 
the host.  The critical pH refers to the pH where a solution is saturated with respect to a particular 
mineral.29  Although acid produced by cariogenic bacteria (e.g., S. mutans) causes cavities, the 
dissolution of enamel only occurs if the local pH is below the critical point required for 
demineralization.  When the pH is above the critical point, minerals will precipitate out of solution. 
Alternatively, when the pH is below the critical point, minerals will dissolve into solution.29  Tooth 
enamel is comprised primarily of hydroxyapatite (HA; Ca10(PO4)6(OH)2) with an infinitesimally 
small solubility product constant (Ksp ~10
-117).  As such, the dissolution process is dictated by the 
ion product (Ip) or the concentration of calcium and phosphate in saliva.
29  When Ip < Ksp, the 
solution is unsaturated and dissolution will occur.  Conversely, when Ip > Ksp, the equilibrium 
shifts to favor precipitation out of solution.  Calcium concentration is unaffected by pH but the 
concentration of phosphate (PO4
3-) is drastically reduced at lower pH.  This decrease in pH results 
in a decrease in Ip and dissolution of the tooth unless salivary concentrations of PO4
3- can be 
maintained.  Although experts cite the critical decalcification pH as 5.5, the actual pH varies not 
just from person to person but even temporally within the same individual.29  The critical pH 
required for dissolution could be as high as 6.5 for individuals with low salivary phosphate levels 
and as low as 5.1 for those with much greater ion levels.29  Due to both genetics and diet, the ion 
content of salivary fluid is constantly fluctuating and highly host-specific.  These factors highlight 
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the variable susceptibility between people to dental caries, even in the presence of cariogenic 
bacteria such as S. mutans.     
 
1.2.2 Periodontal disease  
 In general, periodontal disease refers to inflammation of the periodontium and tooth 
supporting structures caused by dental plaque biofilms.  It encompasses the non-destructive, 
reversible inflammation of the gums known as gingivitis as well as periodontitis, the irreversible 
destruction of tooth-supporting tissue and bone.30  Periodontitis can be further classified as chronic, 
typified by the slow and gradual destruction of bone, or aggressive periodontitis, which results in 
rapid, fast-acting detachment of tooth-supporting structures.  Gingivitis is a fairly common 
ailment, affecting up to 90% of the world’s population, and always precedes periodontitis.30  
However, gingivitis does not always lead to periodontitis, a much more severe condition, affecting 
roughly 30% of the US adult population.30,31  Left untreated, periodontitis can result in tooth loss 
as well as stroke, coronary heart disease, chronic obstructive pulmonary disease (COPD) and 
adverse pregnancy outcomes (APOs).32-38 
 Periodontal disease is caused by an excess of Gram-negative bacteria within subgingival 
plaque biofilms.  Although a number of bacteria are implicated in periodontitis, two key pathogens 
involved in the initiation and progression of the disease are Aggregatibacter 
actinomycetemcomitans (aggressive periodontitis) and Porphyromonas gingivalis (chronic 
periodontitis).39  As illustrated in Figure 1.2,40 these bacteria elicit a strong inflammatory response 
from the host, which initiates a cascade of events responsible for the breakdown of soft tissue and 
bone.  Briefly, these Gram-negative bacteria contain endotoxins in their membrane known as 
lipopolysaccharides (LPS) that initiate an inflammatory cascade.  The LPS recruit  
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Figure 1.2 Schematic of host immune response cascade, initiated by Gram-negative 
lipopolysaccharide (LPS), responsible for the breakdown of bone and soft tissue associated with 
periodontal disease.  Reprinted with permission from Giannobile et al.40 as adapted from Kinney 
et al.41  Copyright 2007, John Wiley and Sons. 
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polymorphonuclear leukocytes (PMNs), that subsequently release matrix metalloproteinases 
(MMPs) acting as powerful collagenases that destroy connective tissues.40  Activated macrophages 
respond to LPS by releasing tumor necrosis factor (TNF)-alpha and interleukin (IL)-1β pro-
inflammatory cytokines which mediate osteoclastogenesis and the breakdown of bone.40  P. 
gingivalis-derived LPS also inhibits osteoblastic differentiation and thus retards periodontal tissue 
regeneration.42  In this manner, the host response to the dental plaque biofilm is responsible for the 
destruction of the bone and tissue structures supporting the tooth.  Persistent bacterial infection 
with concomitant host immune response fosters the progression of periodontal disease to 
destructive periodontitis, eventually resulting in tooth loss.     
Apart from the physical and social ramifications of tooth loss, periodontitis can also affect 
an individual’s health in a number of ways including an increased risk for respiratory disease, heart 
disease, stroke, and even adverse pregnancy outcomes (APOs).32-38  Although confounded by 
smoking and weight, there is a relationship between periodontitis and respiratory issues.  Oral 
bacteria can be aspirated into the lungs, leading to infection (e.g., pneumonia), reduced lung 
volumes, and limited airflow.38,43  Periodontitis has also been implicated in the advancement of 
diseases such as chronic obstructive pulmonary disease (COPD).  Indeed, evidence exists that 
periodontal therapy may be important in reducing COPD exacerbations supporting the link 
between these two diseases.38  Periodontal bacteria can also enter the bloodstream and accumulate 
as arterial plaque, posing a risk for conditions such as coronary heart disease (CHD), a leading 
cause of mortality in the United States.44,45  In fact, the periodontopathogens A. 
actinomycetemcomitans and P. gingivalis have been detected in arterial plaque within blood 
vessels.46  Thus, the incidence of periodontitis increases the risk of CHD and, in one study, patients 
with chronic apical periodontitis were 2.79 times more likely to develop CHD.35  Whereas the link 
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between cardiovascular disease and periodontal disease is well established, the connection 
between periodontal disease and stroke has been investigated more recently.  It has been observed 
that periodontal disease is associated with recurrent vascular events in stroke patients, but it is 
unclear at this time whether periodontal treatment can reduce such risks.32  Other major risks 
involving oral bacteria entering blood circulation are APOs, which are caused by periodontal 
pathogens or their byproducts eliciting an immune response upon reaching the placenta and 
amniotic fluid (Figure 1.3).33  The production of inflammatory cytokines in response to virulence 
factors (e.g., LPS) can lead to premature birth or miscarriage.  Additionally, infection and 
inflammation can cause impaired nutrient transport via pre-eclampsia, leading to low birth weight 
and possibly miscarriage.33  This phenomena has been observed utilizing a subcutaneous chamber 
P. gingivalis infection model in both pregnant hamsters and mice in which both bacteria and 
inflammatory markers caused complications with pregnancy.47,48  It was postulated that 
periodontal biofilms can serve as bacterial reservoirs that can translocate infectious properties 
systemically to negatively impact pregnancy outcomes.47,48      
  
1.3  Current Oral Disease Treatments 
 
The goals of oral therapies are to kill infection-causing bacteria, mitigate disease, and 
ideally prevent the need for invasive clinical procedures.  Unfortunately, current treatments fall 
short of eliminating malignant conditions (i.e., dental caries and periodontal disease), causing 
persistence of the ailment and resulting in painful and costly dental procedures including surgery.  
This is particularly true for periodontal disease in which bacteria are organized in subgingival 
biofilms, making them especially difficult to access and treat.  This section will discuss current  
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Figure 1.3 Possible mechanisms/pathways associating periodontal disease with adverse pregnancy 
outcomes.  Reprinted with permission from Madianos et al.33  Copyright 2013, European 
Federation of Periodontology and American Academy of Periodontology. 
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methods utilized to treat oral disorders, their shortcomings, and improvements that have resulted 
in marginal gains in terms of clinical outcomes. 
 
1.3.1 Non-surgical treatments 
 The most common non-surgical treatments for oral ailments besides tooth brushing include 
disinfectant mouth rinses, fluoride treatments for dental caries, and scaling and root planing for 
periodontal disease.49-51  Oral rinses consist of ethanol-based mouth washes (e.g., Listerine) and 
chemical antiseptics (e.g., chlorhexidine (CHX)).  Chemical antiseptics are more potent than 
ethanol-based rinses and are therefore prescription based and not available over the counter.  Both 
classes of mouth rinses are characterized by direct membrane disruption and bacterial killing via 
cellular leakage.52  Additionally, Listerine’s antibacterial efficacy is enhanced via enzyme 
inhibiton.53  However, the limited broad-spectrum activity of each rinse combined with their 
inability to penetrate deep within plaque restricts killing to the outer layer of the biofilm, rendering 
them ineffective treatment options.53,54  Chemical antiseptics in particular are associated with 
adverse side effects including staining of teeth, desquamation of mucosal surfaces, altered taste, 
and calcified deposits.55,56  Furthermore, the long-term daily use of ethanol-based mouthwashes 
has been linked to oral cancers.  
Topical fluoride therapy for the prevention of dental cavities through the remineralization 
of enamel via fluorapatite (FAP; Ca10(PO4)6F2) formation is well established.
24,57,58  Maintaining 
ample salivary fluoride concentration is essential for properly mitigating demineralization and is 
thus most effectively administered via toothpastes, gels, slow-release devices, and dietary 
supplements.26,57,58  Cariostatic effects of fluoride treatment have also been attributed to a 
reduction in adhesion forces of oral cocci species to hydroxyapatite upon treatment with sodium 
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fluoride solution.59  However, fluoride is not considered an antimicrobial agent for the prevention 
of caries due to the large concentrations necessary to produce such an effect.  High concentrations 
of fluoride can have negative side effects such as gastrointestinal discomfort, dental fluorosis, and 
skeletal fluorosis when applied systemically.60,61 
 Scaling and root planing (SRP), the current “gold standard” non-surgical periodontal 
treatment, involves the physical removal of dental plaque above and below the gum line.30,51  
Scaling refers to tartar removal whereas planing involves smoothing the tooth via scraping to 
reduce bacterial adhesion.  However, even successful treatment is often accompanied by a high 
probability of reinfection, leading to periodontal surgery.  The use of mouth rinses such as CHX 
in conjunction with SRP has shown no significant differences in microbial composition over time, 
making it a poor candidate as an adjunct to SRP therapy.62  While localized delivery of antibiotics 
(e.g., minocycline) have somewhat improved clinical outcomes and represent possible adjuncts to 
SRP,63 their systemic use has undesirable side effects (e.g., pseudomembranous colitis) and may 
also foster the development of antibiotic-resistant bacteria.64,65  
          
1.3.2 Surgical therapies 
 When non-invasive techniques fail, oral surgery is typically required to remove infection 
and eliminate disease.  Untreated dental caries can cause decay down to the tooth root, requiring a 
root canal to prevent the spread of infection.  During a root canal, the tooth is opened to remove 
decay, sometimes removing the associated nerve.  The canals are then filled with gutta-percha and 
sealed with a crown.  Despite the high success rate of root canals, a failed procedure may 
necessitate root canal re-treatment or extraction of the tooth. 
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 Since the areas below the gum line are affected, periodontal diseases require significantly 
more invasive procedures.  The most common procedure for persistent periodontal disease in 
which inflammation and deep periodontal pockets remain after SRP is flap surgery.  This 
procedure involves physically lifting back the gum to remove deep periodontal tartar deposits and 
suturing the gums back into place when completed.  This rids the area of infectious microbes and 
allows the gums to fit more snugly around the tooth, limiting bacterial infiltration to the 
periodontium, ideally preventing reinfection.  In addition removing tartar, the periodontist may 
place a bone or soft tissue graft under the flap to promote bone and tissue regeneration, potentially 
restoring the destroyed periodontal structures.   
 The surgical processes listed above are costly and invasive, but necessary when non-
surgical treatments fail.  Therefore, the goal of current oral disease therapeutic research is focused 
on circumventing surgical procedures.  This objective can be accomplished by improving the 
efficacy of non-surgical therapies in removing infection, reducing inflammation, and eliminating 
oral diseases before more extensive surgical intervention is necessary. 
 
1.4 Current Research into Non-Surgical Oral Disease Therapies         
 As discussed in Section 1.3, the goal of current research into oral health therapeutics is to 
eradicate bacteria, reduce inflammation, and eliminate disease without the need for clinical 
intervention and surgery.  In this section, the ongoing research into developing effective oral 
disease therapies will be discussed.  Considerable research in this area has focused on using metal 
nanoparticles as antimicrobial dental plaque therapies, with antimicrobial peptides and silica 
materials receiving more attention recently.    
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1.4.1 Metal nanoparticles 
 With the increasing prevalence of antibiotic-resistant bacteria, metals that have been used 
as bactericidal agents for centuries such as gold, copper, zinc, and silver are being reevaluated for 
their utility as oral therapeutics.66  As the activity of these metals is highly dependent on surface 
contact, the advent of nanoparticles with increased surface area has greatly improved their 
antimicrobial efficacy over bulk metals.  Although gold (Au) and zinc oxide (ZnO) exhibit 
effective killing of S. mutans, silver (Ag) nanoparticles display the greatest efficacy.66  Similarly, 
Ag is more bactericidal than cuprous oxide (Cu2O), copper oxide (CuO), ZnO, and titanium 
dioxide (TiO2) against the periodontal pathogens P. gingivalis and A. actinomycetemcomitans.
67  
Due to the reliance on UV irradiation for the antimicrobial action of TiO2 and the weak broad-
spectrum activity of Au, neither of these materials have been heavily researched as oral 
antimicrobials.66,68  Copper (CuO), although a more effective antibacterial than ZnO, is known for 
its severe toxicity to eukaryotic cells.69  As such, the majority of dental research has focused on 
evaluating ZnO and Ag nanoparticles as potential oral antimicrobials. 
As zinc (Zn2+ and ZnO) has previously been incorporated into toothpastes to control dental 
plaque, translation into more sophisticated dental therapeutics is relatively simple.70,71  Zinc oxide 
(ZnO) nanoparticles have been used in dental composites for contact based killing with biocidal 
activity against S. sobrinus in both planktonic cultures and biofilms.72  Zinc ions (Zn2+) have been 
shown to limit glucosyltransferase activity and acid production by oral streptococci, thus limiting 
decalcification and impeding dental caries.72  The generation of antibacterial hydrogen peroxide 
(H2O2) from the surface of ZnO particles has been repeatedly demonstrated with UV light initiation 
and regarded as the primary mode of biocidal action.73-75  Although killing observed in the absence 
of UV light supports Zn2+ ion generation as an alternative biocidal mechanism,68,72,76 the increase 
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in antibacterial efficacy with increased surface area (decreased particle size) and reduced 
bactericidal activity without UV light indicate the production of reactive oxygen species (ROS) 
(e.g., H2O2) as the principal bactericidal mechanism.
73-75  Most likely, it is the combination of ROS 
and Zn2+ interacting with bacteria contributing to bactericidal efficacy.  However, Zn2+ is also 
essential in the formation of certain bacterial biofilms (e.g., Staphylococcus aureus).72,77  Zinc’s 
unclear antimicrobial action combined with its potential to promote biofilm formation warrants 
further examination against oral bacteria strains and has limited its utility as a potential oral 
therapeutic thus far.   
Due to highly efficacious, broad-spectrum activity combined with a history of regulatory 
approval for biological applications,78 silver has been the main research focus of metal 
nanoparticles as dental therapeutics.  The multiple modes of action for silver killing are attributable 
to silver ions (Ag+) and include both reaction with thiol groups to deactivate proteins and directly 
interfering with DNA replication.68  Antimicrobial silver has been studied in many forms such as 
metallic silver, silver nitrate, silver sulfadiazine, and silver zeolites.79  For example, when bacteria 
come in contact with silver zeolite, cellular uptake of silver ions exuded from the zeolite via ion 
exchange hinders cell function, damages the cell, and ultimately causes death.79  Indeed, silver 
zeolites have proven effective against several dental bacteria including Porphyromonas gingivalis, 
Aggregatibacter actinomycetemcomitans, S. mutans, and S. sanguinis.80  In general, the Gram-
negative pathogens tested were more susceptible to Ag+ treatment.80  As the cell membranes of 
Gram-positive pathogens incorporate a greater amount of negatively charged peptidoglycan, Ag+ 
binding to the membrane possibly reduces the amount of silver reaching the plasma membrane, 
suggesting a possible reason for the observed difference in susceptibility.80   
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Although most reports claim silver to be non-toxic, there is controversy surrounding its 
prolonged use.  Silver exposure has been shown to result in argyria, or the blue-grey tint of the 
skin, particularly in large doses or after long-term accumulation.  Furthermore, silver has been 
observed to hinder development in fish embryos and plants in a dose-dependent manner.81   To 
reduce toxicity, silver has been impregnated in a number of materials to limit eukaryotic exposure.  
For example, dental resins loaded with silver ions have shown time-dependent efficacy against 
oral streptococci species in vitro.82  Another study investigated silver-doped elastomers on oral 
streptococci species in vivo for long-term (12 week) caries prevention.  Of note, no difference in 
bacterial composition between control elastomers and those loaded with silver was observed.83  
The lack of long-term clinical success, combined with potential in vivo and environmental toxicity 
over time, has limited the success of silver as an antimicrobial oral therapeutic.   
 
1.4.2 Antimicrobial peptides 
 Antimicrobial peptides (AMPs) are a class of peptides ubiquitous in nature as defenses 
against pathogens in both plants and animals.84,85  They are an essential component of the innate 
immune response, exhibiting broad-spectrum antimicrobial activity against Gram-positive and 
Gram-negative bacteria, fungi, and viruses.85  The multi-microorganism efficacy of AMPs is 
primarily attributed to direct membrane disruption, though they have been shown to inhibit DNA 
and protein synthesis, protein folding, enzyme function, cell wall synthesis, and metabolic 
turnover.85  Typically, AMPs are cationic and attracted to negatively charged bacteria membranes.  
Once attached, they insert into the membrane creating transmembrane pores that allow for 
intracellular leakage leading to death.84  The ability of AMPs to reduce infection via multiple 
pathways provides for a potent, naturally occurring antimicrobial with a limited probability of 
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bacteria developing resistance.85  These findings, in concert with advancements in obtaining and 
purifying theses peptides, have propelled investigations into their use as dental antimicrobials to 
mitigate oral disease.  For example, AMPs have been successfully applied as novel bactericidal 
agents against numerous dental pathogens in vitro as both stand-alone therapies and dental implant 
coatings.  Peptides such as Chrysophsin-1 have been cited for their ability to eradicate S. mutans 
biofilms,86 while others, like GL13K, are more effective against periodontopathogens such as P. 
gingivalis.87,88  Certain peptides (GL13NH2 and GL13K) were found to exhibit anti-
lipopolysaccharide (LPS) activity, demonstrating the potential to greatly reduce inflammation in 
vivo and, in turn, possibly mitigate periodontal disease.87  However, each protein sequence is 
unique in form and function with slight derivations in structure resulting in dramatically different 
effects both in vitro and in vivo.  For example, GL13NH2 and GL13K, despite having mutual anti-
LPS activities and similar amino acid sequences (Figure 1.4),89 exhibit dissimilar antimicrobial 
activity. 
Limiting the clinical utility of AMPs are their observed hemolytic activity towards 
mammalian host cells and non-selective eradication of both pathogenic and commensal bacteria 
species.  The latter can intensify the malignant condition or promote reinfection by non-native 
pathogens, potentially sustaining disease.  As such, attempts to functionalize AMPs in order to 
target and selectively kill pathogenic over commensal microflora has been a focus of research.  To 
this end, specifically targeted antimicrobial peptides (STAMPS), gram-selective AMPs, and 
environment-sensing AMPs are being investigated.85  The STAMP technology involves attaching 
a pathogen-specific ligand, like competence stimulating peptide (CSP) for S. mutans, as a targeting 
domain.  This strategy was shown to be effective at eradicating S. mutans while having no effect 
on the other streptococci tested.90     
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Figure 1.4 Structures of two antimicrobial peptides (AMPs).  Bold letters designate altered amino 
acids.  GL13-K is bactericidal while GL13NH2 is not.  Both peptides shown exhibit anti-LPS 
activity.  This highlights the small size of AMPs as well as the minute structural differences that 
greatly impact in vivo activity.  Figure adapted from Gorr et al.89 
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Environment-sensing AMPs that exert antimicrobial activity under certain environmental 
stimuli such as acidic pH, were beneficial in selectively killing the acidogenic S. mutans.91  For 
example, acid-activated peptide 2 (AAP2) demonstrated maximum antimicrobial activity at pH 
5.5 but none at pH 7.5 highlighting its potential to selectively kill cariogenic S. mutans.91  Lastly, 
Gram-selective AMPs have utility in selecting periodontal pathogens, which are primarily Gram-
negative, over Gram-positive species using LPS-binding proteins (LBP), with >200-fold 
selectivity observed.92  High LPS-inactivation was also noted, which can reduce inflammation, 
limit systemic endotoxin exposure, and potentially mitigate periodontal disease.92   
 The lack of AMP selectivity for bacteria over mammalian cells remains a major concern.  
Currently, cationic AMPs rely on electrostatic interactions with negatively charged bacteria for 
preferential association.85,93  Mammalian cell membranes are also cholesterol-stabilized, providing 
rigidity and requiring greater concentrations for membrane disruption-based killing.85  These 
factors contribute to the preferential, but not selective, killing of bacteria versus mammalian cells.  
Much attention has thus focused on bacteria-selective AMPs which attempt to limit hemolytic 
activity by reducing hydrophobicity and amphipathicity (hydrophobic moment).94  One example 
of such a peptide is the glycine-rich adepantin 1 (ADP1), which has a significantly greater bacteria-
human selectivity index (SI) than previously studied AMPs.94  By modeling peptides to predict 
their hydrophobic moments, designer peptides can be synthesized with purpose as opposed to 
shotgun screening techniques to expedite their discovery.    
The non-selective eradication of commensal bacteria along with pathogens, combined with 
their hemolytic activity towards mammalian cells, have limited the clinical utility of AMPs.  
Furthermore, AMP screening is arduous as innumerable peptide variations exist in nature, each 
with its own unique bioactivity.  Indeed, novel AMPs are being isolated from the hydrolysis of 
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bovine milk proteins even after 30 years of investigation.84  Designer AMPs have yet to be 
clinically utilized as their behavior in vivo is unpredictable.  Much work is still necessary in the 
antimicrobial screening, design, and in vivo evaluation of designer AMPs prior to further 
pharmaceutical development.   
 
1.4.3 Silica  
Due to its biocompatibility and low cost,95 silica has been used in toothpastes as an abrasive 
to remove dental plaque and polish teeth.  Indeed, nearly all toothpaste formulations available 
include micron-sized silica in the form of hydrated silica or silicon dioxide.  Recent research has 
focused on utilizing silica nanoparticles over microparticles for polishing teeth as finer particulate 
polishes result in smoother surfaces.96  One study in particular compared nanoparticles (60 ± 4 nm) 
to both NuPro (1 – 180 µm) polishing paste and Crest toothpaste as polishing agents in terms of 
tooth surface roughness and strength of subsequent S. mutans adhesion.96  The nanoparticle slurry 
resulted in single-nanometer surface roughness, an order of magnitude better than the professional 
polishing formula NuPro.96  The smoothness obtained via polishing with silica nanoparticles led 
to reduced bacterial adhesion strength and easier removal of S. mutans from the tooth surface.96  
Thus, polishing with silica nanoparticles versus micron-sized particles, although not antimicrobial 
themselves, could potentially limit caries-induced tooth damage by reducing the numbers of 
cariogenic bacteria on teeth through routine personal oral hygiene (i.e., brushing).   
Silica-based bioactive glass has been investigated for the restoration of eroded dental 
enamel caused by dental caries.  Enamel reconstruction is challenging due to its acellular nature 
and 95 wt% mineral composition which prevents self-remodeling.  Bioactive glass represents a 
possible in vivo dental implant material capable of depositing minerals on the tooth surface, thus 
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repairing carious lesions.  Bioglass 45S5 is a bioactive implant that undergoes a series of reactions 
resulting in the formation of hydroxyapatite, stimulating dental bone repair.97  This material was 
capable of forming a calcium-phosphate layer that resisted abrasion on enamel surfaces within 24 
h.97  At 14 d, this layer had transformed into hydroxyapatite crystals, highlighting its potential use 
for the treatment of incipient carious lesions formed by acidogenic bacteria like S. mutans.97  
Antimicrobial activity can also be imparted on bioactive glass by incorporating biocides 
into the glass, allowing for the potential to kill cariogenic bacteria and simultaneously remineralize 
enamel.  In one study by Palza et al., the bioactive glass formulation was shown to undergo 
chemical transformations resulting in the growth of crystalline hydroxy-carbonate apatite (HCA) 
that could potentially repair early carious lesions via remineralization.98  Biocidal metal ions (i.e., 
silver and copper) were incorporated into the glass and demonstrated antibacterial activity against 
cariogenic S. mutans.98  The bactericidal efficacy of such hybrid materials demonstrates the 
possibility of antimicrobial-doped bioactive glass to simultaneously kill cavity causing bacteria 
and repair minor enamel erosion.  Bioactive glass represents a possible antibacterial/reconstructive 
therapeutic but is still limited by the use of antimicrobial metals known for their toxicity and 
adverse side effects.    
 
1.5  Nitric Oxide 
 Nitric oxide is an endogenously produced gaseous, free radical species central to many 
physiological processes including neurotransmission, angiogenesis, vasodilation, wound healing, 
cancer biology and the innate immune response to invading pathogens.99-104  Although NO’s role 
in the immune response for eliminating bacteria will be the most pertinent in regards to this 
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dissertation, a thorough knowledge of NO’s function in the body is essential to focusing its utility 
as a potential antimicrobial therapy. 
 
1.5.1 Physiological roles of nitric oxide  
 Endogenously, NO is synthesized from L-arginine via NO synthase (NOS), which exists 
as three isoforms and can be classified into two broad categories.  The constitutive class (cNOS) 
is comprised of the endothelium (eNOS) and neuronal (nNOS) isoforms that produce pM–nM  
levels of NO for signaling purposes, and the inducible (iNOS) isoform, which produces greater 
levels of NO (µM) for antimicrobial purposes.104  The cNOS system functions continuously to 
regulate endogenous processes including angiogenesis, neurogenesis, and vasodilation, whereas 
the iNOS system is activated in neutrophils and macrophages by bacterial endotoxins during the 
immune response.  This section will focus on the physiological roles of cNOS, while the 
antimicrobial effects of NO derived from iNOS will be discussed in the next section.   
Calcium binding to the messenger protein calmodulin triggers cNOS to produce low levels 
of NO, which readily diffuses across cell membranes to react with molecular targets that ultimately 
dictate NO’s function.  Within the vascular endothelium, NO reacts with guanylyl cyclase, 
subsequently catalyzing the production of cyclic guanosine monophosphate (cGMP), which leads 
to smooth muscle relaxation and vasodilation similar to that of endothelium-derived relaxing factor 
(EDRF).104  Further cardiovascular utilities of NO include regulation of vascular tone, myocardial 
contractility, endothelial-leukocyte interactions, endothelial integrity, vascular cell proliferation, 
and antithrombotic effects.104  Deficiencies in NO production are directly linked to cardiovascular 
diseases such as hypertension, reperfusion injury, atherosclerosis, and stroke, further highlighting 
NO’s role in the normal function and maintenance of mammalian vasculature.99,105   
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Apart from vascular effects, NO plays a pivotal role in the central nervous system of 
animals.100  The firing of neurons and release of specific neurotransmitters such as acetylcholine 
and serotonin is modulated by NO.  Other neuronal functions like long-term potentiation, long-
term depression, and memory formation are also coordinated by NO.  Reports suggest that a 
majority of NO effects on neurons are modulated via cGMP and glutamate.  Evidence exists that 
NO can either excite or inhibit neuronal activity within major sections of the brain such as the 
hippocampus and hypothalamus.100  Due to the opposing nature of NO-mediated effects on 
neuronal activity, its true role within all neuronal activity is still unclear.  However, it is apparent 
that NO plays a significant role in neuronal function. 
Additionally, NO plays a pivotal role in the progression of wound healing, as it is involved 
in modulating inflammation, angiogenesis, cell proliferation, matrix deposition, and tissue 
remodeling.99,101,102,106,107  Although this process is complex and the exact role of NO in each phase 
is unclear with regards to its concentration and action, the importance of NO in wound healing is 
apparent.  This can be observed for diabetic patients whose healing is impaired due to NO 
deficiencies at the wound site.  Such effects have been verified by the partial reversal of impaired 
wound healing upon supplementation with exogenous NO or arginine.106,107  Nitric oxide is 
paramount to successful wound healing and thus plays a crucial, irreplaceable role in this process.   
   
1.5.2  Antimicrobial properties of nitric oxide 
 Nitric oxide is produced by macrophages and neutrophils in response to invading 
pathogens as part of the innate immune response.  In this instance, larger concentrations of NO 
(µM) are produced by iNOS to provide an antimicrobial effect versus cell signaling and 
angiogenesis.99  Nitric oxide produced in this manner exerts antimicrobial activity primarily 
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through nitrosative and oxidative stress, as depicted in Figure 1.5.108  Outside of the cell, NO exerts 
nitrosative stress by reacting with oxygen to form dinitrogen trioxide (N2O3), which nitrosates 
amines on cell membrane and transmembrane proteins, thereby altering protein function.99,108  
Lipophilic in nature, NO and oxygen can both accumulate within the cell membrane, accelerating 
the formation of N2O3 and fostering nitrosative stress within the cell membrane.  As a diatomic 
gas, NO can also rapidly traverse cell membranes and react with the bacteria respiration product 
superoxide (O2
-) to produce the oxidative species peroxynitrite (OONO-).99,108  This species can 
cause damage to proteins and DNA, or react with nitrogen dioxide radicals in the form of 
peroxynitrous acid to cause lipid peroxidation within the cell membrane.  Membrane destruction 
via OONO- lipid peroxidation is considered to be the primary antibacterial mechanism of NO.108   
Along with its potent antimicrobial efficacy against Gram-positive, Gram-negative, and 
antibiotic-resistant pathogens, NO’s selective biocidal activity against bacteria over mammalian 
cells and multiple killing pathways make it an attractive bactericidal agent.  The selective action 
towards bacteria is due to the endogenous production of NO by mammals, rendering it a normal 
metabolite.  As such, mammals deal with intracellular NO accumulation using superoxide 
dismutase, an enzyme that catalyzes the decomposition of superoxide into oxygen and hydrogen 
peroxide.  This limits local peroxynitrite generation and minimizes NO cytotoxicity.  Nitric oxide’s 
multiple killing mechanisms contribute to its biocidal potency and diminish the chances of bacteria 
developing resistance to NO as an antimicrobial therapy.  Privett et al. studied Gram-positive, 
Gram-negative, and antibiotic resistant bacteria that survived killing assays after several passages 
(20 d) and observed minimal increases in the NO concentrations required for growth inhibition.109  
The antimicrobial potency and lack of observed bacterial resistance highlight the therapeutic 
potential NO.   
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Figure 1.5 The multiple antimicrobial mechanisms of NO and its byproducts through both 
nitrosative and oxidative stress.  Reprinted with permission from Hetrick et al.108  Copyright 2008, 
American Chemical Society. 
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1.5.3  Nitric oxide as an antimicrobial against oral diseases  
 Endogenous NO production to fight infectious pathogens combined with its production by 
mucosal epithelial cells in response to pro-inflammatory stimuli initiated upon the deposition of 
plaque make it an ideal candidate for antimicrobial dental applications.110  Indeed, studies have 
shown a correlation between high salivary nitrite and low incidence of caries, most likely due to 
the production of bactericidal NO from acidified nitrite.111,112  Despite these findings, few studies 
have examined the antibacterial efficacy of exogenous NO against dental pathogens.  Reports of 
NO as a dental antimicrobial have been limited to verifying the role of salivary nitrite in controlling 
oral bacteria levels, but have not investigated the delivery of exogenous NO as a biocidal 
therapeutic. 
 Of note, studies have shown that NO derived from acidified nitrite acts as an antimicrobial 
towards both cariogenic and periodontopathogenic bacteria.113,114  Low concentrations of nitrite 
were added to bacterial suspensions at various pH levels to assess the acid-mediated production of 
NO and subsequent killing.  Allaker et al. reported efficacy against periodontopathogenic F. 
nucleatum and P. gingivalis, while others reported antibacterial effects towards S. mutans.113,114  
These investigations were designed to examine the role of salivary levels of nitrite on bactericidal 
and bacteriostatic effects and were not intended to examine NO directly as a deliverable 
antimicrobial.  However, this work supports the administration of exogenous NO to the oral cavity 
as a potent antibacterial agent for the treatment of oral diseases, namely caries and periodontitis. 
 
1.6 Nitric Oxide-Releasing Materials 
 Nitric oxide has great potential as an antimicrobial therapeutic for oral applications.  
However, its gaseous and highly reactive nature make stable storage and localized delivery 
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challenging.  This section will introduce NO-releasing scaffolds utilizing N-diazeniumdiolate NO 
donors for the chemical storage and delivery of NO.  It should be noted several other NO donors 
exist, including metal nitrosyls, S-nitrosothiols (RSNOs), and organic nitrates/nitrites,115 but this 
section will focus primarily on N-diazeniumdiolate NO donor storage and delivery chemistries.  
N-Diazeniumdiolates can be formed on amine groups through a base catalyzed reaction with 
gaseous NO at elevated pressure.  As shown in Figure 1.6,116 the proton-initiated decomposition 
of N-diazeniumdiolates yields two molecules of NO and the unmodified precursor scaffold.  
Stabilization of the N-diazeniumdiolate moiety by neighboring amines on the delivery scaffold 
allows for extended and controlled NO release.  The potential for greater storage in conjunction 
with spontaneous, yet controllable, generation of NO under physiological conditions (e.g., the oral 
mucosa) makes this NO donor particularly amenable to application as an oral antimicrobial 
therapeutic.        
 
1.6.1  Low molecular weight nitric oxide donors 
 Several low molecular weight small molecules have been modified with N-
diazeniumdiolate moieties to serve as NO donors.  The amino acid proline is well suited for NO 
donor functionalization.  Indeed, “PROLI/NO” is capable of storing large quantities of NO (7.24 
µmol/mg)117 due to easily accessible secondary amines for N-diazeniumdiolate modification.  
Furthermore, the precursor scaffold (regenerated upon liberation of NO) has inherently low 
cytotoxicity.  While PROLI/NO has been demonstrated to reduce arterial pressure for the treatment 
of pulmonary hypertension,118 its antimicrobial therapeutic potential is limited due to minimal N-
diazeniumdiolate stability, resulting in rapid NO release with a short half-life (1.8 s)119 in 
physiological conditions.  As such, a majority of the NO is released from the scaffold before  
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Figure 1.6 The spontaneous proton-initiated decomposition of an amine-stabilized N-
diazeniumdiolate to yield two molecules of NO and the parent polyamine precursor.  Adapted from 
Hetrick et al.116    
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reaching the target site in therapeutic applications, thus limiting both the effective NO dose and 
biological action.  Despite high NO storage and direct application to the site of action, large 
concentrations of PROLI/NO are required to induce vasodilation, with even greater NO levels 
required to exert an antimicrobial effect.  Furthermore, the potential cytotoxicity of NO at these 
concentrations hinders the utility of PROLI/NO and similar small molecule NO donors as potential 
antimicrobial therapeutics.     
 
1.6.2 Macromolecular nitric oxide-releasing scaffolds 
 To circumvent the non-specific and premature NO-release characteristics of small 
molecule donors, macromolecular NO-release scaffolds capable of stabilizing the N-
diazeniumdiolate NO donor moiety have been developed by our lab and others.115,120-127  
Liposomes have been investigated for the encapsulation of both gaseous NO and small molecule 
NO donors to prevent N-diazeniumdiolate degradation and sustain NO release.115,128,129  These 
NO-release vehicles have the potential to produce a bolus of NO when liposome stability is 
compromised via stimuli.115,129  Encapsulation of PROLI/NO within polyethylene oxide-co-lactic 
acid (PELA) microspheres has been achieved, but with limited success in terms of controlling the 
amount of NO donor encapsulated and NO-release kinetics.115  Significant work still remains for 
the encapsulation of NO donors within both liposomes and microspheres to enhance total NO 
storage and control NO-release profiles.    
 Metal nanoparticles have also been investigated as NO-release scaffolds.  Rothrock et al. 
reported on amine-functionalized gold nanoparticles as the first metal nanoparticle NO-release 
system with tunable storage and NO-release kinetics.125  Despite their small size (~2 nm) and high 
surface area to volume ratio, these particles stored <0.04 µmol/mg due to poor N-diazeniumdiolate 
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conversion efficiency (<1%).125  These factors, combined with toxicity concerns, have limited the 
utility of N-diazeniumdiolated metal nanoparticles as antimicrobial agents.  
 Zeolites and metal organic framework (MOF) NO donors exhibit improved NO storage 
(~1.2–1.3 µmol/mg for Zeolite-A) over metal nanoparticles, but are plagued by excessively rapid 
NO-release kinetics (half-life of ~340 s) due to chemisorbed NO storage.115,130  Metal organic 
frameworks have achieved chemisorbed NO loading as high as 9 µmol/mg but have inaccessible 
NO stored within their structures, thus limiting the usable NO payload (~1 nmol/mg MOF).115,131  
N-diazeniumdiolates formed on primary amines of organic linkers between metal sites in MOFs 
improved NO-release totals (~0.51 µmol/mg), but were characterized by fast NO-release kinetics 
(total release <5 min).123  The lack of stable secondary amine N-diazeniumdiolates, combined with 
the inherent toxicity of both zeolites and MOFs, have limited the potential of these scaffolds as 
antimicrobial therapeutics.  
 
1.6.3 Nitric oxide-releasing silica nanoparticles 
 Silica has attracted attention as a drug delivery vehicle due to inherently low cytotoxicity95 
and facile synthesis, which provides for control over physical (size and shape) and chemical 
(composition) characteristics.  Silica’s use in dental applications such as toothpastes makes it 
easily translatable into existing dental therapies.  Zhang et al. first reported on NO-releasing silica 
using aminosilane-grafted fused silica particles and subsequent N-diazeniumdiolate 
modification.124  Subsequently, Shin et al. incorporated aminosilanes throughout the silica by 
synthesizing hybrid alkoxysilane/aminosilane NO-releasing nanoparticles, in which nanoparticle 
size, amine identity, and amine content were easily tunable,126  thus greatly increasing the utility 
of NO-releasing silica particles as antimicrobial therapeutics.   
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Hetrick et al. compared the antimicrobial activity of NO-releasing N-(6-
aminohexyl)aminopropyltrimethoxysilane (AHAP3) particles and the small molecule donor 
PROLI/NO against planktonic cultures of Pseudomonas aeruginosa.108  The particles proved 
bactericidal at lower material concentrations and NO doses compared to PROLI/NO, highlighting 
the advantage of controlled NO storage and release from macromolecular scaffolds.108  A 
subsequent study evaluated the efficacy of N-diazeniumdiolate-modified N-
methylaminopropyltrimethoxysilane (MAP3) and AHAP3 silica particles against biofilms of 
Gram-positive and Gram-negative bacteria, as well as fungus, demonstrating the broad-spectrum 
anti-biofilm capabilities of these NO-release vehicles.132  The particle concentrations tested were 
characterized by reduced toxicity to mouse fibroblasts (L929) compared to clinical concentrations 
of povidone iodine.132  The two NO-releasing particle systems studied exhibited differences in 
bactericidal efficacy, signifying the importance of particle composition and N-diazeniumdiolate 
chemistry on the antibacterial activity of NO-releasing silica nanoparticles.  Additionally, the role 
of physical and chemical properties of NO-release scaffolds on bactericidal efficacy including size, 
shape, and NO-release kinetics remained unclear.  Nevertheless, the strong antimicrobial effect of 
NO and therapeutic potential of NO-releasing silica was validated.   
Physical properties of NO-releasing silica nanoparticles, such as size and shape, are easily 
modified and may affect both particle-bacteria interactions and subsequent killing efficiency.  
Carpenter et al. investigated the role of NO-releasing silica particle size on bactericidal efficacy 
using AHAP-modified tetraethoxysilane (TEOS) silica particles with diameters of 50, 100, and 
150 nm and similar NO totals.133  Bactericidal activity was greatest for the smaller particles (50 
nm), presumably due to faster particle-bacteria association attributable to enhanced diffusion.  
Visualization of particle association with the bacterial membrane via confocal microscopy 
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confirmed enhanced diffusion to the bacteria membrane for the smaller diameter particles.133  The 
effects of shape on the efficacy of silica nanoparticles was also investigated.  Lu et al. synthesized 
surfactant-templated silica nanorods of varying aspect ratios while maintaining constant particle 
volume and NO-release totals.134  This study demonstrated enhanced NO delivery to bacteria for 
elongated, high aspect ratio particles over spherical particles as a result of the greater degree of 
particle-bacteria contact, requiring lower NO concentrations necessary for planktonic bacteria (P. 
aeruginosa and S. aureus) eradication.134   
Chemical properties of silica particle NO donors have also been investigated as parameters 
for enhancing the antimicrobial efficiency of NO-releasing silica particles.  For example, Lu et al. 
investigated the role of NO flux on the antibacterial efficacy of NO-releasing silica 
nanoparticles.134  Utilizing the same silica nanorods described above, the maximum NO flux 
released from the particles was varied while holding the total NO storage constant.134  As expected, 
greater maximum NO-release fluxes resulted in increased bactericidal efficacy against both 
planktonic P. aeruginosa and S. aureus due to greater instantaneous intracellular NO 
concentrations.134  In addition to the apparent dependence of biocidal activity on NO-release 
kinetics, the incorporation of additional biocides into the macromolecular scaffold has been 
investigated as a means to enhance antimicrobial efficacy.  Carpenter et al. reported on NO-
releasing silica particles functionalized with quaternary ammonium (QA)-modified alkyl chains to 
impart an additional mechanism of killing.135  Combining NO release with QA alkyl chains 
resulted in enhanced antibacterial activity and decreased the minimum bactericidal concentration 
of NO-releasing silica necessary to eradicate bacteria.135 
Collectively, these previous studies have verified the potency of NO-releasing silica 
particles as antimicrobial agents, with particular emphasis on how their physical (size and shape) 
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and chemical (NO-release characteristic and additional biocides) properties affect bactericidal 
activity.  At this stage, it is still unclear how NO-release kinetics (e.g., half-life) impact the 
antimicrobial efficacy of NO-releasing silica particles independent of particle size and NO totals.  
Furthermore, NO-releasing silica particles have only been tested against a limited scope of 
bacteria.  
  
1.6.4  Nitric oxide-releasing dendrimers 
  Dendrimers are hyper-branched macromolecular scaffolds whose synthesis provides 
precise control over their size and exterior functionality.  With each added generation, or layer of 
polymer growth, the number of functional end groups increases exponentially creating numerous 
sites for chemical modification while maintaining minimal molecular weight.  As reported by 
Stasko et al., generation 3 and 5 (G3–G5)  polypropylenimine (PPI) dendrimers were 
functionalized with N-diazeniumdiolate moieties at primary amine sites to impart NO-release 
capabilities.127  As primary amine N-diazeniumdiolates are relatively unstable, dendrimers can 
easily be functionalized to include secondary amines and amides prior to N-diazeniumdiolate 
formation.127  In this manner, the controllable storage and delivery of large NO payloads from 
dendrimers is greatly improved, which may enhance their therapeutic utility.   
 Due to increased NO storage, prolonged release kinetics, and exquisite synthetic control 
over resulting chemical properties, secondary amine-functionalized dendrimers have been 
researched as NO-releasing materials for therapeutic applications.  Using a one-step ring-opening 
or conjugation reaction, Lu et al. converted primary amines on the periphery of PPI dendrimers to 
secondary amines imparting new surface chemistries and tunable NO-release properties, thus 
unlocking a series of novel NO-releasing materials.136  This study resulted in dendrimer scaffolds 
40 
 
of varied generation (G2–G5) dendrimers with aromatic, hydrophobic, and hydrophilic exterior 
modifications that greatly affected NO storage (0.9–3.8 µmol NO/mg dendrimer) and release 
kinetics (0.3–4.9 h half-lives), highlighting the effect of both molecular weight and exterior 
functionality on proton-initiated NO-release characteristics.136  Furthermore, the dendrimers 
proved capable of eradicating Gram-positive, Gram-negative, and antibiotic-resistant (i.e., 
methicillin-resistant Staphylococcus aureus) pathogens, with antibacterial efficacy dependent on 
generation (molecular weight) and exterior functionality.137  Although bactericidal efficacy was 
observed for all modified dendrimers, greater efficacy was observed for higher generation and 
more hydrophobic functionalities, likely due to enhanced bacterial membrane damage.137  In 
general, the addition of NO provided improved antimicrobial efficacy and lower cytotoxicity 
versus controls (i.e., modified dendrimer precursor scaffolds).137   
Subsequently, Lu et al. reported on the bactericidal efficacy of amphiphilic NO-releasing 
poly(amidoamine) (PAMAM) dendrimers, characterized by simpler synthesis over previous PPI-
based materials.138  A ring opening reaction was used to modify the exterior primary amines of the 
dendrimers with varying ratios of hydrophilic to hydrophobic functionalities.138  By maintaining 
constant NO-release totals across the dendrimer systems, this study examined the extent of exterior 
hydrophobicity on both bacteria killing and cytotoxicity.138  Through tuning the exterior 
hydrophilic/hydrophobic ratio, a balance in the degree of hydrophobicity was discovered to 
maximize bactericidal efficacy while maintaining suitable biocompatibility with L929 mouse 
fibroblast cells.138  Nitric oxide-releasing PAMAM dendrimers have also been functionalized with 
QA-modified alkyl chains in an attempt to increase the hydrophobic nature of the exterior.139  The 
antimicrobial activity of QA-modified NO-releasing dendrimers increased considerably with 
increasing length of the alkyl chain.  As observed previously, a balance in alkyl chain length (i.e., 
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hydrophobic character) was required to maximize bactericidal efficacy while demonstrating 
minimal cytotoxicity.139   The benefits of combining hydrophobic functionalities with NO release 
to improve the bactericidal efficacy of NO-releasing dendrimers is apparent.  Future work must 
focus on exploiting alkyl chain-modified dendrimer antibacterial activity while mitigating 
cytotoxicity.  Additionally, it is pertinent to evaluate NO-releasing alkyl-modified PAMAM 
dendrimers against different strains of bacteria and alternate cell lines for other biomedical 
applications including oral care.  
 
1.7  Summary of Dissertation Research  
 The goal of my dissertation research was to design and develop NO-release vehicles for 
the treatment of oral diseases (i.e., dental caries and periodontal disease).  In this capacity, I also 
sought to investigate the role of NO-release kinetics and exterior dendrimer modification on 
bactericidal action to enhance antibacterial efficacy against certain oral pathogens and minimize 
cytotoxicity.  Specifically, my research aimed to: 
1. Synthesize monodisperse silica particles with varying amine compositions and 
different NO-release properties (totals and kinetics) for subsequent bactericidal assays; 
2. Evaluate the bactericidal efficacy of multiple NO-release vehicles against common 
strains of oral bacteria to assess the therapeutic utility of NO release; 
3. Examine the role of silica-based NO-release kinetics on bactericidal efficacy against 
oral bacteria for the future development of NO-based dental therapeutics; and,  
4. Utilize alkyl chain modified NO-releasing dendrimers as oral anti-biofilm agents. 
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In this introductory chapter, I sought to explain oral health diseases in terms of their 
detrimental impact on society and treatment challenges due to the complex nature of dental plaque 
biofilms.  Inadequate current treatments and lack of satisfactory ongoing research in the area of 
dental plaque therapeutics has motivated the development and further study of NO-releasing 
materials, which have the potential to serve as future oral health pharmaceuticals.  In Chapter 2, 
the Stöber method of silica particle synthesis is described for creating monodisperse similarly 
sized, spherical particles with varying amine content and identity.  These NO-delivery vehicles 
allowed for microbiological studies in subsequent chapters.  In Chapter 3, three distinct NO-release 
vehicles were evaluated against bacteria associated with dental caries (Streptococcus mutans and 
Streptococcus sanguinis) and periodontal disease (Aggregatibacter actinomycetemcomitans and 
Porphyromonas gingivalis).  In Chapter 4, silica particles with discrete compositions and unique 
NO-release kinetics were evaluated against oral pathogens to elucidate the role of NO-release 
kinetics on bactericidal efficacy.  Chapter 5 describes the evaluation of NO-releasing dendrimers 
against both planktonic and biofilm cultures of Streptococcus mutans as a function of alkyl chain 
length and pH for use as dental caries therapeutics.  Lastly, Chapter 6 provides a summary of my 
work and suggests future steps for the design and implementation of NO-release vehicles to 
mitigate oral diseases.    
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Chapter 2: Stöber Synthesis of N-Diazeniumdiolate-Modified  
Nitric Oxide-Releasing Silica Nanoparticles  
 
2.1 Introduction 
 Nitric oxide (NO) is an endogenously produced free radical central to many physiological 
processes.1-6  At low concentrations (pM–nM), NO acts as a cell signaling molecule involved in 
angiogenesis, neurogenesis, vasodilation, and wound healing.5-8  Greater NO concentrations (µM) 
produced by neutrophils and macrophages exhibit a potent antimicrobial effect, central to the 
innate immune response against infectious pathogens (e.g., bacteria).9,10  Upon dental plaque 
deposition, pro-inflammatory endotoxins stimulate mucosal epithelial cells to release NO as an 
early antimicrobial against oral bacteria.11  Several research groups have demonstrated that 
acidified nitrite is bactericidal against both cariogenic and periodontopathogenic bacteria.12-14  
Despite NO’s promising antibacterial action,15-17 the use of exogenous NO-release systems against 
oral pathogens has yet to be studied.  As the administration of pure NO gas to the oral cavity is 
both impractical and inefficient, requiring a high pressure NO gas tank and lacking specific 
pathogenic targeting, methods for storing and releasing exogenous NO must be developed for 
clinical utility.2   
Several NO donors are capable of stable NO storage and controllable, stimuli-induced 
release, including organic nitrates, metal nitrosyls, S-nitrosothiols, and N-diazeniumdiolates.18  N-
diazeniumdiolate NO donors undergo proton-initiated decomposition in physiological solutions 
(pH 7.4; 37 oC),19 making them well-suited for in vivo applications.  Two moles of NO are  
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produced per mole of N-diazeniumdiolate,19 facilitating the storage and release of large NO 
payloads.  The low molecular weight NO donor proline (PROLI/NO) is capable of high N-
diazeniumdiolate conversion efficiency and large NO storage (7.24 µmol/mg).20  However, 
PROLI/NO is plagued by incredibly rapid NO donor decomposition (PROLI/NO half-life = 1.8 
s),21 releasing a significant amount of NO indiscriminately upon contact with aqueous solutions.  
The inability of PROLI/NO, and other small molecular weight donors, to target NO to a specific 
site of action results in low effective NO doses and raises toxicity concerns, which hinders their 
clinical development.18   
 Macromolecular NO storage vehicles benefit from superior spatiotemporal control over 
exogenous NO-release payloads and release kinetics.2,18,22-29  Silica nanoparticles are one such 
vehicle that exhibits great promise as a drug delivery system due to tolerance by mammalian cells 
and superior surface modification capabilites.30  When considering drug delivery systems for oral 
therapeutics, silica (e.g., hydrated silica and silicon dioxide) is already present in toothpastes as an 
abrasive to remove dental plaque and polish teeth.  Recent research has highlighted the advantage 
of using silica nanoparticles versus micron-sized silica as a polishing agent to reduce S. mutans 
adhesion strength to teeth, rendering bacteria easier to remove.31  Utilizing silica nanoparticles as 
NO storage platforms could prove advantageous for delivering exogenous NO as an antibacterial 
therapeutic with the potential for simple translation into existing oral healthcare modalities.                 
 Zhang et al. first reported on silica-based N-diazeniumdiolate NO storage and delivery 
using amine-grafted fumed silica.28  Although NO storage was limited by the parent amine 
coupling efficiency to the silica surface (≤70%), the apparent half-life of the NO-releasing silica 
(43 min) was substantially lengthened compared to the solution phase N-diazeniumdiolate 
analogues, highlighting the benefit of silica-based NO storage and delivery vehicles.28  To 
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overcome surface-grafting limitations, Shin et al. used the Stöber synthesis32 to incorporate amines 
throughout silica particles via a high throughput, one-pot reaction.29  Compared to previous silica-
based NO-release scaffolds, greater NO storage totals and superior control over particle size, 
composition, and NO-release kinetics were achieved, greatly increasing the utility of NO-releasing 
silica nanoparticles as potential antibacterial agents.29   
Our laboratory evaluated the use of NO-releasing silica nanoparticles against both 
planktonic and biofilm cultures of Gram-positive, Gram-negative, and fungal pathogens.  
Improved efficacy for these scaffolds was observed compared to the low molecular weight NO 
donor PROLI/NO.33,34  Subsequent research focused on tuning the physical (e.g., size and shape) 
and chemical (e.g., NO-releasing kinetics) properties of the silica nanoparticles to further enhance 
bactericidal efficacy.  For example, Carpenter et al. reported on a reverse microemulsion technique 
to synthesize aminosilane-functionalized silica of different sizes (50, 100, 200 nm).  Greater 
bactericidal efficacy was observed for the smaller (50 nm) NO-releasing silica particles due to 
their more rapid diffusion, allowing for faster particle-bacteria association and more efficient 
intracellular NO delivery.35  Lu et al. prepared high aspect ratio NO-releasing silica nanorods via 
surfactant-templated silane growth and subsequent surface grafting with aminosilanes.  The 
improvement in antibacterial activity for the higher aspect ratio NO-releasing silica nanorods 
compared to spherical particles was attributed to the greater degree of particle-bacteria surface 
contact and intracellular NO delivery.36  Additionally, Lu et al. observed that greater initial NO 
fluxes, independent of the total NO delivered, could reduce the concentration of NO-releasing 
particles necessary to kill bacteria.36   
At this stage, physicochemical investigations into the resulting bactericidal efficacy of NO-
releasing silica nanoparticles have involved complex and time-consuming synthetic methods for 
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modifying silica with aminosilanes for subsequent N-diazeniumdiolate modification.  It is also 
unclear as to what effect NO-release kinetics (i.e., half-life) have on the bactericidal efficacy of 
NO-releasing silica nanoparticles.  Furthermore, the antibacterial activity of NO-releasing silica in 
terms of these physicochemical properties have been investigated against a narrow scope of 
nosocomial pathogens (i.e., Pseudomonas aeruginosa).  To this end, Chapter 2 describes the 
straightforward, one-step Stöber synthesis of NO-releasing silica particles for subsequent 
bactericidal evaluation against dental-relevant pathogens and cytotoxicity testing against human 
gingival cells.  Both nanoparticle size and the NO-release properties (i.e., NO-release totals and 
kinetics) were varied systematically to isolate the role of physicochemical properties on the 
bactericidal efficacy of NO release.    
 
2.2 Materials and Methods 
 Tetramethyl orthosilicate (TMOS) was purchased from Sigma-Aldrich (St. Louis, MO).  3-
methylaminopropyltrimethoxysilane (MAP3), N-(6-aminohexyl)aminopropyltrimethoxysilane 
(AHAP3), N-(2-aminoethyl)-3-aminopropyltrimethoxysilane (AEAP3), and (3-
trimethoxysilyl)diethylenetriamine (DET3) were purchased from Gelest (Morrisville, PA).  
Ethanol (EtOH), 1-butanol (BuOH), and ammonium hydroxide (NH4OH; 30 wt%) were purchased 
from Fisher Scientific (Fair Lawn, NJ).  Nitrogen (N2), argon (Ar), and nitric oxide (NO) 
calibration (26.81 ppm, balance N2) gases were purchased from National Welders (Raleigh, NC).  
Anhydrous methanol (MeOH), N,N-dimethlyformamide (DMF), and sodium methoxide (NaOMe; 
5.4 M in MeOH) were purchased from Acros Organics (Geel, Belgium).  Pure NO gas was 
purchased from Praxair (Sanford, NC).  Distilled water (H2O) was purified with a Millipore Milli-
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Q Gradient A-10 water purification system (Bedford, MA) to obtain H2O with ≤6 ppb organic 
content and a final resistivity of 18.2 mΩ·cm.    
    
2.2.1 Synthesis of 150 nm silica particles with varying amine content  
 Hybrid alkoxysilane/aminosilane silica nanoparticles were produced using a modified 
Stöber method.29  Briefly, particles were synthesized by combining TMOS with an aminosilane 
(MAP3, AHAP3, AEAP3, or DET3) (Figure 2.1) and bolus injection into a flask containing H2O 
(27.84 mL), NH4OH (9.8 mL), and EtOH as a co-solvent (balanced to make a final volume of 100 
mL).  Of note, DET3 required less H2O (10.80 mL) and was still balanced with EtOH to a total 
volume of 100 mL. As shown in Table 2.1, the aminosilane precursor amounts were varied to 
synthesize different mol% (35, 50, 60, 70 mol% MAP3; 50, 60, 70 mol% AHAP3; 50, 60, 70, 80 
mol% AEAP3; and 70 mol% DET3) nanoparticles (balanced TMOS).  After 2 h of stirring at room 
temperature, the nanoparticles were collected via centrifugation (2907 x g; 4 oC; 10 min) and 
decanting of the supernatant.  The pellet was resuspended in EtOH, centrifuged and decanted twice 
more to remove unreacted silanes and residual solvent.  The resulting amine-functionalized silica 
particles were dried under vacuum overnight to remove residual EtOH.  
 
2.2.2 Synthesis of 400 and 800 nm 70 mol% MAP3 silica nanoparticles  
 The size of the 70 mol% MAP3 particles was tuned by modifying the above procedure.  
Briefly, the total silane concentration was increased from 0.12 to 0.24 M and butanol used in place 
of ethanol as the co-solvent.  A solution of TMOS (1.076 µL) was combined with MAP3 (3.360 
µL) and injected as a bolus into a flask containing H2O (27.84 mL), NH4OH (9.8 mL), and BuOH 
(57.92 mL) at room temperature (~23 oC) to synthesize the ~800 nm 70% MAP3 silica.    
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Figure 2.1 Structures of aminosilanes and backbone alkoxysilane (TMOS) used in the Stöber 
synthesis of NO-releasing silica nanoparticles.  
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Table 2.1 Concentrations and volumes of silanes used to synthesize 150 nm silica nanoparticles 
with varying amine content.  
 
Aminosilane 
Total Silane 
Concentration (M) 
Mol%      
Aminosilane 
TMOS    
(µL) 
Aminosilane    
(µL) 
MAP3 0.12 35 1.166 0.841 
  50 0.897 1.201 
  60 0.717 1.441 
  70 0.538 1.680 
  80 0.359 1.921 
AHAP3 0.12 50 0.896 1.524 
  60 0.717 1.829 
  70 0.538 2.134 
AEAP3 0.16 50 1.181 1.777 
  60 0.945 2.133 
  70 0.708 2.488 
  80 0.472 2.844 
DET3 0.20 70 0.886 3.610 
 
 
 
 
 
64 
 
The ~400 nm 70 mol% MAP3 silica nanoparticles were synthesized using the same synthetic 
mixture, but at increased reaction temperature (50 oC). 
 
2.2.3 Silica nanoparticle characterization 
 The silica nanoparticles were characterized prior to N-diazeniumdiolate NO donor 
modification.  Nanoparticle size and surface morphology were evaluated using a Hitachi S-4700 
Scanning Electron Microscope (SEM; Chapel Hill Analytical and Nanofabrication Laboratory) 
and ImageJ software.  Nanoparticles were suspended at 0.5 mg/mL in EtOH, cast on glass slides, 
and coated with 2 nm gold/palladium prior to imaging.  Aminosilane content was confirmed and 
quantified as percent nitrogen per mg of nanoparticle using a Perkin Elmer 2400 Series II CHNS/O 
Elemental Analyzer operated in CHN mode (Waltham, MA).  The monodispersity and hydrated 
diameter of the silica nanoparticles was measured in Milli-Q water via dynamic light scattering 
(DLS) using a Malvern Instruments Zetasizer Nano (Worcestershire, UK).  
 
2.2.4 N-Diazeniumdiolate-modified nitric oxide-releasing silica nanoparticles  
 Amine-functionalized silica nanoparticles (30 mg) were suspended in 6 mL 9:1 
DMF:MeOH with 25 µL of NaOMe (50 µL for 70 mol% MAP3, AHAP3, DET3).  The resulting 
solution was sealed in a Parr reaction bottle, flushed with Ar thrice, followed by longer purges 
with Ar (3 x 10 min) to remove oxygen, before being pressurized with NO (10 bar).  After 3 d of 
constant stirring, the Ar purges were again repeated to remove unreacted NO.  Particles were 
collected via centrifugation (2907 x g; 4 oC; 10 min) and decanting of the supernatant.  The 
resulting pellet was resuspended in EtOH before being centrifuged and decanted twice more to 
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remove residual solvent.  The N-diazeniumdiolate NO donor-modified particles were dried under 
vacuum for 2 h and stored at -20 oC in a vacuum-sealed freezer bag until further use.   
 
2.2.5 Characterization of nitric oxide-releasing silica nanoparticles 
 A Sievers 280i Chemiluminescence analyzer (Boulder, CO) was used to measure NO 
release in real-time to ascertain the most important NO-release parameters including total NO 
release (t[NO]), total NO release at 2 h (t[NO]2h), maximum NO flux ([NO]m), and NO-release 
half-life (t1/2).
37  Briefly, ~1 mg NO-releasing silica nanoparticles was added to 30 mL of 
deoxygenated phosphate buffered saline (PBS; pH 7.4; 37 oC).  The PBS solution was continuously 
bubbled with N2 at 80 mL/min to carry liberated NO to the analyzer.  The NO analysis was 
continued until NO levels fell below 10 ppb/mg.   The N-diazeniumdiolate-modified silica 
nanoparticles were also visualized by SEM to ensure no changes in particle morphology or the 
formation of unwanted byproducts.     
 
2.3 Results and Discussion 
 Previous reports have used core-shell or surface grafting techniques to study the connection 
between the physicochemical properties (i.e., size, shape, and maximum NO flux) and the resulting 
bactericidal efficacy of NO-releasing silica nanoparticles against Pseudomonas aeruginosa.35,36  
The effect of particle size, NO-release kinetics, and NO-release totals against other biomedically 
relevant pathogens remains avoid.  Additionally, the previous synthetic burdens (e.g., multi-step 
and low yield) for tuning NO-releasing silica nanoparticle properties have limited both the breadth 
of physicochemical properties and bacteria strains investigated.  As such, we sought to utilize a 
one-step, high throughput Stöber synthesis to create hybrid amino/alkoxysilane NO-releasing 
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nanoparticles for the investigation of physicochemical effects on dental bacteria killing and oral 
eukaryotic cell tolerance.  Specifically, we synthesized similarly sized NO-releasing nanoparticles 
with different aminosilane identities and compositions, altering both NO-release totals and 
kinetics.  We also attempted to tune particle size while maintaining amine identity and 
composition, thus holding both NO-release total and kinetics constant.   
 The formation of monodisperse, spherical silica particles synthesized via a one-step Stöber 
method is known.32,38-40  Indeed, the ability to manipulate particle size based on feed rate of 
reactants, reaction temperature, co-solvent chain length, and molar ratios of silanes, water, and 
ammonia catalyst has been reported.41-43  Previous studies have utilized tetraethyl orthosilicate 
(TEOS) or TMOS as single silane systems and did not attempt to create hybrid organic/inorganic 
silica particles.  Building upon Shin et al.29 and Riccio et al.,44 dual silane hybrid particles were 
synthesized via the Stöber method.  The optimized synthetic parameters and characterization of 
NO-releasing silica nanoparticles are detailed below.  The successful synthesis of monodisperse, 
spherical NO-releasing silica nanoparticles in this chapter allowed for subsequent microbiological 
testing described in later chapters. 
 
2.3.1 Varying aminosilane content of 150 nm silica nanoparticles 
 Bolus injection of silane mixtures (TMOS and aminosilane) into a mixture of water, 
ammonia, and ethanol allowed for the base-catalyzed formation of silica nanoparticles.  To 
produce spherical, monodisperse particles with smooth surface morphologies, several reagent 
concentrations were varied, including total silane content, water, and ammonia in a total volume 
of 50 mL prior to being scaled up to 100 mL reactions.  The total silane concentration used to 
synthesize MAP3 and AHAP3 nanoparticles was 0.12 M, whereas 0.16 and 0.20 M silane was 
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necessary for AEAP3 and DET3, respectively.  The amount of water required for successful DET3 
particle synthesis was 9.4 M.  All other systems (i.e., MAP3, AHAP3, AEAP3) required 18.9 M.  
An ammonia concentration of 1.5 M proved useful for all particle systems.  The initial goal was to 
synthesize 70 mol% aminosilane particles.  As shown in Figure 2.2, SEM imaging revealed high 
sphericity, superior monodispersity, and smooth surface morphology, demonstrating the utility of 
a one-step Stöber synthesis for the co-condensation of TMOS with aminosilanes to create hybrid 
organic/inorganic silica nanoparticles.  
 The geometric diameters of the resulting nanoparticles were estimated using ImageJ 
software for at least n=3 syntheses with repeated measurements per synthesis (n ≥100) to obtain a 
representation of absolute particle size and distribution.  Nanoparticle hydrodynamic diameter and 
polydispersity index (PDI), a measure of particle size uniformity, were measured using DLS.  The 
nanoparticle diameters measured in water by DLS were comparable, but slightly greater than the 
geometric diameters obtained via SEM.  This phenomenon was expected, as the DLS measures 
hydrated (hydrodynamic) diameter, which includes both the particle size and the effective 
electrical double layer size based on mobility interactions with solvent.  Table 2.2 displays both 
the geometric (SEM) and hydrodynamic (DLS) diameters, with coinciding PDI values, measured 
in H2O for the 70 mol% silica nanoparticles, highlighting similar sizes (~150 nm) and small size 
distributions.   
  Once the synthetic parameters were optimized for 70 mol% silica nanoparticles, we sought 
to systematically vary the mol% aminosilane content of the particles.  The percent ratio of each 
silane was varied without altering other synthetic parameters.  In doing so, particle composition 
and potentially NO-release totals and kinetics could be tuned while maintaining spherical 
nanoparticles with smooth surface morphologies (Figure 2.3) and similar sizes across all particle  
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Figure 2.2 Scanning electron micrographs of 70 mol% silica nanoparticles consisting of (A) 
MAP3, (B) AEAP3, (C) AHAP3, and (D) DET3 (balance TMOS). 
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Table 2.2 Sizes for 70 mol% (balance TMOS) silica nanoparticles with different aminosilane 
compositions. 
 
Aminosilane 
Particle Diameterb 
(nm) 
Particle Diameterc 
(nm) 
Particle PDIc 
MAP3 145 ± 15 195 ± 6 0.06 ± 0.02 
AHAP3 161 ± 11 204 ± 25 0.05 ± 0.02 
AEAP3 149 ± 14 169 ± 15 0.08 ± 0.06 
DET3 157 ± 14 205 ± 5 0.03 ± 0.02 
 
aValues shown as mean ± standard deviations for n ≥3 syntheses. bGeometric particle sizes 
measured using SEM. cNanoparticle hydrodynamic diameter and PDI measured in water using 
DLS.     
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Figure 2.3 Scanning electron micrographs of (A) 35, (B) 50, (C) 60, (D) 70, and (E) 80 mol% 
MAP3 (balance TMOS) silica nanoparticles.    
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systems.  The aminosilane content of the 70 mol% DET3 system was not varied systematically as 
control non-NO-releasing particles were bactericidal themselves (unpublished observations), 
rendering the evaluation of their NO-release kinetic-dependent bacterial killing ineffective.  The 
diameter of nanoparticles (~150 nm) was again confirmed using SEM and DLS.  Elemental 
analysis confirmed aminosilane incorporation into the nanoparticles by quantifying the percent 
nitrogen relative to the total nanoparticle mass. The size and percent amine content for all silica 
nanoparticle systems synthesized is provided in Table 2.3.  Unexpectedly, the precursor 
aminosilane amounts do not directly relate to the degree of aminosilane incorporation within the 
particles between different silane systems.  The aminosilane incorporation efficiency is 
inconsistent between silica systems, affecting the final aminosilane content of each particle type.  
Rather, CHN analysis confirmed the presence of amine functionality within the nanoparticles, with 
an observed increase in the nitrogen wt% for nanoparticles of increasing mol% aminosilane 
compositions for individual silica particle systems.  The degree of amine functionalization could 
thus be tuned within a given aminosilane particle system, which could afford different NO-release 
properties.  
          
2.3.2 Increasing 70 mol% MAP3 silica nanoparticle size          
 After synthesizing silica nanoparticles of different aminosilane compositions and similar 
size, attempts were made to increase particle diameter for the 70 mol% MAP3 system.  Several 
strategies have been reported for increasing the size of single silane (TMOS or TEOS) silica 
particles, including altering the ammonia, water, or silane concentrations, and changing the chain 
length of the solvent or the reaction temperature.41-43,45  These parameters were systematically 
varied for the hybrid silane systems and the resulting particles analyzed via SEM.  Specifically, 
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Table 2.3 Diameters, PDIs, and nitrogen wt% for silica nanoparticles synthesized as a function of 
aminosilane type and concentration (mol%).a  
 
Aminosilane 
Mol%      
Aminosilane* 
Particle 
Diameterb  
(nm) 
Particle 
Diameterc 
(nm) 
Particle 
PDIc 
Nitrogen 
wt%d 
MAP3 35 164 ± 21 208 ± 18 0.05 ± 0.03 2.49 ± 0.08 
 50 160 ± 16 197 ± 7 0.04 ± 0.02 3.42 ± 0.17 
 60 152 ± 15 210 ± 29 0.09 ± 0.04 3.84 ± 0.06 
 70 145 ± 15 195 ± 6 0.06 ± 0.02 4.27 ± 0.13 
AHAP3 50 176 ± 16 224 ± 18 0.03 ± 0.02 3.48 ± 0.28 
 60 174 ± 15 239 ± 14 0.05 ± 0.02 4.28 ± 0.07 
 70 161 ± 11 204 ± 25 0.05 ± 0.02 4.80 ± 0.03 
AEAP3 50 170 ± 21 224 ± 7 0.07 ± 0.04 3.37 ± 0.32 
 60 155 ± 16 209 ± 8 0.08 ± 0.04 3.87 ± 0.20 
 70 149 ± 14 169 ± 15 0.08 ± 0.06 4.71 ± 0.27 
 80 125 ± 13 143 ± 9 0.05 ± 0.02 5.83 ± 0.17 
DET3 70 157 ± 14 205 ± 5 0.03 ± 0.02 4.95 ± 0.03 
 
aValues shown as means ± standard deviations for n ≥3 syntheses. bGeometric diameters were 
evaluated using SEM.  cHydrodynamic diameter and PDIs were measured using DLS.  dNitrogen 
wt% was determined using CHNS/O elemental analysis.  *Balance TMOS. 
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the silane concentration was increased from 0.12 to 0.16 M, the ammonia concentration was varied 
from 0.5 to 2.0 M, and the water concentration was decreased to 3.5 M (from the original 18.9 M).  
In each case, the silica nanoparticles were relatively unchanged in appearance as visualized using 
SEM (Figure 2.4).  Nanoparticle sizes were maintained as the mean diameter ranged from 99–173 
compared to the ~150 nm diameter of the original 70 mol% MAP3 silica nanoparticles.   
 Unlike other parameters, the co-solvent alkyl chain length had a profound effect on the 
resulting nanoparticle size.  Initially, the alcohol co-solvent was changed to methanol, propanol, 
isopropanol, and mixtures of these alcohols with no success.  Upon changing the co-solvent to 
butanol, which is immiscible with water, different sized particles were obtained as shown in Figure 
2.5.  The particles were much larger, but lacked the sphericity and smooth surface morphology of 
the original 70 mol% silica nanoparticles.  Although some of the nanoparticles appeared spherical, 
many were variable in both size and shape.  The total silane concentration was also increased to 
0.24 and 0.36 M in an attempt to improve both the monodisperisty and surface morphology of the 
silica nanoparticles.42  As shown in Figure 2.6, the increase in silane concentration improved the 
particle size distribution and surface characteristics at 0.24 M but negatively impacted the resulting 
particles at 0.36 M.  The total concentration of silane impacts the amount of material deposited on 
the particle nuclei during the growth phase.42  With too high of a silica concentration, the particles 
could suffer from an excess of material coating the particle nuclei.  This could result in fused 
particles and particles with poor surface morphologies as observed with 0.36 M total silane 
concentration.   
The 70 mol% MAP3 silica nanoparticles synthesized using a butanol co-solvent and 0.24 
M silanes were further characterized based on these observations.  The geometric size obtained via  
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Figure 2.4 Scanning electron micrographs of 70 mol% MAP3 (balance TMOS) silica 
nanoparticles with (A) the original synthesis with 0.12 M silane, 1.5 M ammonia, and 18.9 M 
water, (B) 0.16 M silane, (C) 0.5 M ammonia, (D) 2.0 M ammonia, (E) 3.5 M water, and (F) 10.4 
M water.  
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Figure 2.5 (A-D) Scanning electron micrographs of 70 mol% MAP3 (balance TMOS) silica 
nanoparticles synthesized in butanol instead of ethanol.  Total silane concentration was 0.12 M. 
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Figure 2.6 Scanning electron micrograph of 70 mol% MAP3 (balance TMOS) silica nanoparticles 
synthesized in butanol instead of ethanol with a total silane concentration of (A) 0.12 M, (B) 0.24 
M, and (C) 0.36 M. 
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SEM and ImageJ was 855 ± 267 nm, which was the target size for this nanoparticle synthesis.  
However, the size distribution was quite large ranging from 500–1600 nm in diameter, possibly 
due to the biphasic nature of the reaction mixture created between immiscible butanol and water.  
Indeed, DLS measurements confirmed the highly polydisperse nature of particle size with 
excessively large PDI values (generally >0.50).  Quality control parameters provided by the DLS 
also indicated that the large particle size distribution hindered accurate hydrodynamic size 
measurement.  Thus, these ~800 nm silica nanoparticles were deemed unfit for a size-dependent 
bactericidal study.  
 Following the synthesis of larger hybrid silica nanoparticles with a non-uniform size 
distribution, improving the monodispersity was paramount for ultimately evaluating the size-
dependent bactericidal efficacy of these silica scaffolds.  Using a modified LaMer model for 
particle synthesis, Huang et al. proposed that size distribution is governed by the duration of the 
nucleation phase in which new particle nuclei are generated.42  When the nucleation phase is long, 
particle nuclei appear at different times in solution and thus experience altered growth phase times, 
resulting in variable final particle sizes.  At short nucleation windows (i.e., burst nucleation), the 
particles are initially formed at similar times and experience similar growth phases resulting in 
similarly sized particles.  Huang et al. further demonstrated that an increase in temperature could 
be useful in speeding up the reaction kinetics to shorten the duration of the nucleation phase.42  
Upon increasing the reaction temperature from ambient (~23 oC) to 50 oC, the particle size 
distribution (monodispersity) was drastically improved (Figure 2.7).  To corroborate the SEM 
images, DLS was then conducted in water to obtain a true sampling of both particle size and 
monodispersity.  Unlike the silica synthesized using a butanol co-solvent at ~23 oC, the particles 
synthesized at 50 oC were monodisperse enough for accurate size assessment, with PDIs less than  
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Figure 2.7 Scanning electron micrographs of 70 mol% MAP3 (balance TMOS) silica 
nanoparticles synthesized at (A,B) ambient temperature (~23 oC) and (C,D) 50 oC. 
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0.10.  The size summary and elemental analysis for 70 mol% MAP3 silica nanoparticles 
synthesized with butanol at 50 oC is provided in Table 2.4. 
 
2.3.3 N-Diazeniumdiolate NO donor-modified silica nanoparticles 
 Under basic conditions and high pressures of NO gas, N-diazeniumdiolate NO donors form 
at secondary amine sites.19  In this work, sodium methoxide was used as a base to facilitate NO 
donor formation.  Initially, an excess of sodium methoxide (NaOMe) was used to ensure maximum 
conversion efficiency.  Unfortunately, N-diazeniumdiolate functionalization resulted in impurities 
observed in SEM images that were not present prior to modification (Figure 2.8).  These 
byproducts were observed as crystal formations on the surface of the particles or in solution, and 
differed in both size and shape between particle systems, and even within repeat modifications 
using the same particle system. 
Despite >100 years of contrary findings, DeRosa et al. reported on NO reacting with 
methoxide to ultimately produce sodium formate as an observable end product.46  The generation 
of sodium formate may compete with the formation of desired products (i.e., N-diazeniumdiolates) 
and impair NO release from these materials.  The presence of an unknown byproduct after washing 
with ethanol corroborated the formation of a salt, possibly sodium formate.  The NO-releasing 
particles were washed with basic water to successfully remove the salt byproduct (Figure 2.9).  
Upon removal of the salt, the NO release from the particles was substantially lower, indicating that 
the salt itself was storing and releasing NO (Table 2.5).  This was unexpected as we anticipated 
that the sodium formate could be removed without impacting the NO-release properties of the 
silica particles.  This result indicates that carbon-bound bis or trisdiazeniumdiolates were 
potentially formed on the formate byproduct.47  In contrast to other C-diazeniumdiolates,  
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Table 2.4 Comparison of material characteristics for 70 mol% MAP3 (balance TMOS) silica 
nanoparticles synthesized at ambient temperature (~23 oC) in ethanol and at 50 oC in butanol.a  
 
Particle Diameterb 
(nm) 
Particle Diameterc 
(nm) 
Particle PDIc Nitrogen wt%d 
145 ± 15 195 ± 6 0.06 ± 0.02 4.27 ± 0.13 
404 ± 184 444 ± 35 0.09 ± 0.06 4.68 ± 0.28 
 
aValues shown as mean ± standard deviations for n ≥3 syntheses. bSilica nanoparticle geometric 
sizes were evaluated using SEM.  cNanoparticle hydrodynamic diameter and PDI measured using 
DLS.  dNitrogen wt% was determined using CHN elemental analysis. 
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Figure 2.8 Scanning electron micrographs of (A) 70 mol% AEAP3 with 150 µL NaOMe (B) 70 
mol% DET3 with 200 µL NaOMe (C) 50 mol% AHAP3 with 200 µL NaOMe (D) 50 mol% 
AHAP3 with 50 µL NaOMe (E) 70 mol% MAP3 with 100 µL NaOMe (F) 70 mol% MAP3 100 
µL. (A-F) balance TMOS.  In addition to the silica nanoparticles, the NO-releasing salt is also 
observed.  
 
82 
 
 
 
 
 
Figure 2.9 Scanning electron micrographs of (A) N-diazeniumdiolated 50 mol% AHAP3 (B) N-
diazeniumdiolated 70 mol% DET3 (C) N-diazeniumdiolated 50 mol% AHAP3 washed with basic 
water to remove salt, and (D) N-diazeniumdiolated 70 mol% DET3 washed with basic water to 
remove salt.  (A-D) balance TMOS.  
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Table 2.5 Silica nanoparticle nitric oxide release properties before and after washing with basic 
water.a 
 
NO Release Scaffold* 
t[NO]b 
(µmol/mg) 
[NO]mc            
(ppb/mg) 
t ½d            
(min) 
 t[NO]2he    
(µmol/mg) 
50 mol% AHAP3 pre wash 0.31 5288 27.4 0.26 
50 mol% AHAP3 post wash 0.14 585 36.7 0.12 
70 mol% DET3 pre wash 0.23 2000 47.1 0.16 
70 mol% DET3 post wash 0.06 141 59.0 0.05 
 
aResults shown are from one trial to evaluate NO-releasing byproduct removal.  bTotal amount of 
NO released.  cMaximum NO flux achieved.  dTime to release half of total NO payload.  eTotal 
amount of NO released after 2 h.  *Balance TMOS.     
 
 
 
 
 
 
 
 
84 
 
trisdiazeniumdiolates undergo rapid decomposition47,48 and the NO release would thus be 
observable in our NO-release analysis.   
Regardless of the identity and nature of the salt byproduct, the storage and release of NO 
from undesirable salt byproducts clearly hinders the study and application of NO-releasing silica 
nanoparticles as antibacterial therapeutics.  As it is important to keep the sodium methoxide 
concentration large to maximize NO loading (and release), the amount of sodium methoxide used 
was systematically decreased until the formation of the salt byproduct was eliminated (as noted by 
SEM).  At a sodium methoxide concentration of 74 mM, no salt was observed for the 50, 60, and 
80 mol% silica nanoparticles.  The 70 mol% formulations did not form salt up to 148 mM sodium 
methoxide.  Once the maximum concentration of sodium methoxide was determined, the NO-
release properties for the silica nanoparticles were characterized (Table 2.6).  Of note, the total NO 
release and half-lives varied as a function of the aminosilane system, demonstrating the potential 
to alter NO release while maintaining constant particle size (~150 nm).  Additionally, the NO-
release totals and half-lives were similar for the 70 mol% MAP3 particles, demonstrating the 
ability to alter size while maintaining constant NO release.  As described in subsequent chapters, 
the NO-releasing silica systems developed herein proved useful for microbiological testing. 
 
2.4  Conclusions 
 The Stöber co-condensation of aminosilanes and TMOS in ethanol proved useful for 
synthesizing hybrid silica nanoparticles of spherical nature and high monodispersity.  Amine 
incorporation into the silica particles was tunable by altering the aminosilane precursor mol%.  
Particle size could be altered by increasing the reaction temperature (23–50 oC) and replacing 
ethanol with butanol as the co-solvent for particle synthesis.  The conditions necessary to maximize 
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Table 2.6 Summary of nitric oxide release properties for hybrid silica nanoparticles synthesized 
via the Stöber method.a 
 
Aminosilane 
Scaffold 
Mol% 
Aminosilane* 
t[NO]b 
(µmol/mg) 
[NO]mc            
(ppb/mg) 
t ½d                      
(min) 
Conversion        
Efficiencye 
(%) 
MAP3 50 0.19  ±  0.02 1490  ±  907 20.6  ±  5.5 3.9 
 70 1.03  ±  0.13 24678  ±  12079 11.9  ±  4.3 16.9 
400 nm 70 1.02  ±  0.19 20573  ±  6301 18.9  ±  4.1 15.3 
AHAP3 50 0.17  ±  0.01 614  ±  160 42.9  ±  6.4 6.8 
 60 0.25  ±  0.05 1721  ±  956 33.8  ±  5.5 8.2 
 70 0.38  ±  0.01 4689  ±  758 29.5  ±  3.6 11.1 
DET3 70 0.22  ±  0.04 793  ±  307 61.9  ±  6.2 9.3 
AEAP3 80 0.33  ±  0.06 718  ±  496 122.8  ±  9.6 7.9 
 
aResults shown as mean ± standard deviation for n ≥3 separate syntheses.  bTotal amount of NO 
released.  cMaximum NO flux achieved.  dTime to release half of total NO payload.  eConversion 
efficiency calculated from nitrogen wt% as determined via CHN elemental analysis and the total 
NO release from each particle system.  *Balance TMOS.     
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NO storage and release while eliminating the formation of unwanted salt byproducts were 
determined to be a function of sodium methoxide concentration.  The synthesis of silica scaffolds 
with distinct sizes and NO-release properties facilitated the bactericidal and cytotoxicity testing in 
subsequent chapters.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
87 
 
2.5 References 
(1) Ferrari, C. K. B.; Franca, E. L.; Honorio-França, A. C. "Nitric oxide, health and disease" 
Journal of Applied Biomedicine 2009, 7, 163-173. 
(2) Carpenter, A. W.; Schoenfisch, M. H. "Nitric oxide release: Part II. Therapeutic applications" 
Chemical Society Reviews 2012, 41, 3742-3752. 
(3) Witte, M. B.; Barbul, A. "Role of nitric oxide in wound repair" The American Journal of 
Surgery 2002, 183, 406-412. 
(4) Schwentker, A.; Vodovotz, Y.; Weller, R.; Billiar, T. R. "Nitric oxide and wound repair: Role 
of cytokines?" Nitric Oxide 2002, 7, 1-10. 
(5) Prast, H.; Philippu, A. "Nitric oxide as modulator of neuronal function" Progress in 
Neurobiology 2001, 64, 51-68. 
(6) Ziche, M.; Morbidelli, L. "Nitric oxide and angiogenesis" Journal of Neuro-Oncology 2000, 
50, 139-148. 
(7) Witte, M. B.; Thornton, F. J.; Tantry, U.; Barbul, A. "L-Arginine supplementation enhances 
diabetic wound healing: Involvement of the nitric oxide synthase and arginase pathways" 
Metabolism 2002, 51, 1269-1273. 
(8) Witte, M.; Kiyama, T.; Barbul, A. "Nitric oxide enhances experimental wound healing in 
diabetes" British Journal of Surgery 2002, 89, 1594-1601. 
(9) Loscalzo, J.; Welch, G. "Nitric oxide and its role in the cardiovascular system" Progress in 
Cardiovascular Diseases 1995, 38, 87-104. 
(10) Bogdan, C. "Nitric oxide and the immune response" Nature Immunology 2001, 2, 907-916. 
(11) Carossa, S.; Pera, P.; Doglio, P.; Lombardo, S.; Colagrande, P.; Brussino, L.; Rolla, G.; 
Bucca, C. "Oral nitric oxide during plaque deposition" European Journal of Clinical 
Investigation 2001, 31, 876-879. 
(12) Silva Mendez, L.; Allaker, R.; Hardie, J.; Benjamin, N. "Antimicrobial effect of acidified 
nitrite on cariogenic bacteria" Oral Microbiology and Immunology 1999, 14, 391-392. 
88 
 
(13) Allaker, R.; Silva Mendez, L.; Hardie, J.; Benjamin, N. "Antimicrobial effect of acidified 
nitrite on periodontal bacteria" Oral Microbiology and Immunology 2001, 16, 253-256. 
(14) Doel, J.; Hector, M.; Amirtham, C.; Al‐Anzan, L.; Benjamin, N.; Allaker, R. "Protective 
effect of salivary nitrate and microbial nitrate reductase activity against caries" European 
Journal of Oral Sciences 2004, 112, 424-428. 
(15) Ghaffari, A.; Miller, C.; McMullin, B.; Ghahary, A. "Potential application of gaseous nitric 
oxide as a topical antimicrobial agent" Nitric Oxide 2006, 14, 21-29. 
(16) Ghaffari, A.; Jalili, R.; Ghaffari, M.; Miller, C.; Ghahary, A. "Efficacy of gaseous nitric 
oxide in the treatment of skin and soft tissue infections" Wound Repair and Regeneration 2007, 
15, 368-377. 
(17) Miller, C.; McMullin, B.; Ghaffari, A.; Stenzler, A.; Pick, N.; Roscoe, D.; Ghahary, A.; 
Road, J.; Av-Gay, Y. "Gaseous nitric oxide bactericidal activity retained during intermittent 
high-dose short duration exposure" Nitric Oxide 2009, 20, 16-23. 
(18) Riccio, D. A.; Schoenfisch, M. H. "Nitric oxide release: Part I. Macromolecular scaffolds" 
Chemical Society Reviews 2012, 41, 3731-3741. 
(19) Hrabie, J. A.; Keefer, L. K. "Chemistry of the nitric oxide-releasing diazeniumdiolate 
(“nitrosohydroxylamine”) functional group and its oxygen-substituted derivatives" Chemical 
Reviews 2002, 102, 1135-1154. 
(20) Hunter, R. A.; Storm, W. L.; Coneski, P. N.; Schoenfisch, M. H. "Inaccuracies of nitric 
oxide measurement methods in biological media" Analytical Chemistry 2013, 85, 1957-1963. 
(21) Keefer, L. K.; Saavedra, J. E. "Nitrogen-based diazeniumdiolates: Versatile nitric oxide-
releasing compounds for biomedical research and potential clinical applications" Journal of 
Chemical Education 2002, 79, 1427-1434. 
(22) Hrabie, J. A.; Saavedra, J. E.; Roller, P. P.; Southan, G. J.; Keefer, L. K. "Conversion of 
proteins to diazeniumdiolate-based nitric oxide donors" Bioconjugate Chemistry 1999, 10, 838-
842. 
(23) Jeh, H. S.; Lu, S.; George, S. C. "Encapsulation of PROLI/NO in biodegradable 
microparticles" Journal of Microencapsulation 2004, 21, 3-13. 
89 
 
(24) Parzuchowski, P. G.; Frost, M. C.; Meyerhoff, M. E. "Synthesis and characterization of 
polymethacrylate-based nitric oxide donors" Journal of the American Chemical Society 2002, 
124, 12182-12191. 
(25) Nguyen, J. G.; Tanabe, K. K.; Cohen, S. M. "Postsynthetic diazeniumdiolate formation and 
NO release from MOFs" CrystEngComm 2010, 12, 2335-2338. 
(26) Rothrock, A. R.; Donkers, R. L.; Schoenfisch, M. H. "Synthesis of nitric oxide-releasing 
gold nanoparticles" Journal of the American Chemical Society 2005, 127, 9362-9363. 
(27) Stasko, N. A.; Schoenfisch, M. H. "Dendrimers as a scaffold for nitric oxide release" 
Journal of the American Chemical Society 2006, 128, 8265-8271. 
(28) Zhang, H.; Annich, G. M.; Miskulin, J.; Stankiewicz, K.; Osterholzer, K.; Merz, S. I.; 
Bartlett, R. H.; Meyerhoff, M. E. "Nitric oxide-releasing fumed silica particles: Synthesis, 
characterization, and biomedical application" Journal of the American Chemical Society 2003, 
125, 5015-5024. 
(29) Shin, J. H.; Metzger, S. K.; Schoenfisch, M. H. "Synthesis of nitric oxide-releasing silica 
nanoparticles" Journal of the American Chemical Society 2007, 129, 4612-4619. 
(30) Barbe, C.; Bartlett, J.; Kong, L.; Finnie, K.; Lin, H. Q.; Larkin, M.; Calleja, S.; Bush, A.; 
Calleja, G. "Silica particles: A novel drug‐delivery system" Advanced Materials 2004, 16, 1959-
1966. 
(31) Gaikwad, R.; Sokolov, I. "Silica nanoparticles to polish tooth surfaces for caries prevention" 
Journal of Dental Research 2008, 87, 980-983. 
(32) Stöber, W.; Fink, A.; Bohn, E. "Controlled growth of monodisperse silica spheres in the 
micron size range" Journal of Colloid and Interface Science 1968, 26, 62-69. 
(33) Hetrick, E. M.; Shin, J. H.; Stasko, N. A.; Johnson, C. B.; Wespe, D. A.; Holmuhamedov, 
E.; Schoenfisch, M. H. "Bactericidal efficacy of nitric oxide-releasing silica nanoparticles" ACS 
Nano 2008, 2, 235-246. 
(34) Hetrick, E. M.; Shin, J. H.; Paul, H. S.; Schoenfisch, M. H. "Anti-biofilm efficacy of nitric 
oxide-releasing silica nanoparticles" Biomaterials 2009, 30, 2782-2789. 
90 
 
(35) Carpenter, A. W.; Slomberg, D. L.; Rao, K. S.; Schoenfisch, M. H. "Influence of scaffold 
size on bactericidal activity of nitric oxide-releasing silica nanoparticles" ACS Nano 2011, 5, 
7235-7244. 
(36) Lu, Y.; Slomberg, D. L.; Sun, B.; Schoenfisch, M. H. "Shape‐and nitric oxide flux‐
dependent bactericidal activity of nitric oxide‐releasing silica nanorods" Small 2013, 9, 2189-
2198. 
(37) Coneski, P. N.; Schoenfisch, M. H. "Nitric oxide release: Part III. Measurement and 
reporting" Chemical Society Reviews 2012, 41, 3753-3758. 
(38) Van Blaaderen, A.; Van Geest, J.; Vrij, A. "Monodisperse colloidal silica spheres from 
tetraalkoxysilanes: Particle formation and growth mechanism" Journal of Colloid and Interface 
Science 1992, 154, 481-501. 
(39) Van Blaaderen, A.; Kentgens, A. "Particle morphology and chemical microstructure of 
colloidal silica spheres made from alkoxysilanes" Journal of Non-Crystalline Solids 1992, 149, 
161-178. 
(40) Van Blaaderen, A.; Vrij, A. "Synthesis and characterization of monodisperse colloidal 
organo-silica spheres" Journal of Colloid and Interface Science 1993, 156, 1-18. 
(41) Park, S. K.; Kim, K. D.; Kim, H. T. "Preparation of silica nanoparticles: Determination of 
the optimal synthesis conditions for small and uniform particles" Colloids and Surfaces A: 
Physicochemical and Engineering Aspects 2002, 197, 7-17. 
(42) Huang, Y.; Pemberton, J. E. "Synthesis of uniform, spherical sub-100nm silica particles 
using a conceptual modification of the classic LaMer model" Colloids and Surfaces A: 
Physicochemical and Engineering Aspects 2010, 360, 175-183. 
(43) Yoo, J. W.; Yun, D. S.; Kim, H. J. "Influence of reaction parameters on size and shape of 
silica nanoparticles" Journal of Nanoscience and Nanotechnology 2006, 6, 3343-3346. 
(44) Riccio, D. A.; Nugent, J. L.; Schoenfisch, M. H. "Stober synthesis of nitric oxide-releasing 
S-nitrosothiol-modified silica particles" Chemistry of Materials 2011, 23, 1727-1735. 
(45) Yano, K.; Fukushima, Y. "Particle size control of mono-dispersed super-microporous silica 
spheres" Journal of Materials Chemistry 2003, 13, 2577-2581. 
91 
 
(46) DeRosa, F.; Keefer, L. K.; Hrabie, J. A. "Nitric oxide reacts with methoxide" Journal of 
Organic Chemistry 2008, 73, 1139-1142. 
(47) Arulsamy, N.; Bohle, D. S. "Multiplicity control in the polygeminal diazeniumdiolation of 
active hydrogen bearing carbons: Chemistry of a new type of trianionic molecular propeller" 
Journal of the American Chemical Society 2001, 123, 10860-10869. 
(48) Hrabie, J. A.; Citro, M. L.; Chmurny, G. N.; Keefer, L. K. "Carbon-bound 
diazeniumdiolates from the reaction of nitric oxide with amidines" Journal of Organic Chemistry 
2005, 70, 7647-7653. 
92 
 
Chapter 3: Antibacterial Efficacy of Exogenous Nitric Oxide on Periodontal Pathogens 
 
3.1 Introduction 
 Oral care comprises a significant fraction of health care costs in the United States, with 
$104.8 billion devoted to dental services in 2010.1  A considerable portion of these expenses is 
attributed to periodontal disease caused by dental plaque biofilms.  Approximately 30% of the US 
population is afflicted by periodontitis.2  Left unmanaged, periodontitis can result in tooth loss and 
has been associated with increased risk for systemic conditions such as cardiovascular disease and 
stroke.3,4 
 The current “gold standard” non-surgical periodontal treatment is scaling and root planing 
(SRP).  However, even successful treatment via SRP is accompanied by a high probability of 
reinfection, with periodontal surgery to reduce periodontal pockets as a likely treatment outcome.3  
Other non-surgical treatments for periodontal disease, such as the use of chlorhexidine (CHX), 
have undesirable side-effects, including altered taste, discoloration of the mouth, and mucosal 
irritation.5,6  In combination, CHX (0.2% w/w) with SRP does not significantly affect the microbial 
composition compared with SRP alone.  Quirynen et al. suggested that CHX treatment should be 
re-evaluated as an adjunct to periodontal therapy.7  While the use of antibiotics (e.g., minocycline 
and tetracycline) represents a possible complement to SRP, and local drug delivery systems can 
improve clinical and microbial outcomes,8 their systemic use has undesirable side-effects (e.g.,  
antibiotic  resistance, pseudomembranous colitis).9,10  The development of alternative treatments 
for periodontitis thus remains an important area of current oral health care research. 
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 Nitric oxide (NO) is a reactive, gaseous radical produced endogenously during the immune 
response to invading organisms.11  For example, oral mucosal epithelial cells generate NO in 
response to bacteria and pro-inflammatory stimuli initiated upon the deposition of dental plaque.12  
While exogenous NO has been utilized as an antimicrobial agent with no previously observed 
resistance,13,14 the application of NO-releasing scaffolds for the treatment of periodontitis 
represents an unexplored opportunity. 
 The design of macromolecular scaffolds (e.g., dendrimers, silica, polymers) capable of 
storing and delivering biocidal levels of NO is crucial to the application of gaseous NO as an 
antimicrobial therapy.15,16  Previously, we have synthesized N-diazeniumdiolate-modified silica 
and dendrimer scaffolds capable of spontaneous NO release under biological conditions as 
potential in vivo antimicrobial agents.17,18  The antimicrobial activity of such scaffolds was 
demonstrated against several Gram-positive, Gram-negative, and antibiotic-resistant bacteria18,19 
as well as biofilms.20,21  Collectively, this prior work suggests exogenous NO delivered via 
macromolecular NO-release scaffolds may prove useful against dental microbes, including those 
organized within supragingival and subgingival biofilms. 
 Herein, we investigated the bactericidal efficacy of NO-releasing 3-
methylaminopropyltrimethoxysilane (MAP3) silica particles and propylene oxide (PO)-modified 
generation 1 (G1) poly(amidoamine) (PAMAM) dendrimers against cariogenic bacteria 
(Streptococcus mutans and Streptococcus sanguinis) and periodontopathogens (Aggregatibacter 
actinomycetemcomitans and Porphyromonas gingivalis).  The cytotoxicity of the NO-release 
scaffolds to human gingival fibroblasts (HGF-1) was also evaluated and compared with CHX to 
ascertain the therapeutic potential of these materials for oral care.   
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3.2 Materials and Methods 
3.2.1 Synthesis of nitric oxide-release scaffolds 
 We prepared N-diazeniumdiolate NO donor-modified proline by dissolving 2.05 g proline 
and 2.00 g of sodium methoxide in 25 mL methanol.  After brief mixing, this solution was placed 
in a Parr reaction bottle.22  The bottle was purged with argon (Ar) and subsequently pressurized 
with NO gas (10 bar).  After 3 days, the bottle was purged again with Ar, and the solution was 
treated with cold ether to precipitate the N-diazeniumdiolate-modified product.  The NO donor 
(PROLI/NO) was collected by vacuum filtration, washed with cold ether, and stored at -20 oC. 
 Hybrid tetramethyl orthosilicate (TMOS) (Sigma; St. Louis, MO, USA) MAP3 (Gelest; 
Morrisville, PA, USA) particles were synthesized via injection of a solution containing 0.538 mL 
TMOS and 1.68 mL MAP3 into a flask containing 60.1 mL ethanol, 27.8 mL water, and 9.8 mL 
aqueous ammonium hydroxide (30 wt%).17  This solution was stirred for 2 h under ambient 
conditions, and then centrifuged at 2907 x g at 4 oC for 10 min.  After decanting the supernatant, 
the pellet was resuspended in ethanol, centrifuged, and decanted twice more to remove unreacted 
silanes and residual solvent.  The resulting amine-functionalized MAP3 particles (70 mol% 
aminosilane) were dried under vacuum, and a portion (30 mg) suspended in 6 mL 9:1 N,N-
dimethylformamide (DMF):methanol.  This solution was sealed in a Parr bottle containing 50 µL 
sodium methoxide (5.4 M in methanol).  The bottle was flushed with Ar to remove oxygen and 
pressurized to 10 bar with NO.  After 3 d, the bottle was flushed with Ar again to remove unreacted 
NO.  The particles were collected by centrifugation and decanting of the supernatant.  The pellet 
was resuspended in ethanol, centrifuged and decanted twice more to remove residual solvent and 
sodium methoxide.  Particles were dried under vacuum to yield N-diazeniumdiolate NO donor-
modified MAP3 silica and stored in a vacuum-sealed bag at -20 oC until use. 
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 Secondary amine-functionalized G1 PAMAM dendrimers were synthesized by the 
dissolution of primary amine-functionalized G1 dendrimers (100 mg) in methanol (1 mL) with 
39.2 µL propylene oxide (PO).21  After 3 days of constant stirring, the solvent was removed under 
vacuum to yield PO-modified PAMAM dendrimers.  Sodium methoxide (51.8 µL; 5.4 M in 
methanol) was then added to 45 mg of dendrimers in methanol (1 mL), and the resulting solution 
was placed in a Parr reaction bottle, sealed, flushed with Ar, and filled with NO (10 bar).  After 3 
d, the bottle was purged again with Ar to remove unreacted NO.  The NO-releasing G1-PAMAM-
PO dendrimers were stored at -20 oC.   
 
3.2.2 Characterization of nitric oxide release 
 A Sievers 280i Chemiluminescence Nitric Oxide Analyzer (Boulder, CO, USA) was used 
to quantify NO release at 37 oC.23  The NO-releasing material (~1 mg) was added to a flask 
containing 30 mL of deoxygenated phosphate-buffered saline (PBS; pH = 7.4).  Nitrogen was used 
to purge this solution continuously and thus carry liberated NO to the analyzer (80 mL/min flow 
rate).  The NO analysis was conducted in real-time and continued until the NO levels fell below 
10 ppb. 
 
3.2.3 Bacteria-killing assays 
 Streptococcus mutans (ATCC #25715), Streptococcus sanguinis (ATCC #49297), and 
Aggregatibacter actinomycetemcomitans (ATCC #43717) were purchased from the American 
Type Tissue Culture Collection (Manassas, VA, USA).  Porphyromonas gingivalis strain A7463 
was provided by the UNC School of Dentistry (Chapel Hill, NC, USA).  Stock cultures, initially 
stored in 15% (v/v) glycerol in PBS at -80 oC, were grown overnight in brain heart infusion (BHI) 
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broth or Difco anaerobic broth for P. gingivalis.  A 500 µL aliquot of this solution was reinoculated 
into 50 mL fresh broth, incubated at 37 oC, and grown to 108 colony-forming units per milliliter 
(CFU/mL).  S. mutans and S. sanguinis were cultured aerobically.  A. actinomycetemcomitans was 
cultured in a microaerophilic environment (6–16% O2 and 2–10% CO2) in a GasPak EZ Campy 
Container System (Becton, Dickinson and Company; Franklin Lakes, NJ, USA).  P. gingivalis was 
cultured anaerobically in an atmosphere of 5% CO2, 10% H2, and 85% N2.   
 We quantified the antimicrobial activity of the NO-releasing materials against planktonic 
cultures of bacteria by determining the minimum bactericidal concentration (MBC2h) required to 
achieve a 3-log reduction in viability after 2 h.  Bacteria (108 CFU/mL) were resuspended in 
tris(hydroxymethyl)aminomethane phosphate-buffered saline solution (Tris-PBS; pH = 7.4) and 
diluted to 106 CFU/mL.  This bacteria solution was added to vials containing NO-releasing material 
and respective controls, sonicated or vortexed briefly, and incubated at 37 oC with shaking.  After 
2h, these solutions were diluted and spiral-plated on BHI agar or Wilkins-Chalgren agar for P. 
gingivalis.  Agar plates containing S. mutans and S. sanguinis were incubated aerobically for 72 
h.  A. actinomycetemcomitans plates were incubated under microaerophilic conditions for 48 h.  P. 
gingivalis plates were incubated for 96 h under anaerobic conditions.  
 
3.2.4 Cytotoxicity evaluation 
 Human gingival fibroblasts (HGF-1) (ATCC #CRL-2014) were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 10% v/v fetal bovine serum and 1 wt% 
penicillin/streptomycin.  The cells were incubated in 5% v/v CO2 and humidified conditions at 37 
oC.  After reaching confluence, cells were trypsinized and seeded onto a 96-well plate.  The NO-
release scaffolds or controls were added to the wells.  Following incubation for 2 h at 37 oC, the 
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supernatant was aspirated, and a mixture of DMEM, phenazine methosulfate (PMS), and [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (MTS) 
(100/20/1 v/v/v) was added to the wells.  After incubation for an additional 2 h at 37 oC, solutions 
were transferred to a microtiter plate for absorbance measurement at 490 nm.  Cell viability was 
quantified with respect to untreated cells and subtraction of blanks.  The cytotoxicity of 
chlorhexidine was evaluated similarly. 
 
3.3 Results and Discussion 
 This study examined the antimicrobial efficacy of macromolecular NO-release scaffolds 
against 4 microbes affecting oral health (S. mutans, S. sanguinis, A. actinomycetemcomitans, and 
P. gingivalis).  While NO release from macromolecular scaffolds has proven effective against 
Candida, Escherichia, Pseudomonas, and Staphylococcus species,18,19 its efficacy against dental 
microorganisms and the impact of NO-release scaffold on antibacterial activity are unexplored 
topics.  Although prior research has indicated salivary nitrite-derived NO as a means to inhibit 
cariogenic and periodontopathogenic growth,24,25 this work is the first to evaluate the effects of 
exogenous NO delivered via macromolecular scaffolds against periodontopathogens. 
 Nitric oxide-release half-life (t1/2), maximum NO flux ([NO]m), and total NO released over 
2 h (t[NO]2h) were determined for the three NO donor systems (Table 3.1).  Of note, t[NO]2h 
represents the NO dose delivered during the MBC2h bacterial killing assay.  Of the three NO 
donors, N-diazeniumdiolate-modified proline (PROLI/NO) had the largest NO payload (6.29 ± 
0.24 µmol/mg) and fastest NO release (t1/2 = 2.3 ± 0.1 min).  The t[NO]2h and the t[NO] for 
PROLI/NO were equal, since the NO release is exhausted within 10 min.  Compared with 
PROLI/NO, the silica particles released less NO (t[NO]2h = 0.81 ± 0.15 µmol/mg) and did so more  
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Table 3.1 Characterization of nitric oxide-releasing materials.a 
aResults shown for particles (70 mol% MAP3), dendrimers (G1-PAMAM-PO), and the small 
molecule NO donor NO-releasing proline (PROLI/NO).  aValues presented as means ± standard 
deviations for n = 3 or more pooled experiments.  bTotal amount of NO released.  cMaximum NO 
flux achieved.  dTime to release half of the total NO payload.  eTotal NO released after 2 h.   
 
 
 
 
 
 
 
 
 
 
NO-Release        
Scaffold 
t[NO]b       
(µmol/mg) 
[NO]mc        
(ppb/mg) 
t ½d                 
(min) 
t[NO]2he 
(µmol/mg) 
70 mol% MAP3 0.84  ±  0.14 9200  ±  4300 19.8  ±  3.3 0.81  ±  0.15 
G1-PAMAM-PO 0.96  ±  0.11 2900  ±  800 43.8  ±  4.3 0.77  ±  0.11 
Proline 6.29  ±  0.24 370000  ±  11000 2.3  ±  0.1 6.29  ±  0.24 
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slowly (t1/2 = 19.8 ± 3.3 min).  Despite releasing an equivalent amount of NO (t[NO]2h = 0.77 ± 
0.11 µmol/mg) to the silica, the dendrimer system exhibited the slowest NO release (t1/2 = 43.8 ± 
4.3 min).   
 With respect to bactericidal efficacy (MBC2h), a 3-log reduction in viability was observed 
for A. actinomycetemcomitans at 4 mg/mL NO-releasing silica or PROLI/NO (Figure 3.1).  These 
scaffold concentrations correspond to NO doses of 3.2 and 25.2 µmol/mL, respectively.  Less NO-
releasing dendrimer was required for analogous killing (MBC2h = 2 mg/mL; NO dose = 1.5 
µmol/mL).  P. gingivalis proved even more sensitive to NO treatment, with a 3-log reduction in 
viability observed at 0.5, 1, and 2 mg/mL for NO-releasing proline, dendrimers, and silica, 
corresponding to NO doses of 3.1, 0.8, and 1.6 µmol/mL, respectively (Figure 3.1).  In contrast, 
cariogenic Streptococcus species were less susceptible to NO-releasing silica, with no observed 3-
log killing up to 64 mg/mL.  As shown in Figure 3.2, similarly large concentrations of NO-
releasing proline and dendrimers (48 mg/mL) were required to kill S. mutans (NO doses of 301.9 
and 37.0 µmol/mL, respectively).  Likewise, S. sanguinis require 32 and 48 mg/mL PROLI/NO 
and NO-releasing dendrimers, respectively (NO doses = 201.3 and 37.0 µmol/mL). 
 Similar to an earlier study showing enhanced action against Gram-negative species,19 NO 
treatment was highly effective against A. actinomycetemcomitans and P. gingivalis.  The NO-
releasing dendrimers possessed superior bactericidal activity compared with silica, even though 
they released similar amounts of NO (t[NO]2h).  Indeed, less NO was required to eradicate A. 
actinomycetemcomitans (1.5 versus 3.2 µmol/mL for dendrimer and silica, respectively) and P. 
gingivalis (0.8 and 1.6 µmol/mL for dendrimers and silica, respectively) due to enhanced bacterial 
association of the dendritic scaffold.18  Similar concentrations of PROLI/NO were required to kill 
periodontopathogens, albeit at larger NO levels (3.1 and 25.2 µmol/mL for P. gingivalis and    
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Figure 3.1 Bactericidal efficacy of (A) 70 mol% MAP3 particles, (B) G1-PAMAM-PO 
dendrimers, and (C) proline against A. actinomycetemcomitans in Tris-PBS after 2 h.  Bactericidal 
efficacy of (D) 70 mol% MAP3 particles, (E) G1-PAMAM-PO dendrimers, and (F) proline against 
P. gingivalis in Tris-PBS after 2 h. NO-releasing material denoted by rectangles (■) and non-NO-
releasing controls denoted by circles (●).  Error bars signify standard deviation of the mean 
viability (CFU/mL).  For all measurements n = 3 or more pooled experiments.   
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Figure 3.2 Bactericidal efficacy of (A) 70 mol% MAP3 particles, (B) G1-PAMAM-PO 
dendrimers, and (C) proline against S. mutans in Tris-PBS after 2 h.  Bactericidal efficacy of (D) 
70 mol% MAP3 particles, (E) G1-PAMAM-PO dendrimers, and (F) proline against S. sanguinis 
in Tris-PBS after 2 h. NO-releasing material denoted by rectangles (■) and non-NO-releasing 
controls denoted by circles (●).  Error bars signify standard deviation of the mean viability 
(CFU/mL).  For all measurements n=3 or more pooled experiments.   
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A. actinomycetemcomitans, respectively), despite storing and releasing more NO.  This result 
would be expected, since the PROLI/NO produces NO without bacterial association – and thus 
indiscriminately – whereas macromolecular scaffolds associate with bacteria and localize (i.e., 
target) the NO.19  The efficient killing of A. actinomycetemcomitans and P. gingivalis with 
dendrimers or silica illustrates the advantage of macromolecular NO-release scaffolds over small 
molecule NO donors for delivering bactericidal levels of NO. 
 As evidenced by the larger NO-donor scaffold concentrations and NO doses required for 
equivalent killing, S. mutans and S. sanguinis were less sensitive to treatment with NO.  While 
these bacteria are Gram-positive species with a thicker peptidoglycan layer, the substantial 
disparity in bactericidal efficacy relative to the Gram-negative periodontopathogens was surprising 
and has not been previously observed.  Of note, S. mutans makes use of nitrite reductase, an 
enzyme that converts nitrite to NO, to facilitate its survival in nitrite-rich, acidic environments.26  
Gusarov and Nudler reported that NO facilitates bacterial protection against oxidative stress (“NO-
mediated cytoprotection”) in Bacillus subtilis,27 and this may be observed for other Gram-positive 
species.  In this respect, S. mutans and S. sanguinis may tolerate NO due to its role as a metabolite 
rather than a biocidal agent.  
 Both NO-releasing dendrimers and silica showed reductions in human gingival fibroblast 
(HGF-1) viabilities (75 ± 3 and 61 ± 12% compared with untreated cells) at concentrations required 
to kill periodontopathogens (2 and 4 mg/mL, respectively), but only minimally when compared to 
clinical concentrations of chlorhexidine (0.12 and 0.20% (w/w)) (Figure 3.3).  In contrast, 
PROLI/NO was more toxic to HGF-1 at the maximum concentration required to kill 
periodontopathogens (18 ± 2% compared with untreated cells at 4 mg/mL).  This result is attributed 
to both the magnitude (25.2 µmol/mL) and the rapid nature of the NO release from this small 
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Figure 3.3 Cytotoxicity of NO-releasing materials and non-NO-releasing controls at MBC2h 
concentrations (or maximum concentration tested) against HGF-1 cells.  Viability measured as 
metabolically active fibroblasts using MTS and presented as normalized percent relative to 
untreated cells.  Chlorhexidine toxicity shown for clinical doses (0.12 and 0.20% (w/w)).  Of note, 
the numbers after the materials (e.g., 2, 4, 48, and 64) correspond to the MBC data (in mg/mL).  
Error bars represent standard deviation of the mean.  For all values n=4 or more replicate 
measurements.  
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molecule NO donor.  Hetrick et al. noted similar toxicity to L929 murine fibroblasts for PROLI/NO 
concentrations ≥5 mg/mL.19  Likewise, 0.12 and 0.20% (w/w) chlorhexidine (CHX) negatively 
affected HGF-1 viability (17 ± 2 and 22 ± 3% compared with untreated cells, respectively).  As 
expected, the relative cytotoxicity for all NO donor systems was much greater at the concentrations 
required for complete eradication of the cariogenic bacteria (S. mutans and S. sanguinis) due to 
exceedingly large material and NO concentrations. 
 
3.4 Conclusions 
 The sharp disparity in NO susceptibility between the two classes of oral microbes 
investigated suggests the utility of NO-releasing macromolecular scaffolds as potential therapies 
for periodontal disease.  While S. mutans and S. sanguinis are cariogenic, caries-associated 
bacteria, A. actinomycetemcomitans and P. gingivalis are periodontopathogens linked to 
periodontal disease.28  In this manner, NO-releasing macromolecular scaffolds may prove useful 
in killing periodontopathogenic Gram-negative bacteria over Gram-positive cariogenic 
microorganisms.  Although the concept of therapeutics to kill periodontopathogens is appealing, 
methods for delivering antimicrobials locally without fostering antibiotic resistance and substantial 
toxicity to mammalian cells remains elusive.  Macromolecular NO-release scaffolds represent a 
potential strategy for achieving this goal.  Future work must evaluate the antibacterial activity of 
these NO-release scaffolds against other dental microbes to validate the proposed enhanced 
susceptibility of periodontopathogens over cariogenic microbes to NO treatment.  The efficacy of 
these NO-release scaffolds against bacterial biofilms of both periodontopathogens and cariogenic 
microflora must also be examined, since plaque exists as a complex biofilm.  Last, in vivo models 
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of periodontal disease must be used to elucidate the full potential of NO release as an effective 
adjuvant therapy.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
106 
 
3.5 References 
(1) Ebersole, J.; D’Souza, R.; Gordon, S.; Fox, C. "Oral health disparities and the future face of 
America" Journal of Dental Research 2012, 91, 997-1002. 
(2) Kandelman, D.; Arpin, S.; Baez, R. J.; Baehni, P. C.; Petersen, P. E. "Oral health care 
systems in developing and developed countries" Periodontology 2000 2012, 60, 98-109. 
(3) Cobb, C. M. "Microbes, inflammation, scaling and root planing, and the periodontal 
condition" American Dental Hygienists Association 2008, 82, 4-9. 
(4) Sen, S.; Sumner, R.; Hardin, J.; Barros, S.; Moss, K.; Beck, J.; Offenbacher, S. "Periodontal 
disease and recurrent vascular events in stroke/transient ischemic attack patients" Journal of 
Stroke and Cerebrovascular Diseases 2013, 22, 1420-1427. 
(5) Charbonneau, D.; Snider, A. "Reduced chlorhexidine tooth stain coverage by sequential 
administration of monoperoxyphthalic acid in the beagle dog" Journal of Dental Research 1997, 
76, 1596-1601. 
(6) Gürgan, C. A.; Zaim, E.; Bakirsoy, I.; Soykan, E. "Short-term side effects of 0.2% alcohol-
free chlorhexidine mouthrinse used as an adjunct to non-surgical periodontal treatment: A 
double-blind clinical study" Journal of Periodontology 2006, 77, 370-384. 
(7) Quirynen, M.; Mongardini, C.; de Soete, M.; Pauwels, M.; Coucke, W. "The rôle of 
chlorhexidine in the one-stage full-mouth disinfection treatment of patients with advanced adult 
periodontitis. Long-term clinical and microbiological observations" Journal of Clinical 
Periodontology 2000, 27, 578-589. 
(8) Williams, R. C.; Paquette, D. W.; Offenbacher, S.; Adams, D. F.; Armitage, G. C.; Bray, K.; 
Caton, J.; Cochran, D. L.; Drisko, C. H.; Fiorellini, J. P. "Treatment of periodontitis by local 
administration of minocycline microspheres: A controlled trial" Journal of Periodontology 2001, 
72, 1535-1544. 
(9) Radvar, M.; Pourtaghi, N.; Kinane, D. "Comparison of 3 periodontal local antibiotic therapies 
in persistent periodontal pockets" Journal of Periodontology 1996, 67, 860-865. 
(10) Kinane, D.; Radvar, M. "A six-month comparison of three periodontal local antimicrobial 
therapies in persistent periodontal pockets" Journal of Periodontology 1999, 70, 1-7. 
107 
 
(11) DeGroote, M. A.; Fang, F. C. In Nitric Oxide and Infection; Springer, 2002, pp 231-261. 
(12) Carossa, S.; Pera, P.; Doglio, P.; Lombardo, S.; Colagrande, P.; Brussino, L.; Rolla, G.; 
Bucca, C. "Oral nitric oxide during plaque deposition" European Journal of Clinical 
Investigation 2001, 31, 876-879. 
(13) Privett, B. J.; Broadnax, A. D.; Bauman, S. J.; Riccio, D. A.; Schoenfisch, M. H. 
"Examination of bacterial resistance to exogenous nitric oxide" Nitric Oxide 2012, 26, 169-173. 
(14) Schairer, D. O.; Chouake, J. S.; Nosanchuk, J. D.; Friedman, A. J. "The potential of nitric 
oxide releasing therapies as antimicrobial agents" Virulence 2012, 3, 271-279. 
(15) Riccio, D. A.; Schoenfisch, M. H. "Nitric oxide release: Part I. Macromolecular scaffolds" 
Chemical Society Reviews 2012, 41, 3731-3741. 
(16) Carpenter, A. W.; Schoenfisch, M. H. "Nitric oxide release: Part II. Therapeutic 
applications" Chemical Society Reviews 2012, 41, 3742-3752. 
(17) Shin, J. H.; Metzger, S. K.; Schoenfisch, M. H. "Synthesis of nitric oxide-releasing silica 
nanoparticles" Journal of the American Chemical Society 2007, 129, 4612-4619. 
(18) Sun, B.; Slomberg, D. L.; Chudasama, S. L.; Lu, Y.; Schoenfisch, M. H. "Nitric oxide-
releasing dendrimers as antibacterial agents" Biomacromolecules 2012, 13, 3343-3354. 
(19) Hetrick, E. M.; Shin, J. H.; Stasko, N. A.; Johnson, C. B.; Wespe, D. A.; Holmuhamedov, 
E.; Schoenfisch, M. H. "Bactericidal efficacy of nitric oxide-releasing silica nanoparticles" ACS 
Nano 2008, 2, 235-246. 
(20) Hetrick, E. M.; Shin, J. H.; Paul, H. S.; Schoenfisch, M. H. "Anti-biofilm efficacy of nitric 
oxide-releasing silica nanoparticles" Biomaterials 2009, 30, 2782-2789. 
(21) Lu, Y.; Slomberg, D. L.; Shah, A.; Schoenfisch, M. H. "Nitric oxide-releasing amphiphilic 
poly (amidoamine)(PAMAM) dendrimers as antibacterial agents" Biomacromolecules 2013, 14, 
3589-3598. 
 
108 
 
(22) Saavedra, J. E.; Southan, G. J.; Davies, K. M.; Lundell, A.; Markou, C.; Hanson, S. R.; 
Adrie, C.; Hurford, W. E.; Zapol, W. M.; Keefer, L. K. "Localizing antithrombotic and 
vasodilatory activity with a novel, ultrafast nitric oxide donor" Journal of Medicinal Chemistry 
1996, 39, 4361-4365. 
(23) Coneski, P. N.; Schoenfisch, M. H. "Nitric oxide release: Part III. Measurement and 
reporting" Chemical Society Reviews 2012, 41, 3753-3758. 
(24) Silva Mendez, L.; Allaker, R.; Hardie, J.; Benjamin, N. "Antimicrobial effect of acidified 
nitrite on cariogenic bacteria" Oral Microbiology and Immunology 1999, 14, 391-392. 
(25) Allaker, R.; Silva Mendez, L.; Hardie, J.; Benjamin, N. "Antimicrobial effect of acidified 
nitrite on periodontal bacteria" Oral Microbiology and Immunology 2001, 16, 253-256. 
(26) Choudhury, T.; Sato, E.; Inoue, M. "Nitrite reductase in Streptoccocus mutans plays a 
critical role in the survival of this pathogen in oral cavity" Oral Microbiology and Immunology 
2007, 22, 384-389. 
(27) Gusarov, I.; Nudler, E. "NO-mediated cytoprotection: Instant adaptation to oxidative stress 
in bacteria" Proceedings of the National Academy of Sciences of the United States of America 
2005, 102, 13855-13860. 
(28) Silva, B. R. d.; Freitas, V. A. A. d.; Nascimento-Neto, L. G.; Carneiro, V. A.; Arruda, F. V. 
S.; Aguiar, A. S. W. d.; Cavada, B. S.; Teixeira, E. H. "Antimicrobial peptide control of 
pathogenic microorganisms of the oral cavity: A review of the literature" Peptides 2012, 36, 315-
321. 
 
 
 
 
109 
 
Chapter 4: Kinetic-Dependent Bactericidal Efficacy of Nitric  
Oxide-Releasing Silica Nanoparticles against Oral Pathogens 
 
4.1 Introduction 
 Due to stability and tolerability by mammalian cells,1-3 silica particles are employed as 
abrasive scouring agents in toothpastes to facilitate the removal of bacteria.  Recent evidence 
suggests that polishing with nanoparticles versus micron-sized silica helps decrease the surface 
roughness of teeth and further lessens the strength of bacterial adhesion, making Streptococcus 
mutans removal easier.4  Although effective at reducing overall bacterial counts, silica 
nanoparticles are not inherently antimicrobial and thus dental plaque biofilms still form.  Other 
materials including fibers, gels, polymers, and microspheres modified to release antibiotics (e.g., 
minocycline, doxycycline, and tetracycline) have demonstrated promise for the treatment of oral 
diseases.5,6  Unfortunately, these scaffolds are less suitable for the physical removal of plaque-
forming bacteria.  While local drug delivery systems may limit the risk of systemic side effects 
(e.g., pseudomembranous colitis),6,7 the overuse of antibiotics fosters antibiotic-resistant 
pathogens.8  Therefore, the combination of silica (as a polishing agent) with new antibacterial 
agents that do not foster bacterial resistance could potentially lead to improved therapeutics for 
treating periodontal disease and dental caries that are easily implemented into existing dental 
hygiene practices (i.e., teeth brushing).   
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Nitric oxide (NO) is a gaseous, free radical produced endogenously during the immune 
response to invading organisms.9  In oral biology, both bacteria and pro-inflammatory stimuli 
present in dental plaque biofilms elicit the generation of NO from oral mucosal epithelial cells.10  
The antibacterial activity of NO is attributed to reactive byproducts causing oxidative and 
nitrosative stress on bacteria.  For example, NO reacts with superoxide to form peroxynitrite, 
which elicits significant membrane damage via lipid peroxidation, while reaction with oxygen 
produces dinitrogen trioxide, a nitrosative species that disables protein function.11  With broad-
spectrum activity and no observed bacterial resistance to date,12,13 the delivery of exogenous NO 
is a promising antibacterial for oral care.  Although NO produced via the acidification of nitrite 
has bactericidal properties against cariogenic14 and periodontopathogenic bacteria,15 precise 
control over NO generation is pivotal in designing effective antibacterial delivery systems.1,16 
Shin et. al first reported the Stöber17 synthesis of hybrid NO-releasing silica nanoparticles 
of varying size (20–500 nm).18  The aminosilane composition (10–87 mol%) of the silica 
nanoparticles was tunable, which enabled a thorough evaluation of NO’s utility against Gram-
positive, Gram-negative, and fungal biofilms.18,19  Subsequent research has focused on studying 
the physicochemical properties (e.g., size, shape, and release kinetics) of NO donor-modified silica 
nanoparticles to maximize bactericidal efficacy.  Carpenter et al. observed that ~50 nm NO-
releasing silica particles were more effective at killing bacteria than larger particles (e.g., 100 and 
200 nm) due to enhanced diffusion and faster bacteria-particle association.20  Lu et al. described 
the synthesis of NO-releasing silica rods, noting improved bactericidal activity for oblong over 
spherical particles due to increased bacteria/particle surface contact and intracellular NO 
delivery.21  In the same study, a greater initial flux of NO showed improved killing, suggesting 
that faster NO-release kinetics may enhance NO’s antibacterial activity against Pseudomonas 
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aeruginosa.21  To date, the antibacterial activity of NO-releasing silica nanoparticles as a function 
of NO-release kinetics has not been systematically evaluated, particularly against oral pathogens.    
Herein, we investigated the influence of NO-release kinetics on bactericidal efficacy 
against common periodontopathogens independent of particle size and NO-release totals.  
Comparatively, the kinetic-dependent killing of a cariogenic strain was also examined using a 
single NO-releasing silica particle system with greater NO-release totals.      
 
4.2 Materials and Methods 
 Tetramethyl orthosilicate (TMOS), trypsin, penicillin streptomycin (PS), phenazine 
methosulfate (PMS), 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium inner salt (MTS), Dulbecco’s modified Eagle’s medium (DMEM), 
phosphate buffered saline (PBS) for cell culture, and fetal bovine serum (FBS) were purchased 
from Sigma-Aldrich (St. Louis, MO).   3-methylaminopropyltrimethoxysilane (MAP3), N-(6-
aminohexyl)aminopropyltrimethoxysilane (AHAP3), and N-(2-aminoethyl)-3-
aminopropyltrimethoxysilane (AEAP3) were obtained from Gelest (Morrisville, PA).  Anhydrous 
methanol (MeOH), N,N-dimethylformamide (DMF), and sodium methoxide (5.4 M in MeOH) 
were purchased from Acros Organics (Geel, Belgium).  Ethanol (EtOH), ammonium hydroxide 
(30 wt%), Tris(hydroxymethyl)aminomethane (Tris), and Tris hydrochloride were purchased from 
Fisher Scientific (Fair Lawn, NJ).  Pure nitric oxide (NO) gas (99.5%) was purchased from Praxair 
(Sanford, NC).  Nitrogen (N2), argon (Ar), carbon dioxide (CO2), biological atmosphere mixture 
(5% CO2, 10% H2, 85 % N2), and NO calibration (26.81 ppm, balance N2) gases were acquired 
from National Welders (Raleigh, NC).  4,5-Diaminofluorescein diacetate (DAF-2 DA) was 
purchased from Calbiochem (San Diego, CA).  Brain heart infusion (BHI) broth, BHI agar, 
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Wilkins-Chalgren agar, and anaerobe broth were obtained from Becton, Dickinson, and Company 
(Sparks, MD).  Streptococcus mutans (ATCC #25715), Aggregatibacter actinomycetemcomitans 
(ATCC #43717), and human gingival fibroblasts (HGF-1) (ATCC #CRL-2014) were purchased 
from the American Type Culture Collection (Manassas, VA).  Porphyromonas gingivalis (strain 
A7436) was provided by the UNC Dental School.  Distilled water was purified to a resistivity of 
18.2 MΩ and a total organic content of <6 ppb using a Millipore Milli-Q Gradient A-10 system 
(Bedford, MA).  All other solvents and reagents were analytical grade and used as received. 
 
4.2.1  Synthesis of nitric oxide-releasing silica particles  
 The Stöber co-condensation of aminosilanes with alkoxysilanes to create secondary amine-
modified silica particles has been reported previously.18  Briefly, hybrid particles were synthesized 
by combining TMOS with an aminosilane (MAP3, AHAP3, AEAP3) and bolus injection of the 
resulting silane mixture into a flask containing water (27.84 mL), ammonium hydroxide (9.8 mL), 
and EtOH as a co-solvent to a total volume of 100 mL.  After stirring for 2 h under ambient 
conditions, the particles were collected via centrifugation (2907 x g; 4 oC; 10 min) and decanting 
the supernatant.  The pellet was resuspended in EtOH, centrifuged, and decanted twice more to 
remove unreacted silanes and residual solvent.  To achieve different particle compositions (i.e., 50 
and 70 mol% MAP3, 60 mol% AHAP3, and 80 mol% AEAP3), the total silane concentration (0.12 
M for MAP3 and AHAP3; 0.16 M for AHAP3) for each particle system was held constant while 
varying the mol% aminosilane (balance TMOS).  For example, 50 mol% MAP3 particles were 
prepared by mixing 1.20 mL of MAP3 and 0.90 mL of TMOS.   
The resulting secondary amine-functionalized silica particles were dried under vacuum.  A 
portion (30 mg) of the particles was suspended in 6 mL 9:1 DMF:MeOH with 25 or 50 µL of 
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NaOMe.  This solution was sealed in a Parr reaction bottle, flushed briefly with Ar three times, 
and followed by three longer (10 min) purges with Ar to remove oxygen before being pressurized 
to 10 bar NO.  After 3 d of constant stirring, the Ar purging process was repeated to remove 
unreacted NO before opening the reaction vessel to ambient conditions.  Particles were then 
collected via centrifugation (2907 x g; 4 oC; 10 min) and decanting of the supernatant.  The pellet 
was resuspended in EtOH, centrifuged and decanted twice more to remove residual solvent and 
NaOMe.  The resulting N-diazeniumdiolate NO donor-modified silica particles were dried under 
vacuum for 2 h prior to storage in a vacuum-sealed freezer bag at -20 oC until further use.  
 
4.2.2  Hybrid particle characterization 
 Particle size (i.e., hydrated diameter) and monodispersity were measured by dynamic light 
scattering (DLS) using a Malvern Instruments Zetasizer Nano (Worcestershire, UK).  Samples 
were suspended in water at either 0.1 or 0.2 mg/mL, and sonicated for 20 min prior to analysis at 
room temperature.  Zeta potential measurements were performed at the same concentrations but 
using Tris-PBS (pH = 7.4) or PBS (pH = 6.4) as the dispersant.  Particle morphologies and sizes 
were evaluated using a Hitachi S-4700 Scanning Electron Microscope (SEM; Chapel Hill 
Analytical Nanofabrication Laboratory) and ImageJ software.  The concentration of aminosilane 
was quantified as nitrogen wt% using a Perkin Elmer 2400 Series II CHNS/O Elemental Analyzer 
operated in CHN mode (Waltham, MA).  
 
4.2.3  Characterization of nitric oxide release 
  Real-time NO release was measured at 37 oC using a Sievers 280i Chemiluminescence 
Nitric Oxide Analyzer (NOA; Boulder, CO) to quantify NO-release kinetics (i.e., half-life).22  
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Briefly, the NO-releasing material (~1 mg) was added to a flask containing 30 mL of deoxygenated 
phosphate buffered saline (PBS; pH = 7.4 or 6.4).  The flask was purged continuously with N2 at 
80 mL/min to carry liberated NO to the analyzer.  Analysis was terminated when NO levels 
decreased to <10 ppb/mg.  
 
4.2.4  Bactericidal efficacy of NO-releasing silica nanoparticles  
 S. mutans was cultured aerobically.  A. actinomycetemcomitans was cultured in a 
microaerophilic environment (6–16% oxygen and 2–10% carbon dioxide) produced by a GasPak 
EZ Campy Container System (Becton, Dickinson, and Company; Franklin Lakes, NJ).  P. 
gingivalis was cultured anaerobically in 5% CO2, 10% H2, and 85 % N2 using a Coy Laboratory 
Products anaerobic chamber (Grass Lake, MI).  Initially stored in 15% (v/v) glycerol in PBS at -
80 oC, bacterial cultures were grown overnight in BHI broth at 37 oC or Difco anaerobe broth (P. 
gingivalis).   A 500 µL aliquot of this solution was reinoculated into 50 mL of fresh broth, 
incubated at 37 oC, and grown to 108 colony-forming units per milliliter (CFU/mL) as determined 
by optical density (OD) at 600 nm.  This bacteria solution was then pelleted via centrifugation 
(2355 x g) for 10 min, resuspended in distilled water, and diluted to 106 CFU/mL in Tris-PBS (pH 
= 7.4) with 5 or 1% (v/v) broth for periodontopathogens and S. mutans, respectively.  Nitric oxide’s 
antibacterial activity on S. mutans was also tested in PBS (pH = 6.4), with 5% BHI (v/v).  Bacteria 
solutions were then added to vials containing either NO-releasing or control (non-NO-releasing) 
silica, sonicated to disperse particles, and incubated aerobically at 37 oC with moderate shaking 
under static growth conditions.  After 2 h, these solutions were diluted and spiral-plated using an 
Eddy Jet spiral plater (IUL; Farmingdale, NY) on BHI agar or Wilkins-Chalgren agar (P. 
gingivalis) and incubated at 37 oC under the aforementioned environmental conditions.  Viable 
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colonies were enumerated on agar plates using a Flash and Go colony counter (IUL; Farmingdale, 
NY).  The concentration resulting in a 3-log reduction in bacterial viability to below 2.5 x 103 
CFU/mL (the limit of detection for this plating method)23 was determined to be the minimal 
bactericidal concentration (MBC2h).         
 
4.2.5  Confocal microscopy for intracellular nitric oxide detection 
 A. actinomycetemcomitans and S. mutans were cultured as described above and diluted to 
106 CFU/mL in Tris-PBS (pH 7.4) containing 5% BHI broth and 10 µM DAF-2 DA.  S. mutans 
was also diluted to 106 CFU/mL in PBS (pH 6.4) containing 5% BHI broth and 10 µM DAF-2 
DA.  Aliquots of the bacteria solutions were incubated in a glass bottom confocal dish (MatTek 
Corporation; Ashland, MA) for 45 min at 37 °C.  A Zeiss 510 Meta inverted laser scanning 
confocal microscope with a 488 nm Ar excitation laser (30.0 mW, 2.0% intensity) and a 505–530 
nm band-pass filter was used to obtain DAF-2 (green) fluorescence images.  Both bright field and 
fluorescence images were collected using a N.A. 1.2 C-Apochromat water immersion lens with a 
40x objective.  Solutions of 50 mol% MAP3, 60 mol% AHAP3, and 80 mol% AEAP3 NO-
releasing particles (2.0 mg/mL) in 1.5 mL Tris-PBS (containing 10 µM DAF-2 DA) were added 
to 1.5 mL of the A. actinomycetemcomitans bacterial suspension in the glass confocal dish to 
achieve a final concentration of 1.0 mg/mL.  Solutions of 70 mol% MAP3 NO-releasing particles 
(0.75 mg/mL) in 1.5 mL pH 7.4 Tris-PBS or 1.5 mL pH 6.4 PBS (containing 10 µM DAF-2 DA) 
were added to 1.5 mL of the S. mutans bacterial suspension in the glass confocal dish to achieve a 
final concentration of 0.25 mg/mL.  Images were collected every 5 min to observe the changes in 
intracellular NO concentration over time.  Of note, the fluorescence signal was color inverted for 
clarity.  Confocal micrographs of S. mutans were noise filtered with Matlab (Natick, MA) using a 
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background subtraction threshold value equal to the average background pixel intensity.  The 
resulting total fluorescence signal density was then summed for the image.   
 
4.2.6  In vitro cytotoxicity 
Human gingival fibroblasts (HGF-1) were grown in DMEM supplemented with both 10% 
(v/v) FBS and 1 wt% PS, and incubated at 37 oC under humidified conditions in 5% CO2 (v/v).  
After reaching 80% confluency, cells were trypsinized, seeded onto a tissue culture-treated 96-
well plate, and incubated again at 37 oC.  Solutions of NO-releasing and control silica particles in 
DMEM were added to the cells.  The supernatant was aspirated to remove particles following 
incubation for 2 h at 37 oC.  A DMEM, PMS, and MTS solution (120 µL; 100/20/1 v/v/v) was 
then added to the wells.  After incubation for an additional 2 h at 37 oC, the solutions were 
transferred to a new microtiter plate without cells.  A Thermoscientific Multiskan EX plate reader 
(Waltham, MA) was used to measure the absorbance at 490 nm.  The absorbance measurements 
were adjusted by subtracting blanks (i.e., DMEM/PMS/MTS without cells).  Cell viability was 
then quantified relative to untreated cells.     
 
4.3 Results and Discussion 
 We have previously reported the synthesis of hybrid silica nanoparticles capable of NO 
release,18 with proven antibacterial and anti-biofilm activity against Gram-positive and Gram-
negative bacteria.19,24  Subsequent work evaluated the effects of size and shape on the bactericidal 
efficacy of NO-releasing silica nanoparticles against Pseudomonas aeruginosa.20,21  In the present 
study, we synthesized NO-releasing silica nanoparticles of varying aminosilane identity and 
composition (50 mol% MAP3, 60 mol% AHAP3, and 80 mol% AEAP3) to investigate the role of 
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NO-release half-life on the killing of periodontal pathogens.  For clarity, the particle systems are 
hereafter referred to as MAP3, AHAP3, and AEAP3. 
 
4.3.1  Nitric oxide-releasing silica nanoparticle characterization 
 Hybrid alkoxysilane/aminosilane silica nanoparticles were synthesized via the Stöber 
method.17  Through careful variation of the synthetic reaction parameters, MAP3, AHAP3, and 
AEAP3 silica nanoparticles were produced to have similar geometric diameters (~150 nm) and a 
high degree of monodispersity, as indicated by the low polydispersity index (PDI) values (≤0.06; 
Table 4.1).  Maintaining a constant size was crucial as this parameter has been shown to influence 
bactericidal efficacy.20  Successful incorporation of the aminosilanes within the silica 
nanoparticles was confirmed via CHN elemental analysis (Table 4.1).  As expected, the nitrogen 
wt% increased with increasing mol% aminosilane precursor used for the particle synthesis (3.42, 
4.28, and 5.83 wt% for MAP3, AHAP3, and AEAP3, respectively).  The positively charged (i.e., 
protonated) surface amines of the particles resulted in positive zeta potentials, dependent on 
aminosilane identity (Table 4.1).  In Tris-PBS (pH = 7.4), MAP3 and AEAP3 particles were 
characterized as having similar zeta potentials (~20 mV), while AHAP3 particles exhibited a 
greater positive surface charge (31.4 mV).  The ability to tune both the identity and degree of silica 
nanoparticle aminosilane functionalization while maintaining constant geometric diameters 
enabled the decoupling of particle size-mediated killing from NO release and scaffold surface 
charge.  
 The kinetics of proton-initiated N-diazeniumdiolate decomposition from aminosilane NO 
donors is dependent on structure.18  As such, MAP3, AHAP3, and AEAP3 NO-release was 
characterized in PBS (pH = 7.4; 37 oC) using a chemiluminescent NO analyzer to obtain  
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Table 4.1 Silica nanoparticle characterization.a 
aResults presented as mean ± standard deviation for n = 3 or more pooled experiments.   bGeometric 
diameter estimated using SEM and ImageJ software.  cHydrodynamic diameter and particle PDI 
measured in water using DLS.  dZeta potential measured using DLS in Tris-PBS (pH = 7.4).    
eQuantified using CHN elemental analysis.  
 
 
 
 
 
 
 
 
 
Aminosilane 
Diameterb        
(nm) 
Diameterc        
(nm) 
PDIc 
Zeta Potentiald 
(mV) 
Nitrogen 
wt%e 
MAP3 166 ± 14 197 ± 7 0.04 ± 0.02 20.9 ± 1.8 3.42 ± 0.17 
AHAP3 174 ± 15 239 ± 14  0.05 ± 0.02 31.4 ± 2.5 4.28 ± 0.07 
AEAP3 125 ± 13 148 ± 9 0.06 ± 0.02 18.3 ± 1.1 5.83 ± 0.17 
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NO-release totals, 2 h NO-release totals, and NO-release kinetics (i.e., half-lives).22  As shown in 
Table 4.2, the total NO release for the MAP3, AHAP3, and AEAP3 particles was 0.22, 0.25, and 
0.39 µmol/mg, respectively.  Of importance, the 2 h NO-release totals were equivalent (~0.20 
µmol/mg) across all three particle systems and representative of the NO concentration delivered 
during the 2 h bacteria killing assays.  The NO-release half-lives were also similar for MAP3 and 
AHAP3 (~32 min), but significantly longer for AEAP3 (112.5 min) due to N-diazeniumdiolate 
stabilization via hydrogen bonding with neighboring cationic amines on the AEAP3 aminosilane 
scaffold.25  The bactericidal efficacy of MAP3 and AEAP3 was thus compared as a function of 
NO-release kinetics, independent of particle size, scaffold surface charge, and 2 h NO-release 
totals.  The influence of scaffold particle charge on the antibacterial action of NO-releasing silica 
nanoparticles was compared between MAP3 (20.9 mV) and AHAP3 (31.4 mV), independent of 
NO-release kinetics.  Lastly, we also evaluated the importance of increased positive scaffold 
surface charge (AHAP3) versus extended NO-release kinetics (AEAP3) on periodontopathogen 
killing.          
 
4.3.2  Kinetic-dependent killing of periodontopathogens with NO-releasing particles  
 To study the role of NO-release kinetics and particle surface charge on bactericidal 
efficacy, 2 h bacteria killing assays were conducted against periodontopathogens in Tris-PBS (pH 
= 7.4; 37 oC).  As expected from our previous work,26 both A. actinomycetemcomitans and P. 
gingivalis were readily susceptible to NO, with bactericidal NO doses of <10 µmol/mL (Figure 
4.1).  However, we also observed differences in the bacteria killing efficiency dependent on both 
the NO-release kinetics and surface charge of the particles.  For example, decreased minimum  
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Table 4.2 Characterization of NO-releasing silica particles in PBS (pH = 7.4 at 37 oC) by means 
of a chemiluminescent nitric oxide analyzer.a   
aResults shown for 50 mol% MAP3, 60 mol% AHAP3, and 80 mol% AEAP3 NO-releasing silica 
particles and presented as mean ± standard deviation for n = 3 or more pooled experiments.  bTotal 
amount of NO released.  cMaximum NO flux achieved.  dTime to release half of total NO payload.  
eTotal amount of NO released after 2 h.     
 
 
 
 
 
 
 
 
 
NO Release  
Scaffold      
t[NO]b       
(µmol/mg) 
[NO]mc              
(ppb/mg) 
t ½d                      
(min) 
t[NO]2he      
(µmol/mg) 
MAP3 0.22  ±  0.04 900  ±  300 31.6  ±  6.7 0.19  ±  0.04 
AHAP3 0.25  ±  0.05 1700  ±  1000 33.8  ±  5.5 0.21  ±  0.04 
AEAP3  0.39  ±  0.05 1400  ±  200 112.5  ±  18.0 0.20  ±  0.02 
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Figure 4.1 Bactericidal efficacy of (A) 50 mol% MAP3 particles, (B) 60 mol% AHAP3 particles, 
and (C) 80 mol% AEAP3 particles against A. actinomycetemcomitans in Tris-PBS (pH = 7.4) after 
2 h.  Bactericidal efficacy of (D) 50 mol% MAP3 particles, (E) 60 mol% AHAP3 particles, and 
(F) 80 mol% AEAP3 particles against P. gingivalis in Tris-PBS (pH = 7.4) after 2 h.  NO-releasing 
material denoted by rectangles (■) and non-NO-releasing controls denoted by circles (●).  Error 
bars signify standard deviation of the mean bacterial viability (CFU/mL).  For all measurements n 
= 3 or more pooled experiments.   
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bactericidal concentrations (MBC2h) were observed for AHAP3 over MAP3 particles against both 
A. actinomycetemcomitans (32 versus 48 mg/mL, respectively) and P. gingivalis (16 versus 32 
mg/mL, respectively).  Due to the similar NO-release half-lives (~32 min) of these two systems, 
the improved bactericidal efficacy of AHAP3 was postulated to be a function of the increased 
particle surface charge (31.4 versus 20.9 mV for AHAP3 and MAP3 particles, respectively).  
Greater positive surface charge enhances the particle-bacteria association,27 and most likely 
increases the buildup of intracellular NO and thus NO-mediated death.  Confocal microscopy and 
the use of a fluorescent probe DAF-2 DA (to visualize intracellular NO levels) confirmed greater 
NO delivery to A. actinomycetemcomitans from AHAP3 versus MAP3 particles over a 30–120 
min window (Figure 4.2).  In contrast, intracellular NO from the MAP3 particle system was 
observed only after 120 min.  The improved antibacterial activity of NO-releasing AHAP3 over 
MAP3 particles is thus attributed to the more efficient delivery of NO. 
 The most effective killing of periodontopathogens was observed for NO-releasing AEAP3 
particles (Figure 1).  Indeed, the minimum bactericidal concentration (MBC2h) for NO-releasing 
AEAP3 was 8 mg/mL against both periodontopathogens, corresponding to a bactericidal NO dose 
of 1.6 µmol/mL.  This NO dose is reduced from that of NO-releasing MAP3 (9.1 and 6.1 µmol/mL 
of NO to kill A. actinomycetemcomitans and P. gingivalis, respectively).  We hypothesize that the 
extended NO-release kinetics (i.e., half-lives) characteristic of AEAP3 (112.5 min) compared to 
MAP3 (31.6 min) particles facilitates the enhanced killing.  As shown in Figure 4.2, intracellular 
NO fluorescence was observed for the AEAP3 particle system after only 30 min of exposure to A. 
actinomycetemcomitans compared to MAP3, which required 120 min for any fluorescence to be 
seen.  Furthermore, the intracellular NO from AEAP3 increased to a maximum at 60 min before 
decreasing at 120 min coinciding with outer membrane decomposition and bacterial death.24,28 
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Figure 4.2 Confocal microscopy images of A. actinomycetemcomitans exposed to 1 mg/mL NO-
releasing silica nanoparticles (50 mol% MAP3, 60 mol% AHAP3, and 80 mol% AEAP3) after (A) 
30 min, (B) 60 min, and (C) 120 min of particle exposure.  DAF-2 fluorescence is depicted as 
black in this image for clarity and represents intracellular NO concentrations. 
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The antibacterial activity of NO donor-modified AHAP3 and AEAP3 particles were 
compared to evaluate the relative importance of increased positive particle surface charge versus  
extended NO-release kinetics for enhancing the bactericidal efficacy of NO-releasing silica 
particles.  Despite the decreased particle surface charge for AEAP3 (18.3 mV) versus AHAP3 
(31.4 mV) particles, the antibacterial action of the NO-releasing AEAP3 (MBC2h = 8) was 
enhanced over AHAP3 (MBC2h ≥16 mg/mL).  The decreased minimum bactericidal concentration 
for NO-releasing AEAP3 suggests that extended NO-release kinetics may be more beneficial for 
killing periodontopathogens than a greater positive particle surface charge and enhanced particle-
bacteria association.  Confocal microscopy confirmed more efficient NO delivery to A. 
actinomycetemcomitans from NO-releasing AEAP3 versus AHAP3 particles (Figure 4.2).  After 
only 30 min of exposure, intracellular NO was observable for both NO-releasing particle systems.  
Of note, the fluorescent signal intensity was greater for the NO-releasing AEAP3 particles at 60 
min, indicating more accumulation of intracellular NO from AEAP versus AHAP3 particles.  The 
fluorescence signal associated with the AHAP3 particles continued to rise up to 120 min, 
indicating the bacteria are able to handle this NO payload.  In contrast, the NO-releasing AEAP3 
particles deliver bactericidal levels of NO within 120 min resulting in cell death.24,28  The 
visualization of intracellular NO concentrations confirms the benefit of slower NO-release kinetics 
over greater (positive) particle surface charge for enhancing the bactericidal action of 
macromolecular NO-release scaffolds against periodontopathogens.  The combination of extended 
NO-release kinetics and greater positive surface charge might further optimize 
periodontopathogen killing. 
The improvement in the antibacterial activity of NO-releasing silica against 
periodontopathogens with extended NO-release kinetics was somewhat surprising as it contradicts 
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previous reports.  For example, Lu et al. observed that a greater initial NO-release flux and more 
rapid NO-release kinetics enhanced the bactericidal efficacy of silica-based NO release against P. 
aeruginosa.21  Of importance, P. aeruginosa utilizes the enzyme nitric oxide reductase (NOR) as 
a defense against NO-based host immunity.29  As NOR functions as an NO detoxification 
mechanism, it successfully mitigates low concentrations of intracellular NO.  Under such 
conditions, larger instantaneous NO concentrations are required to overload protective processes 
and elicit NO-mediated killing.  Conversely, A. actinomycetemcomitans and P. gingivalis do not 
possess these anti-oxidative pathways and are unable to effectively eliminate intracellular NO.  
Rather, NO accumulates within the bacteria over time, without the need for a substantial 
instantaneous NO concentration to induce NO-mediated cellular damage.  Nitric oxide-releasing 
silica particles that can associate with bacteria prior to releasing a majority of their NO payload 
(slow NO-releasing AEAP3 particles) more effectively deliver bactericidal levels of NO than fast 
NO-releasing systems (MAP3 and AHAP3 particles) that release substantial amounts of NO prior 
to association with bacteria.  The instantaneous NO concentration appears to be less critical for 
killing periodontal pathogens than total intracellular NO delivered over time.  The benefit of 
extended NO-release kinetics for more effective periodontopathogen killing may influence the 
design of NO-releasing therapeutics for periodontal diseases treatments. 
 
4.3.3  In vitro cytotoxicity 
 Human gingival fibroblasts (HGF-1) were used to evaluate the cytotoxicity of NO-
releasing and control silica particles.  As shown in Figure 4.3, the toxicity of control particles 
increased (i.e., decreased cell viability) as a function of the silica concentration.  For the AHAP3 
and MAP3 particle systems, NO release further decreased cell viability (31 and 21% relative to  
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Figure 4.3 Cytotoxicity of NO-releasing and control silica particles against HGF-1 human gingival 
fibroblasts at the greatest MBC2h values to kill periodontopathogens.  The concentrations to kill A. 
actinomycetemcomitans were 8, 32, and 48 mg/mL for 80 mol% AEAP3, 60 mol% AHAP3, and 
50 mol% MAP3, respectively.  Viability measured as metabolic activity versus untreated cells.  
Error bars represent standard deviation of the mean.  For all values, n = 4 replicate measurements.  
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untreated cells).  Of note, NO release for the AEAP3 system improved HGF-1 viability.  The 
ability of HGF-1 cells to tolerate low instantaneous levels of intracellular NO, such as those 
provided by AEAP3 particles, is attributed to the enzymatic breakdown of superoxide (O2
-) by 
superoxide dismutase, an enzyme that limits the formation of reactive NO byproducts and 
concomitantly mitigates the nitrosative and oxidative stress associated with NO-mediated killing.30  
The increase in cell viability is likely the result of NO stimulating cell growth as reported 
previously.31-33  The antibacterial characteristics and low cytotoxicity of the NO-releasing AEAP3 
system warrants further investigation into slow NO-releasing silica-based materials as periodontal 
therapeutics.  Increasing the total NO payload while maintaining slow release kinetics may prove 
optimal in the clinical implementation of NO-based oral therapeutics. 
 
4.3.4  Kinetic-dependent killing of Streptococcus mutans with NO-releasing particles    
 We previously reported reduced sensitivity of S. mutans to NO treatment compared to 
periodontopathogens.26  Even increasing the NO storage for the most rapid NO-releasing particle 
system (i.e., MAP3) to ~1 µmol/mg did not influence or enhance S. mutans killing (Figure 4.4).  
S. mutans is a unique pathogen that generates NO from nitrite via nitrite reductase to protect itself 
in nitrite-rich acidic environments such as the mouth.26,34  Clearly S. mutans possesses a 
mechanism to mitigate intracellular NO, thus limiting the antibacterial activity of both NO and its 
reactive byproducts.  We hypothesized that faster NO release might overload this protective 
mechanism and facilitate S. mutans killing.  To accelerate the NO-release kinetics of MAP3, NO-
release characterization and bacterial killing assays were conducted at lower pH (6.4). 
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Figure 4.4 Bactericidal efficacy of 70 mol% MAP3 particles against S. mutans in (A) Tris-PBS 
(pH = 7.4) and (B) PBS (pH = 6.4) after 2 h exposure.  NO-releasing material denoted by rectangles 
(■) and non-NO-releasing controls denoted by circles (●).  Error bars signify standard deviation 
of the mean bacterial viability (CFU/mL).  For all measurements n = 3 or more pooled experiments. 
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Table 4.3 Characterization of MAP3 NO-releasing silica particles in PBS (37 oC) at different pH 
values (7.4 and 6.4) using a chemiluminescent nitric oxide analyzer.a   
aResults shown for 70 mol% MAP3 NO-releasing particles and presented as mean ± standard 
deviation for n = 3 or more pooled experiments.  bTotal amount of NO released.  cMaximum NO 
flux achieved.  dTime to release half of total NO payload.  eTotal amount of NO released after 2 h.     
 
 
 
 
 
 
 
 
 
pH 
t[NO]b       
(µmol/mg) 
[NO]mc              
(ppb/mg) 
t ½d                      
(min) 
t[NO]2he      
(µmol/mg) 
7.4 0.84  ±  0.14 9200  ±  4300 19.8  ±  3.3 0.81  ±  0.15 
6.4 0.95  ±  0.17 25800  ±  7500 4.5  ±  0.2 0.95  ±  0.17 
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As expected, MAP3 NO-release kinetics were significantly enhanced at pH 6.4 because 
the NO donor system (i.e., N-diazeniumdiolate) decomposes more rapidly with increasing proton 
concentration (Table 4.3).  Indeed, the NO-release properties included a greater initial NO flux 
(9200 to 25800 ppb/mg) and shorter half-life (19.8 to 4.5 min).  The zeta potential for MAP3 
particles at pH 6.4 (26.3 mV) also indicated a greater positive charge, which would be expected 
given that the NO donor precursors would be protonated to a larger extent at lower pHs.  This 
combination (i.e., faster NO release and positive surface charge) resulted in S. mutans killing (3-
log) at pH 6.4 with 32 mg/mL MAP3 particles.  As shown in Figure 4.5, confocal microscopy 
confirmed more efficient NO delivery at this pH.  For example, greater intracellular NO levels 
were observed at pH 6.4 compared to pH 7.4, as evidenced by a larger DAF-2 fluorescence 
intensity at 60 min. 
 
4.4 Conclusions 
 Our study details the synthesis of ~150 nm NO-releasing silica nanoparticles with tunable 
NO-release kinetics and their antibacterial activity.  Slower NO-release kinetics enhanced the 
bactericidal efficacy of NO-releasing silica particles against periodontopathogens while only 
minimally impacting human gingival fibroblast viability.  The enhanced antibacterial action and 
reduced cytotoxicity for a macromolecular NO-release scaffold that slowly release NO warrants 
careful attention with respect to the development of NO-releasing therapeutics against 
periodontopathogens.  A differential sensitivity to NO-release totals and kinetics was observed 
between periodontopathogens and cariogenic bacteria.  The incorporation of additional biocides 
onto NO-releasing silica nanoparticles would be required to facilitate more complete killing of S. 
mutans.32 
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Figure 4.5 Confocal microscopy images of S. mutans exposed to 0.25 mg/mL 70 mol% MAP3 
NO-releasing silica nanoparticles at (A) 40, (B) 60, and (C) 90 min post particle exposure.  DAF-
2 fluorescence is depicted as black in the images for clarity.  Numbers in images represent the 
relative summed signal intensities normalized to the fluorescence intensity at 0 min and pH 7.4. 
 
  
132 
 
4.5 References 
(1) Barbe, C.; Bartlett, J.; Kong, L.; Finnie, K.; Lin, H. Q.; Larkin, M.; Calleja, S.; Bush, A.; 
Calleja, G. "Silica particles: A novel drug‐delivery system" Advanced Materials 2004, 16, 1959-
1966. 
(2) Riccio, D. A.; Schoenfisch, M. H. "Nitric oxide release: Part I. Macromolecular scaffolds" 
Chemical Society Reviews 2012, 41, 3731-3741. 
(3) Brunner, T. J.; Wick, P.; Manser, P.; Spohn, P.; Grass, R. N.; Limbach, L. K.; Bruinink, A.; 
Stark, W. J. "In vitro cytotoxicity of oxide nanoparticles: Comparison to asbestos, silica, and the 
effect of particle solubility" Environmental Science & Technology 2006, 40, 4374-4381. 
(4) Gaikwad, R.; Sokolov, I. "Silica nanoparticles to polish tooth surfaces for caries prevention" 
Journal of Dental Research 2008, 87, 980-983. 
(5) Greenstein, G.; Polson, A. "The role of local drug delivery in the management of periodontal 
diseases: a comprehensive review" Journal of periodontology 1998, 69, 507-520. 
(6) Williams, R. C.; Paquette, D. W.; Offenbacher, S.; Adams, D. F.; Armitage, G. C.; Bray, K.; 
Caton, J.; Cochran, D. L.; Drisko, C. H.; Fiorellini, J. P. "Treatment of periodontitis by local 
administration of minocycline microspheres: A controlled trial" Journal of Periodontology 2001, 
72, 1535-1544. 
(7) Radvar, M.; Pourtaghi, N.; Kinane, D. "Comparison of 3 periodontal local antibiotic therapies 
in persistent periodontal pockets" Journal of Periodontology 1996, 67, 860-865. 
(8) Kinane, D.; Radvar, M. "A six-month comparison of three periodontal local antimicrobial 
therapies in persistent periodontal pockets" Journal of Periodontology 1999, 70, 1-7. 
(9) Bogdan, C. "Nitric oxide and the immune response" Nature Immunology 2001, 2, 907-916. 
(10) Carossa, S.; Pera, P.; Doglio, P.; Lombardo, S.; Colagrande, P.; Brussino, L.; Rolla, G.; 
Bucca, C. "Oral nitric oxide during plaque deposition" European Journal of Clinical 
Investigation 2001, 31, 876-879. 
(11) Hetrick, E. M.; Schoenfisch, M. H. "Reducing implant-related infections: Active release 
strategies" Chemical Society Reviews 2006, 35, 780-789. 
133 
 
(12) Schairer, D. O.; Chouake, J. S.; Nosanchuk, J. D.; Friedman, A. J. "The potential of nitric 
oxide releasing therapies as antimicrobial agents" Virulence 2012, 3, 271-279. 
(13) Privett, B. J.; Broadnax, A. D.; Bauman, S. J.; Riccio, D. A.; Schoenfisch, M. H. 
"Examination of bacterial resistance to exogenous nitric oxide" Nitric Oxide 2012, 26, 169-173. 
(14) Silva Mendez, L.; Allaker, R.; Hardie, J.; Benjamin, N. "Antimicrobial effect of acidified 
nitrite on cariogenic bacteria" Oral Microbiology and Immunology 1999, 14, 391-392. 
(15) Allaker, R.; Silva Mendez, L.; Hardie, J.; Benjamin, N. "Antimicrobial effect of acidified 
nitrite on periodontal bacteria" Oral Microbiology and Immunology 2001, 16, 253-256. 
(16) Carpenter, A. W.; Schoenfisch, M. H. "Nitric oxide release: Part II. Therapeutic 
applications" Chemical Society Reviews 2012, 41, 3742-3752. 
(17) Stöber, W.; Fink, A.; Bohn, E. "Controlled growth of monodisperse silica spheres in the 
micron size range" Journal of Colloid and Interface Science 1968, 26, 62-69. 
(18) Shin, J. H.; Metzger, S. K.; Schoenfisch, M. H. "Synthesis of nitric oxide-releasing silica 
nanoparticles" Journal of the American Chemical Society 2007, 129, 4612-4619. 
(19) Hetrick, E. M.; Shin, J. H.; Paul, H. S.; Schoenfisch, M. H. "Anti-biofilm efficacy of nitric 
oxide-releasing silica nanoparticles" Biomaterials 2009, 30, 2782-2789. 
(20) Carpenter, A. W.; Slomberg, D. L.; Rao, K. S.; Schoenfisch, M. H. "Influence of scaffold 
size on bactericidal activity of nitric oxide-releasing silica nanoparticles" ACS Nano 2011, 5, 
7235-7244. 
(21) Lu, Y.; Slomberg, D. L.; Sun, B.; Schoenfisch, M. H. "Shape‐ and nitric oxide flux‐
dependent bactericidal activity of nitric oxide‐releasing silica nanorods" Small 2013, 9, 2189-
2198. 
(22) Coneski, P. N.; Schoenfisch, M. H. "Nitric oxide release: Part III. Measurement and 
reporting" Chemical Society Reviews 2012, 41, 3753-3758. 
(23) Breed, R. S.; Dotterrer, W. "The number of colonies allowable on satisfactory agar plates" 
Journal of Bacteriology 1916, 1, 321. 
134 
 
(24) Hetrick, E. M.; Shin, J. H.; Stasko, N. A.; Johnson, C. B.; Wespe, D. A.; Holmuhamedov, 
E.; Schoenfisch, M. H. "Bactericidal efficacy of nitric oxide-releasing silica nanoparticles" ACS 
Nano 2008, 2, 235-246. 
(25) Lu, Y.; Sun, B.; Li, C.; Schoenfisch, M. H. "Structurally diverse nitric oxide-releasing poly 
(propylene imine) dendrimers" Chemistry of Materials 2011, 23, 4227-4233. 
(26) Backlund, C. J.; Sergesketter, A. R.; Offenbacher, S.; Schoenfisch, M. H. "Antibacterial 
efficacy of exogenous nitric oxide on periodontal pathogens" Journal of Dental Research 2014. 
(27) Aoki, W.; Kuroda, K.; Ueda, M. "Next generation of antimicrobial peptides as molecular 
targeted medicines" Journal of Bioscience and Bioengineering 2012, 114, 365-370. 
(28) Slomberg, D. L.; Lu, Y.; Broadnax, A. D.; Hunter, R. A.; Carpenter, A. W.; Schoenfisch, M. 
H. "Role of size and shape on biofilm eradication for nitric oxide-releasing silica nanoparticles" 
ACS Applied Materials & Interfaces 2013, 5, 9322-9329. 
(29) Kakishima, K.; Shiratsuchi, A.; Taoka, A.; Nakanishi, Y.; Fukumori, Y. "Participation of 
nitric oxide reductase in survival of Pseudomonas aeruginosa in LPS-activated macrophages" 
Biochemical and Biophysical Research Communications 2007, 355, 587-591. 
(30) Fridovich, I. "Superoxide radical: An endogenous toxicant" Annual of Review 
Pharmacology and Toxicology 1983, 23, 239-257. 
(31) Papapetropoulos, A.; García-Cardeña, G.; Madri, J. A.; Sessa, W. C. "Nitric oxide 
production contributes to the angiogenic properties of vascular endothelial growth factor in 
human endothelial cells" Journal of Clinical Investigation 1997, 100, 3131. 
(32) Carpenter, A. W.; Worley, B. V.; Slomberg, D. L.; Schoenfisch, M. H. "Dual action 
antimicrobials: Nitric oxide release from quaternary ammonium-functionalized silica 
nanoparticles" Biomacromolecules 2012, 13, 3334-3342. 
(33) Worley, B. V.; Slomberg, D. L.; Schoenfisch, M. H. "Nitric oxide-releasing quaternary 
ammonium-modified poly (amidoamine) dendrimers as dual action antibacterial agents" 
Bioconjugate Chemistry 2014, 25, 918-927. 
(34) Choudhury, T.; Sato, E.; Inoue, M. "Nitrite reductase in Streptoccocus mutans plays a 
critical role in the survival of this pathogen in oral cavity" Oral Microbiology and Immunology 
2007, 22, 384-389.
135 
 
Chapter 5: Anti-Biofilm Efficacy of Poly(amidoamine) Alkyl-Modified Nitric  
Oxide-Releasing Dendrimers against Streptococcus mutans 
 
5.1 Introduction 
 Dental caries is one of the most costly and prevalent diseases worldwide, with 94% of the 
population experiencing cavities.1,2  Oral infections are caused by dental plaque biofilms, and the 
presence of Gram-positive lactobacilli and streptococci acidogenic species is considered a risk 
factor for dental caries.3-6  Cariogenic bacteria like Streptococcus mutans metabolize dietary sugars 
and produce lactic acid, which demineralizes tooth enamel.6,7  The resulting acidic environment 
promotes preferential biofilm colonization by acidophilic species over native flora, furthering 
tooth decay.8  Current treatments for dental caries are thus focused on eliminating acidogenic S. 
mutans biofilms.    
 Dental plaque biofilms are more difficult to treat than planktonic bacteria for numerous 
reasons.4,8,9  Secreted exopolymers create a physical boundary that limits drug (e.g., antibiotics) 
penetration and prevents biofilm eradication.9  Phenotypic differences in surface-attached bacteria 
alter potential antibiotic targets, ultimately mitigating drug/bacteria interactions.9  The slower 
metabolic activity of biofilm bacteria also decreases antibiotic efficacy.8,9  Lastly, antibiotic action 
is often inhibited by either the acidic environment or gingival fluid-derived β-lactamases within 
oral biofilms.8-11  Collectively, these factors require greater drug concentrations to effectively  
eradicate dental biofilms at the expense of undesirable systemic side effects (e.g., 
pseudomembranous colitis and promoting antibiotic-resistant bacteria).12 
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Although the use of local antibiotic delivery systems has been shown to reduce systemic 
toxicity, continued emergence of antibiotic-resistant bacteria remains a concern, necessitating 
alternative treatments for dental caries.13,14  Antiseptic mouthwash rinses including chlorhexidine 
(CHX; 0.20% w/w) have been used to combat oral infections,15 but with modest success. Vitkov 
et al. reported only minor structural alterations to the exterior of mature biofilms upon CHX 
exposure.16  Moreover, CHX may cause changes in taste, mouth discoloration, mucosal irritation, 
and desquamation of the gums.17,18  Due to the undesirable side effects and insufficient biofilm 
suppression associated with CHX, the search for new anti-plaque therapeutics is a continuing 
effort.    
 Nitric oxide (NO) is an endogenous, diatomic radical that plays a pivotal role in wound 
healing, neurotransmission, and the immune response to pathogens.19,20  Nitric oxide’s 
antimicrobial activity results from its reaction with superoxide and oxygen to form peroxynitrite 
and dinitrogen trioxide, respectively.  These species kill bacteria through lipid peroxidation, DNA 
cleavage, and protein dysfunction.21  The multiple bactericidal pathways of NO make it a potent 
broad-spectrum antimicrobial agent with low risk for promoting bacterial resistance.22,23  Due to 
the highly reactive nature of NO gas, the design of storage vehicles that controllably release 
biocidal levels of NO is crucial to its application as a dental therapeutic.24,25 
 Our laboratory has previously reported on the synthesis of silica and dendrimer-based 
macromolecular NO-release scaffolds capable of eradicating planktonic and biofilm cultures of 
Gram-positive, Gram-negative, and fungal pathogens.21,26-28  More recently, we reported on the 
controlled delivery of exogenous NO to kill S. mutans.29  To further enhance S. mutans killing, the 
use of non-depleting secondary biocides was proposed to create dual-action NO-releasing 
antibacterial agents.  Carpenter et al. previously functionalized NO donor-modified silica with long 
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alkyl chain quaternary ammonium (QA) groups to improve bactericidal efficacy over the single 
action (i.e., solely NO-releasing) silica particles.30  Likewise, Worley et al. described the 
modification of NO-releasing poly(amidoamine) (PAMAM) dendrimers with alkyl chain QA 
moieties, which exhibited improved antibacterial activity over both single action QA-modified 
dendrimers and NO-releasing QA-modified silica.31  Due to the reduced concentrations required 
to kill bacteria, QA-modified NO-releasing dendrimers were less toxic to mouse fibroblasts than 
QA-modified silica.30,31 
The superior bactericidal efficacy of the QA-modified NO-releasing dendrimers has been 
attributed to increased cell damage via membrane intercalation of the hydrophobic alkyl 
chains.30,31  Due to the highly cationic nature inherent to PAMAM dendrimers, we hypothesized 
that alkyl chain functionalization without QA groups would reduce the synthetic burden to achieve 
dual-action killing while still enhancing the bactericidal efficacy over single-action NO-releasing 
dendrimers.  Herein, we investigated the bactericidal and anti-biofilm activity of NO-releasing 
alkyl-modified dendrimers against cariogenic S. mutans as a function of alkyl chain modification, 
pH, and NO-release kinetics. 
 
5.2 Materials and Methods 
5.2.1 Materials 
Streptococcus mutans (ATCC #27517) was purchased from the American Type Tissue 
Culture Collection (Manassas, VA).  Brain heart infusion (BHI) broth and agar were purchased 
from Becton, Dickinson, and Company (Franklin Lakes, NJ).  Murine fibroblasts (L929) were 
obtained from the UNC Tissue Culture Facility (Chapel Hill, NC).  Hydroxyapatite (HA) disks (5 
x 2 mm) were purchased from Clarkson Chromatography Products, Inc. (South Williamsport, PA).  
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Tris(hydroxymethyl)aminomethane (Tris), and Tris hydrochloride were acquired from Fisher 
Scientific (Fair Lawn, NJ).  Trypsin, penicillin streptomycin (PS), phenazine methosulfate (PMS), 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
inner salt (MTS), Dulbecco’s modified Eagle’s medium (DMEM), phosphate-buffered saline 
(PBS) for cell culture, fetal bovine serum (FBS), rhodamine B isothiocyanate (RITC), 
triethylamine (TEA), propylene oxide (PO), epoxybutane (EB), epoxyhexane (EH), epoxyoctane 
(EO), and epoxydodecane (ED) were purchased from Sigma-Aldrich (St. Louis, MO).  Methanol 
(MeOH), sodium methoxide (NaOMe; 5.4 M in MeOH), and tetrahydrofuran (THF) were obtained 
from Acros Organics (Geel, Belgium).  Argon (Ar), carbon dioxide (CO2), nitrogen (N2), and nitric 
oxide (NO) calibration (25.87 PPM, balance N2) gases were acquired from National Welders 
(Raleigh, NC).  Nitric oxide gas (99.5%) was purchased from Praxair (Sanford, NC).  Distilled 
water was purified with a Millipore Milli-Q Gradient A-10 water purification system (Bedford, 
MA) to ≤6 ppb organic content and a final resistivity of 18.2 mΩ·cm.  Other solvents and reagents 
were analytical grade and used as received.        
 
5.2.2 Synthesis of alkyl chain-modified nitric oxide-releasing PAMAM dendrimers 
 Generation 1 (G1) poly(amidoamine) (PAMAM) dendrimer core scaffolds were 
synthesized as described previously.32,33  Primary-amine functionalized G1 PAMAM dendrimers 
(200 mg) were then dissolved in MeOH (2 mL) with TEA and an alkyl epoxide (i.e., PO, EB, EH, 
EO, or ED) at a 1:1:1 molar ratio (TEA:alkyl epoxide:primary amines on the PAMAM dendrimer) 
to synthesize propyl-, butyl-, hexyl-, octyl-, and dodecyl-functionalized G1 PAMAM dendrimers, 
respectively.  After 3 d of constant stirring, the MeOH solvent and unreacted epoxides were 
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removed under vacuum to purify the dendrimer product.  Following purification, dendrimers were 
resuspended in MeOH and stored at -20 oC. 
 Secondary amines on the alkyl-modified dendrimers were converted to N-diazeniumdiolate 
NO donors by combining alkyl-modified G1 PAMAM dendrimers (30 mg) with 1 molar 
equivalent NaOMe (with respect to the primary amines on the unmodified G1 PAMAM scaffold) 
in 1mL MeOH/THF.  The mixtures were placed in a stainless steel Parr reaction vessel, flushed 
with Ar three times to a pressure of 7 bar, and then filled with Ar three times for longer durations 
(10 min) to remove trace oxygen from the solutions.  Following deoxygenation, the reaction 
chamber was filled with NO and held at 10 bar with constant stirring.  After 3 d, the chamber was 
flushed again with Ar three times at short durations prior to extended Ar purges (3 x 10 min) to 
remove unreacted NO.  The solutions were then collected and excess solvent was removed under 
vacuum.  The NO-releasing dendrimers were resuspended in MeOH and stored at -20 oC until 
further use. 
 
5.2.3 Characterization of nitric oxide release 
  Real-time NO release was measured using a Sievers 280i Chemiluminescence Nitric 
Oxide Analyzer (Boulder, CO) to quantify total NO release (t[NO]), total NO released after 2 h 
(t[NO]2h), NO-release half-life (t1/2), and maximum NO flux ([NO]max).
34  The NO-releasing 
dendrimers were added to a flask containing 30 mL of deoxygenated phosphate-buffered saline 
(PBS; 37 oC) at either pH 7.4 or 6.4.  Nitrogen was bubbled continuously through the solution to 
carry liberated NO to the analyzer at a flow rate of 80 mL/min.  The NO analysis was terminated 
when NO levels fell to <10 ppb/mg dendrimer.    
 
140 
 
5.2.4 Planktonic bactericidal assays 
To evaluate the bactericidal efficacy of the alkyl-modified dendrimers against planktonic 
S. mutans, the 2 h minimum bactericidal concentration (MBC2h) (i.e., the minimum dendrimer 
concentration required to achieve a 3-log reduction in bacterial viability) was determined under 
static growth conditions.  Briefly, bacteria was cultured overnight at 37 oC in ~3 mL BHI broth 
from a frozen stock (15% (v/v) glycerol in PBS at -80 oC).  The next day, a 1 mL aliquot of the 
resulting bacterial suspension was inoculated into 50 mL fresh BHI broth and grown at 37 oC with 
moderate shaking to a concentration of 108 colony forming units per milliliter (CFU/mL) as 
confirmed by optical density (OD; 600 nm).  The bacteria were then collected by centrifugation 
(2355 x g; 10 min), resuspended in distilled water, and diluted to 106 CFU/mL in either Tris-PBS 
(pH 7.4) with 1% (v/v) BHI broth or PBS (pH 6.4) with 5% (v/v) BHI broth.  The bacterial 
solutions were then added to vials containing NO-releasing or non-NO-releasing dendrimers, 
mixed, and incubated at 37 oC with moderate shaking.  After 2 h, the bacteria suspensions were 
diluted and plated on BHI agar using an IUL Eddy Jet spiral plater (Farmingdale, NY).  Plates 
were incubated at 37 oC for 72 h before viable colonies were enumerated using a Flash & Go 
colony counter (IUL; Farmingdale, NY).  The dendrimer concentration resulting in bacterial 
viability below 2.5 x 103 CFU/mL (the limit of detection for this plating method)35 from the initial 
106 CFU/mL culture was taken to be the MBC2h.            
 
5.2.5 Biofilm-killing assays 
Suspensions of S. mutans (108 CFU/mL) were prepared as described above and collected 
by centrifugation (2355 x g; 10 min).  Following centrifugation, bacteria were resuspended in 
distilled water and diluted to 106 CFU/mL in 40 mL of 50/50 BHI/distilled water with 1% w/v 
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glucose and sucrose.  The bacterial suspension (3 mL) was added to a 12-well culture plate with 
each well containing one hydroxyapatite (HA) disk.  Each disk was incubated with bacteria at 37 
oC and gentle shaking.  After 24 h, the disks were removed, rinsed in distilled water, and added to 
test suspensions of NO-releasing or non-NO-releasing dendrimers in Tris-PBS (pH 7.4) or PBS 
(pH 6.4).  After 2 h of moderate shaking under static growth conditions, the disks were removed, 
rinsed in distilled water again, and sonicated in 3 mL of distilled water at low power for 10 min.  
The resulting bacterial solutions were then plated on BHI agar using the aforementioned spiral 
plating system, and incubated further at 37 oC.  After 72 h, viable colonies were enumerated as 
described above.  The dendrimer concentration resulting in a 3-log or greater reduction in viable 
bacteria to below 2.5 x 104 CFU/mL (the limit of detection for this plating method)35 was 
determined to be the 2 h biofilm killing concentration (BKC)2h.   
 
5.2.6 Confocal microscopy to assess dendrimer-bacteria association 
 Fluorescently-labeled G1 PAMAM dendrimers were synthesized as described 
previously.26,31,36  Briefly, 100 mg G1 PAMAM were added to a vial containing one molar 
equivalent of RITC (3.75 mg) per mole of dendrimer in methanol (2 mL).  One mole equivalent 
of triethylamine (with respect to the number of dendrimer primary amines) was then added to the 
vial and the solution was stirred for 24 h in the dark.  After removal of the solvent under vaccum, 
dendrimers were dissolved in water, purified via dialysis against water (1 d), and then lyophilized.  
The dendrimers were functionalized with alkyl chains per the above procedure in the dark to create 
fluorescently-labeled butyl-modified G1 PAMAM dendrimers.   
S. mutans was cultured as described above and diluted to 106 CFU/mL in Tris-PBS (pH 
7.4) or PBS (pH 6.4), each containing 3% (v/v) BHI broth.  Aliquots of the bacteria solution were 
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incubated in a glass bottom confocal dish (MatTek Corporation; Ashland, MA) at 37 °C for 45 
min.  A Zeiss 510 Meta inverted laser scanning confocal microscope with a 543 nm HeNe 
excitation laser (1.0 mW, 25.0% intensity) and a 560–615 nm band-pass filter was used to obtain 
fluorescence images of the RITC-modified dendrimers.  Both bright field and fluorescence images 
were collected using an N.A. 1.2 C-Apochromat water immersion lens with a 40x objective.  
Solutions of RITC-labeled butyl-modified dendrimers (200 µg/mL) in Tris-PBS or PBS (1.5 mL) 
were added to 1.5 mL of the respective bacteria solution in the glass confocal dish to achieve a 
final concentration of 100 µg/mL.  Images were collected in 2 min intervals to temporally monitor 
dendrimer association with the bacteria.  The image colors were modified and inverted for clarity 
using ImageJ software. 
 
5.2.7 In vitro cytotoxicity  
Murine fibroblasts (L929) were grown in DMEM supplemented with 10% (v/v) FBS and 
1 wt% PS.  The cells were incubated at 37 oC under humidified conditions in 5% CO2 (v/v).  After 
reaching confluency, cells were trypsinized and seeded onto a 96-well plate.  The supernatant was 
then aspirated, and solutions of both NO-releasing and non-NO-releasing dendrimers in DMEM 
were added to the wells.  Following incubation for 2 h at 37 oC, the supernatant was aspirated, and 
120 µL of a DMEM, PMS, and MTS (100/20/1 v/v/v) mixture was added to the wells.  After 
incubation for an additional 2 h at 37 oC, the supernatant was transferred to a new 96-well plate.  
Absorbance was measured at 490 nm using a Thermoscientific Multiskan EX plate reader 
(Waltham, MA) and subtraction of blanks (i.e., DMEM/PMS/MTS without cells).  A DMEM 
solution containing 10% DMSO (v/v) served as a positive control.  Cell viability was quantified 
with respect to untreated cells. 
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5.3 Results and Discussion 
We have previously reported on the modification of PAMAM dendrimers to create 
secondary amine-functionalized scaffolds that store and release NO.26  The chemistry of NO 
release was also combined with a non-depleting, membrane-disrupting QA biocide, which proved 
highly effective at killing nosocomial pathogens (i.e., Pseudomonas aeruginosa and 
Staphylococcus aureus).31  In the present study, we investigated the effects of exterior dendrimer 
hydrophobicity, pH, and NO release on the antibacterial and anti-biofilm activity of NO-releasing 
propyl-, butyl-, hexyl-, octyl-, and dodecyl-modified G1 PAMAM dendrimers against S. mutans, 
an etiological agent of dental caries.   
 
5.3.1 Characterization of nitric oxide-releasing dendrimers 
N-Diazeniumdiolate NO donor-modified dendrimers were synthesized by 1) modifying 
PAMAM to contain secondary amines; and 2) reacting the dendrimer scaffold with NO gas at high 
pressure under basic conditions.37  Nitric oxide release was measured in PBS at both pH 7.4 and 
6.4 (Table 5.1).  At pH 7.4, the total NO released (0.90–1.12 µmol/mg) and maximum 
instantaneous NO concentrations (3980–5700 ppb/mg) were similar for each dendrimer system, 
independent of alkyl chain modification.  The NO-release half-life increased slightly (~21 to 37 
min) with longer alkyl chains (i.e., increased hydrophobicity), which we attributed to impeded 
water diffusion to the proton-labile N-diazeniumdiolate NO donors.  Of importance, the total NO 
released after 2 h was similar (~0.9 µmol/mg) regardless of alkyl chain length, allowing us to 
examine the effect of exterior hydrophobicity on bactericidal efficacy and anti-biofilm activity, 
independent of NO-release totals and kinetics.    
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Table 5.1 Characterization of NO-releasing alkyl-modified G1 PAMAM dendrimers in PBS (37 
oC) at pH 7.4 and 6.4 by means of a chemiluminescent nitric oxide analyzer.a   
 
 
pH Dendrimer 
Modification 
t[NO]b    
(µmol/mg) 
t[NO]2hc    
(µmol/mg) 
t1/2d                       
(min) 
[NO]maxe 
(ppb/mg) 
7.4 
Propyl 0.90 ± 0.20 0.82 ± 0.10 21.8 ± 3.9 5700 ± 2293 
Butyl 1.06 ± 0.10 0.97 ± 0.10 21.7 ± 5.0 4933 ± 689 
Hexyl 0.98 ± 0.11 0.90 ± 0.14 23.5 ± 5.5 4344 ± 1069 
Octyl 1.07 ± 0.13 0.88 ± 0.08 29.8 ± 5.4 3980 ± 936 
Dodecyl 1.12 ± 0.10 0.90 ± 0.05 37.3 ± 6.3 4200 ± 952 
6.4 
Propyl 1.09 ± 0.19 1.09 ± 0.19 4.2 ± 0.8 25975 ± 3783 
Butyl 0.98 ± 0.22 0.98 ± 0.22 4.4 ± 0.5 21433 ± 6962 
Hexyl 1.04 ± 0.34 1.03 ± 0.34 4.3 ± 0.2 22600 ± 6222 
Octyl 1.06 ± 0.24 1.04 ± 0.24 5.0 ± 0.1 20467 ± 4839 
Dodecyl 1.10 ± 0.31 1.07 ± 0.29 8.9 ± 0.8 15067 ± 1848 
aResults shown as mean ± standard deviation for n=3 or more pooled experiments.  bTotal amount 
of NO released.  cTotal amount of NO released after 2 h.  dTime to release half of total NO payload.  
eMaximum NO flux achieved. 
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To more accurately represent the in vivo environment associated with dental caries, NO 
release from alkyl-modified dendrimers was also characterized at pH 6.4 (Table 5.1).  As expected 
with proton-initiated decomposition of N-diazeniumdiolate NO donors, faster NO-release kinetics 
were observed under acidic conditions.  The more rapid NO release at pH 6.4 is evident by the 
greater maximum NO release (15067–25975 ppb/mg) versus pH 7.4 (3980–5700 ppb/mg) and the 
shorter NO-release half-life (4–9 versus 21–37 min, respectively).  Despite the faster NO-release 
kinetics, the 2 h total NO release was similar at pH 6.4 (~1.0 µmol/mg) compared to pH 7.4 (~0.9 
µmol/mg).   
 
5.3.2 Bactericidal efficacy of alkyl-modified dendrimers 
The bactericidal efficacy of alkyl-modified G1 PAMAM dendrimers against planktonic 
cultures of S. mutans was evaluated at both pH 7.4 and 6.4 by determining the minimum 
bactericidal concentration (MBC2h) required to elicit a 3-log reduction in bacterial viability relative 
to untreated cultures (Table 5.2).  At pH 7.4, the non-NO-releasing short alkyl chain (i.e., propyl 
and butyl) dendrimers were ineffective at killing S. mutans, with no reduction in bacterial viability 
up to a concentration of 48 mg/mL.  This result was somewhat expected as minimal membrane 
intercalation by less hydrophobic tails should limit the bacterial membrane damage caused by these 
scaffolds.30,31  Compared to the shorter alkyl chains, the longer alkyl chain (i.e., hexyl, octyl, and 
dodecyl) dendrimers were considerably more bactericidal (MBC2h values ≤2 mg/mL).  Clearly, 
membrane intercalation causes significant membrane damage, as has been reported 
previously.26,30,31  Under more acidic conditions (pH 6.4), little to no antibacterial action was again 
observed for the propyl-modified dendrimers (MBC2h
 >48 mg/mL).  The bactericidal efficacy of 
butyl-modified dendrimers was improved at pH 6.4, but still required large dendrimer  
146 
 
 
 
 
 
 
Table 5.2 Comparison of minimum bactericidal concentrations (MBC2h) and bactericidal NO 
doses of alkyl-modified G1 PAMAM dendrimers against planktonic S. mutans at pH = 7.4 and pH 
= 6.4.a  
 pH = 7.4  pH = 6.4 
 
MBC2h                    
(mg/mL) 
NO Dose 
(µmol/mL) 
 
MBC2h                      
(mg/mL) 
NO Dose 
(µmol/mL) 
Propyl >48   >48  
Propyl-NO 48 39.4  8 8.7 
Butyl >48   32  
Butyl-NO 48 46.6  8 7.8 
Hexyl 2   1  
Hexyl-NO 2 1.8  1 1.0 
Octyl 0.05   0.012  
Octyl-NO 0.1 0.1  0.025 <0.1 
Dodecyl 0.05   0.025  
Dodecyl-NO 0.05 0.1  0.025 <0.1 
aResults of n ≥3 pooled experiments. 
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concentrations (32 mg/mL) to elicit killing.  The lack of exterior hydrophobic character associated 
with short alkyl chains seems to limit the biocidal activity of the dendrimer scaffolds, regardless 
of pH.  In contrast, the bactericidal action of longer alkyl chain-modified dendrimers was enhanced 
at lower pH (6.4), as evidenced by the reduced MBC2h values relative to those at pH 7.4 (Table 
5.2).  The increased bactericidal action at pH 6.4 is likely due to greater protonation of pendant 
amines (i.e., increased positive surface charge) on the dendrimer scaffold promoting more efficient 
dendrimer-bacteria association and improving membrane intercalation of the hydrophobic chains.     
Dendrimer diffusion to bacteria in real-time was visualized with confocal microscopy to 
confirm enhanced dendrimer-bacteria association at lower pH (Figure 5.1).  At pH 6.4, a 
substantial fluorescence signal from RITC-labeled butyl-modified dendrimers associating with S. 
mutans was observed after only 30 min of dendrimer exposure.  This signal continued to increase 
in intensity up to 60 min.  In contrast, the fluorescence signal intensity at pH 7.4 was negligible, 
and did not change through the same period of study.  The greater fluorescence signal at pH 6.4 
both initially and over time suggests more rapid and extensive dendrimer-bacteria association 
under acidic conditions.  Enhanced dendrimer-bacteria association would translate to more 
extensive bacterial damage as alkyl chain-induced death is contact-based.30,31  This hypothesis is 
consistent with the lower MBC2h values observed for butyl-, hexyl-, octyl-, and dodecyl-modified 
dendrimers at pH 6.4 compared to pH 7.4.     
The incorporation of NO release did not improve the biocidal action of the hexyl-, octyl-, 
and dodecyl-modified dendrimer scaffolds (Table 5.2).  The hydrophobic alkyl chains of these 
PAMAM analogues likely compromise the bacterial membrane prior to significant accumulation 
of intracellular NO, thus limiting NO-induced killing.31  Upon lowering the pH to 6.4, similar 
behavior was again observed, with NO-releasing and control dendrimers exhibiting no difference 
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in killing efficiency.  The highly efficient membrane disruption of hydrophobic alkyl chains clearly 
precludes intracellular NO accumulation, alleviating NO-mediated cell death.31 
The addition of NO release moderately improved the bactericidal activity for propyl- and 
butyl-modified dendrimers at pH 7.4, albeit requiring large doses of NO (39.4 and 46.6 µmol/mL, 
respectively) to elicit a 3-log reduction in bacterial viability (MBC2h = 48 mg/mL).  In contrast to 
the long alkyl chain-modified dendrimers, the antibacterial efficacy of NO-releasing propyl- and 
butyl-modified dendrimers was significantly enhanced at pH 6.4.  Indeed, the bactericidal 
concentration was 6-fold lower at pH 6.4 (8 mg/mL) versus pH 7.4 (48 mg/mL) for both NO-
releasing propyl- and butyl-modified dendrimers.  The lower MBC2h values translate to reduced 
bactericidal NO doses for propyl-modified (39.4 to 8.7 µmol/mL) and butyl-modified (46.6 to 7.8 
µmol/mL) dendrimers.  As shown in Figure 5.1, the bacterial association of butyl-modified 
dendrimers was enhanced at lower pH.  However, the lack of antibacterial activity by the butyl-
modified controls (MBC2h = 32 mg/mL) at pH 6.4 suggests minimal membrane disruption via 
alkyl chain intercalation.  Similarly, no antibacterial activity was observed up to 48 mg/mL for the 
propyl-modified controls at pH 6.4.  The disparity in killing efficiency between the NO-releasing 
and control propyl- and butyl-modified dendrimers at pH 6.4 unequivocally demonstrates that 
rapid NO release in combination with enhanced dendrimer-bacteria association are responsible for 
the improved bactericidal efficacy.  These findings suggest that large instantaneous NO 
concentrations are more effective for eradicating S. mutans, an important consideration when using 
single-action NO-releasing macromolecular scaffolds to kill S. mutans and possibly other 
cariogenic bacteria as well.   
Several factors may contribute to the increased bactericidal efficacy observed with faster 
NO-release kinetics.  For example, S. mutans makes use of nitrite reductase, an enzyme capable  
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Figure 5.1 Confocal microscopy images of S. mutans exposed to 100 µg/mL RITC-labeled G1 
butyl dendrimers at pH 6.4 and 7.4 imaged at (A) 0, (B) 30, and (C) 60 min.  Image colors modified 
and inverted for clarity.  Scale bar = 10 µm. 
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of generating NO from nitrite to promote survival in nitrite-rich acidic environments.38  Gusarov 
and Nudler reported on the ability of Bacillus subtillus to utilize NO for protection against 
oxidative stress (“NO-mediated cytoprotection”) and suggested other Gram-positive species may 
utilize this cellular detoxification mechanism as well.39  In this regard, low instantaneous 
concentrations of NO may act as a metabolite rather than a biocidal agent for Gram-positive 
bacteria such as S. mutans, thus necessitating more rapid delivery of large NO payloads to induce 
NO-mediated killing.  
 
5.3.3 Anti-biofilm activity of alkyl-modified dendrimers 
Although studying microbes in planktonic, nutrient-rich batch cultures is useful for initial 
drug activity screening, in vivo infections are typically caused by bacterial biofilms.5,40  Dental 
caries is associated with persistent biofilms composed of mainly streptococci and lactobacilli, with 
S. mutans considered a primary causative agent.2,7,41-44  The eradication of cariogenic S. mutans 
biofilms is thus important for the treatment of dental caries.  The concentration of NO-releasing 
and control alkyl-modified dendrimers required to elicit at least a 3-log reduction in bacterial 
viability for S. mutans biofilms (BKC2h) was thus evaluated at pH 7.4 and 6.4 to more accurately 
represent the in vivo environment associated with dental caries. 
As expected, the anti-biofilm activity for control (non-NO-releasing) propyl- and butyl-
modified dendrimers was negligible at pH 7.4 (BKC2h >64 mg/mL) due to insufficient membrane 
disruption by the shorter alkyl chains (Table 5.3).30,31  Biofilm killing was substantially improved 
by increasing the alkyl chain length, with significantly reduced BKC2h values for hexyl- (8 mg/mL) 
and octyl- and dodecyl-modified dendrimers (2 mg/mL).  Similar to planktonic killing, this 
enhancement in anti-biofilm activity is attributed to increased membrane disruption by the long  
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Table 5.3 Comparison of 2 h biofilm killing concentrations (BKC2h) and bactericidal NO doses of 
alkyl-modified G1 PAMAM dendrimers against S. mutans biofilms at pH = 7.4 and pH = 6.4.a   
 
 pH = 7.4  pH = 6.4 
 
BKC2h                    
(mg/mL) 
NO Dose 
(µmol/mL) 
 
BKC2h                      
(mg/mL) 
NO Dose 
(µmol/mL) 
Propyl >64   >48  
Propyl-NO 64 52.5  8 8.7 
Butyl >64   48  
Butyl-NO 48 46.6  8 7.8 
Hexyl 8   8  
Hexyl-NO 8 7.2  8 8.2 
Octyl 2   2  
Octyl-NO 2 1.8  2 2.1 
Dodecyl 2   1  
Dodecyl-NO 2 1.8  2 2.1 
aResults of n ≥3 pooled experiments. 
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hydrophobic chains compared to minimal membrane damage caused by shorter alkyl chains.30,31  
Of note, Lu et al. previously reported decreased P. aeruginosa biofilm killing with the greatest 
hydrophobic dendrimer exterior tested due to less efficient penetration of the exopolysaccharide 
matrix.26  Such a phenomenon was not observed with S. mutans, as biofilm eradication was 
continually improved with increasing exterior dendrimer hydrophobicity.  The addition of NO 
improved the anti-biofilm activity of propyl- and butyl-modified dendrimers with BKC2h values 
of 64 and 48 mg/mL, respectively.  However, significant NO doses (52.5 and 46.6 µmol/mL, 
respectively) were required for biofilm eradication.  Again, the combination of NO release and 
longer chain (i.e., hexyl, octyl, and dodecyl) dendrimer modifications did not improve biofilm 
killing over control dendrimers at pH 7.4, most likely due to efficient membrane disruption 
precluding significant intracellular accumulation of NO and mitigating NO-mediated killing.31  
Additionally, the efficient removal of intracellular NO by S. mutans may have further hindered 
bacterial killing via NO.38,39 
At pH 6.4, the longer alkyl chain-modified control dendrimers were characterized as 
having similar BKC2h values to those at pH 7.4.  The highly efficient bacterial membrane 
disruption caused by longer alkyl chain-modified dendrimers at pH 7.4 likely prevents any further 
enhancement in killing with greater dendrimer-bacteria association at lower pH.30  Similarly, the 
difference in biofilm killing for longer alkyl chain-modified NO-releasing dendrimers at pH 7.4 
versus 6.4 was negligible, indicating that greater dendrimer-bacteria association in combination 
with faster NO release does not enhance biofilm killing.   
Unlike the long alkyl chains, the addition of NO release to propyl- and butyl-modified 
dendrimers significantly enhanced biofilm killing at pH 6.4.  While BKC2h values for NO-releasing 
propyl and butyl dendrimers at pH 7.4 were 64 and 48 mg/mL, respectively, substantial killing 
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was observed at pH 6.4 (8 mg/mL).  The corresponding NO doses required to eradicate the S. 
mutans biofilms were decreased from 52.5 to 8.7 µmol/mL for propyl- and 46.6 to 7.8 µmol/mL 
for butyl-modified dendrimers.  The disparity in BKC2h values cannot be attributed to increased 
membrane damage via enhanced dendrimer-bacteria association, as control propyl- and butyl-
modified dendrimers displayed little to no antibacterial activity (BKC2h ≥48 mg/mL) at either pH.  
Rather, the enhanced anti-biofilm activity of propyl- and butyl-modified NO-releasing dendrimers 
at pH 6.4 must be the result of more efficient dendrimer-bacteria association (Figure 5.1) combined 
with faster NO-release kinetics (Table 5.1).  This dramatically improved killing of S. mutans 
biofilms could have implications for the future design of NO-releasing materials to treat cariogenic 
dental plaque biofilms.    
As biofilms often require greater concentrations for eradication compared to planktonic 
cultures,4,8,9 it was not surprising that the BKC2h values for longer alkyl chain (i.e., hexyl, octyl, 
and dodecyl) dendrimers were greater than the MBC2h values (Tables 5.2 and 5.3).  Unexpectedly, 
this trend was not apparent for the propyl- and butyl-modified NO-releasing dendrimers, as no 
difference between the planktonic killing and biofilm eradication concentrations was observed at 
pH 6.4.  The amounts of NO from the propyl- and butyl-modified dendrimers for eradicating S. 
mutans biofilms and planktonic cultures were equivalent (8.7 and 7.8 µmol/mL, respectively) at 
lower pH (6.4).  These two shorter chain alkyl modifications are unique in that their NO-mediated 
antibacterial activity against biofilms is not diminished relative to planktonic cultures as is 
observed for many antibacterial agents, including antibiotics and CHX.4,8,9,16  This result could 
lead to the development of NO-releasing materials with no decrease in bactericidal efficacy against 
dental biofilms, an important consideration when designing antibacterial agents for treating oral 
infections.     
154 
 
5.3.4 In vitro cytotoxicity 
 To evaluate dendrimer cytotoxicity, murine fibroblasts (L929) were exposed to NO-
releasing and control dendrimers for 2 h at the maximum concentrations required to kill S. mutans 
biofilms at both pH 7.4 and 6.4 (Figure 5.2).  As postulated, short alkyl chain (i.e., propyl and 
butyl) dendrimer controls were non-toxic to L929 fibroblasts (>90% cell viability relative to 
untreated cells) at the concentrations required for anti-biofilm activity (8 and 64 mg/mL at pH 6.4 
and 7.4, respectively).  However, the addition of NO to these scaffolds proved lethal to mammalian 
cells (0% cell viability), even at the concentration necessary for biofilm eradication at pH 6.4 (8 
mg/mL).  The toxicity of NO-releasing short alkyl chain dendrimers is attributed to the large dose 
of NO required to eradicate S. mutans biofilms, as evidenced by the tolerance of mammalian cells 
to the control dendrimers at similar concentrations.  Of note, microscopic examination of the 
tissue-culture plate revealed that the cells were actually removed from the surface when treated 
with 8 mg/mL of NO-releasing propyl- and butyl-modified dendrimers.  As such, these materials 
may not be as toxic as indicated.   
The cells also showed poor tolerance to hexyl-modified control dendrimers (3 ± 1% cell 
viability) at 8 mg/mL, likely the result of membrane disruption by the hydrophobic alkyl chains.  
Not surprisingly, hexyl-modified NO-releasing dendrimers also revealed significant toxicity (0% 
cell viability relative to untreated cells).  The octyl- and dodecyl-modified control dendrimers 
proved less toxic, with cell viabilities of 18 ± 3 and 11 ± 3%, respectively.  The lower material 
concentrations (2 mg/mL) necessary for anti-biofilm activity compared with hexyl-modified 
dendrimers (8 mg/mL) made this an expected result.  Interestingly, the addition of NO to the octyl- 
and dodecyl-modified dendrimers further improved the tolerance of the cells to these dendrimers,  
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Figure 5.2 Cytotoxicity of NO-releasing and non-NO-releasing dendrimers against L929 mouse 
fibroblasts at the concentrations required for biofilm killing.  10% DMSO was used as a positive 
control.  Numbers following each dendrimer modification (i.e., 2, 8, 48, and 64) represent the 
BKC2h in mg/mL.  Error bars represent the standard deviation of the mean.  For all values n = 3 or 
more replicate measurements.  
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with cell viabilities of 34 ± 7 and 43 ± 6%.  We have previously observed that low levels of NO 
are capable of improving cell viability for NO-release systems over controls.30,31  The reduced 
toxicity observed for NO-releasing long alkyl chain dendrimers, while maintaining superior anti-
biofilm activity, demonstrates their potential utility as dental caries therapeutics.    
 
5.4 Conclusions 
The bactericidal and anti-biofilm activity of NO-releasing PAMAM dendrimers was 
increased with greater exterior hydrophobicity at both pH 7.4 and 6.4.  Improved bactericidal 
action was observed at lower pH (6.4) as a result of enhanced dendrimer-bacteria association and 
faster NO-release kinetics.  Long alkyl chain (i.e., octyl and dodecyl) dendrimer modifications 
demonstrated superior anti-biofilm activity and NO release was found to partially mitigate the 
cytotoxicity of the dendrimer scaffold against mammalian cells.  Collectively, these results 
demonstrate the potential utility of NO-releasing long alkyl chain-modified dendrimers as anti-
biofilm agents for the treatment of dental caries.  Studies involving complex, poly-microbial 
biofilms that more closely resemble dental plaque are necessary to better predict the clinical utility 
of alkyl chain-modified NO-releasing dendrimers.   
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Chapter 6: Summary and Future Directions 
 
6.1 Summary 
 The synthesis and subsequent microbiological testing of NO-releasing silica nanoparticles 
and dendrimers with different chemical and physical properties was described.  Chapter 1 provided 
an overview of specific oral health ailments (i.e., dental caries and periodontal disease), current 
research into treating oral diseases, and the need for alternative therapies to effectively combat oral 
infections.  The introduction established the potential advantages to using NO-release vehicles as 
dental therapeutics, with an emphasis on tuning their physical and chemical properties to maximize 
bactericidal efficacy while minimizing cytotoxicity.  In Chapter 2, similarly sized (~150 nm), 
monodisperse NO-releasing silica particles with tunable NO storage and release kinetics were 
synthesized via the Stöber method.  Optimization of N-diazeniumdiolate modification solution 
parameters (i.e., sodium methoxide concentration) was performed to maximize silica particle NO 
storage while limiting the formation of unwanted byproducts.  Alteration of synthetic parameters 
provided 70 mol% MAP3 silica particles with increased size (~400 nm), but with similar NO-
release totals (~1 µmol/mg) and release kinetics (half-life of ~15 min) to the 150 nm MAP3 
particles.  Additional N-diazeniumdiolate modification studies afforded ~150 nm NO-releasing 
silica particles with different NO-release half-lives allowing the effect of NO-release kinetics on 
bacterial killing, independent of both particle size and 2 h NO-release totals, to be studied.  The 
bactericidal efficacy and cytotoxicity for a portion of the NO-releasing nanoparticles developed in 
Chapter 2 was described in subsequent chapters.   
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In Chapter 3, the antibacterial activity of NO-releasing silica nanoparticles, dendrimers, 
and proline (PROLI/NO) was evaluated against pathogenic oral bacteria.  Despite storing less NO, 
the bactericidal efficacy of macromolecular NO-release vehicles (i.e., dendrimers and silica) was 
greater than that of the small molecule NO donor PROLI/NO. The stabilization of the N-
diazeniumdiolate donor (i.e., longer half-lives) by macromolecular NO-release scaffolds provided 
more efficient biocidal NO delivery to bacteria.  Cariogenic bacteria (i.e., S. mutans and S. 
sanguinis) were less susceptible to macromolecular-based NO release (≥37.0 µmol NO/mL 
required to kill) than periodontopathogens (i.e., A. actinomycetemcomitans and P. gingivalis), 
which required ≤3.2 µmol NO/mL for eradication.  The greatest concentrations of NO-releasing 
dendrimers and silica required to kill periodontopathogens (2 and 4 mg/mL, respectively) proved 
relatively non-toxic to human gingival fibroblasts (HGF-1) compared to untreated cells (viabilities 
≥60%) and especially when compared to chlorhexidine (~20% cell viability).  These results 
suggested a differential sensitivity between cariogenic bacteria and periodontopathogens to NO 
treatment and supported further investigation into macromolecular NO-release vehicles as 
potential periodontal disease therapeutics.   
 Chapter 4 described the bactericidal efficacy of NO-releasing silica particles with varied 
NO-release kinetics (i.e. half-lives) against oral bacteria.  Extended NO-release kinetics (half-lives 
of ~130 min versus ~32 min) proved to be more effective at killing periodontal pathogens (i.e., A. 
actinomycetemcomitans and P. gingivalis) and reduced the bactericidal NO dose by at least half.  
Confocal microscopy using the intracellular NO-sensitive dye DAF-2 DA confirmed more 
efficient NO delivery to A. actinomycetemcomitans from silica particles with extended NO-release.  
Furthermore, the slower NO-release kinetics combined with the lower silica concentrations 
necessary to kill bacteria reduced HGF-1 cytotoxicity, supporting the use of extended NO-release 
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vehicles to kill periodontopathogens.  As observed previously, S. mutans was significantly less 
sensitive to NO treatment, with no observed reduction in bacterial viability up to 51.8 µmol 
NO/mL at pH 7.4.  However, faster NO-release kinetics obtained under acidic conditions (pH 6.4) 
increased the bactericidal efficacy of NO-releasing silica particles and reduced the NO dose 
required to kill (30.4 µmol NO/mL).  Confocal microscopy using DAF-2 DA confirmed more 
rapid intracellular NO accumulation and greater bacterial killing with faster NO-release kinetics 
at pH 6.4.  
 In Chapter 5, NO-releasing propyl-, butyl-, hexyl-, octyl-, and dodecyl-modified PAMAM 
dendrimers were synthesized to create dual-action antibacterial agents.  The bactericidal efficacy 
and anti-biofilm activity of NO-releasing alkyl-modified dendrimers were evaluated against S. 
mutans with respect to pH, NO-release kinetics, and alkyl chain length.  Greater bactericidal and 
anti-biofilm efficacy was observed for longer alkyl chain (i.e., hexyl, octyl, dodecyl) dendrimers 
versus shorter alkyl chain (i.e., propyl and butyl) modifications, attributed to more extensive 
bacterial damage from membrane intercalation of the longer hydrophobic chains.  The addition of 
NO did not improve the bactericidal efficacy of longer alkyl chains, as the highly efficient 
membrane damage caused by the hydrophobic tails resulted in bacterial death prior to significant 
intracellular NO accumulation.  At lower pH, confocal microscopy using RITC-modified butyl 
dendrimers confirmed greater dendrimer-bacteria association.  The enhanced bactericidal efficacy 
of longer alkyl chain dendrimers at lower pH was thus due to increased pendant amine protonation, 
resulting in improved dendrimer-bacteria association and greater bacterial membrane damage.  
Since the shorter alkyl chain dendrimer scaffolds demonstrated minimal bactericidal efficacy at 
pH 6.4, the enhanced antibacterial and anti-biofilm activity at lower pH was attributed to faster 
NO-release kinetics.  The greater instantaneous concentration of NO resulted in lower NO doses 
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required to kill S. mutans.  Short alkyl chain dendrimers proved to be non-toxic against L929 
mouse fibroblasts, but were extremely toxic (0% viability relative to untreated cells) with the 
addition of NO release due to the large NO dose required to kill bacteria.  Although the octyl- and 
dodecyl-modified dendrimer scaffolds were toxic to murine fibroblasts, the addition of NO release 
increased cell viability, partially mitigating the cytotoxicity of the scaffolds.  The superior 
bactericidal efficacy of octyl- and dodecyl-modified dendrimers, combined with the reduced 
cytotoxicity observed with integrated NO release, supports the development of NO-releasing long 
alkyl chain-modified dendrimers as anti-biofilm dental caries therapeutics.   
 
6.2 Future Directions 
 Although macromolecular NO-release vehicles have been employed as bactericidal and 
anti-biofilm agents previously,1-6 this is the first report investigating their use for the management 
of oral health diseases.  Both the physical and chemical properties of NO-release vehicles were 
systematically altered to maximize bactericidal and anti-biofilm activity for the treatment of dental 
caries and periodontal disease.  While the results described herein represent foundational research 
toward achieving successful oral disease therapeutics, much work is still required to utilize NO-
release vehicles in a clinical setting.  The concerted effort of NO-release chemists and oral health 
microbiologists may realize the full potential of NO-releasing materials for the treatment of oral 
health diseases. 
 
6.2.1 Studies to increase the synthetic versatility of nitric oxide-releasing silica nanoparticles 
 In Chapter 2, silica particles were synthesized with various aminosilane precursors, 
different mol% aminosilane compositions, and two different sizes (i.e., 150 and 400 nm) to create 
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a toolbox of NO-releasing materials for subsequent microbiological testing.  While the Stöber 
method7 provides a one-step, high-throughput approach to achieve hybrid 
aminosilane/alkoxysilane NO-releasing nanoparticles,8 the co-condensation of different silanes in 
a bolus fashion limits the physical and chemical flexibility of the resulting nanoparticles.  After 
extensive systematic alteration of synthetic parameters, the particles created were still restricted to 
dual-silane systems (i.e., TMOS and one aminosilane) of only two sizes (i.e., 150 and 400 nm).  
Furthermore, the dense silica particle core limited N-diazeniumdiolate modification to the exterior, 
restricting the total NO storage for non-porous particles.  To circumvent these issues, alternative 
synthetic procedures to create more versatile NO-releasing silica nanoparticles for biomedical 
applications are necessary.   
Mesoporous silica nanoparticles are synthesized using a surfactant-templated method to 
create an alkoxysilane core with channels that traverse the inside of the particle and provide 
superior control over size, shape, and pore size/structure.9-12  Surface-grafting techniques can 
incorporate aminosilanes into both the channels and the exterior of the particle, thereby increasing 
total NO storage compared to non-porous silica particles.  Furthermore, surface-grafting of 
targeting ligands (e.g., sugars, imidazoles, positive charges) on the particle exterior prior to 
surfactant removal and aminosilane functionalization can potentially improve particle-bacteria 
association while maintaining NO-mediated antibacterial activity, thus improving the overall 
bactericidal efficacy of NO-releasing silica particles.13-16  Similarly, selective aminosilane 
functionalization of the particle exterior and subsequent internal modification with a distinct 
aminosilane could create dual-aminosilane NO-releasing particles, with the advantage of more 
finely controlled NO-release kinetics (i.e., both burst and extended NO-release capabilities).  
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Indeed, the ability to tune both the chemical and physical properties of mesoporous NO-releasing 
nanoparticles is superior to nonporous silica-based systems.     
 
6.2.2  Susceptibility of cariogenic and periodontopathogenic bacteria to nitric oxide 
 Chapter 3 highlighted the advantage of macromolecular NO-release vehicles versus small 
molecule NO donors (PROLI/NO) as bactericidal agents against oral pathogens.  Furthermore, 
periodontopathogens (i.e., A. actinomycetemcomitans and P. gingivalis) were more susceptible to 
NO treatment than cariogenic bacteria (i.e., S. mutans and S. sanguinis).  In Chapter 4, slower NO-
release kinetics were shown to be superior for killing periodontopathogenic bacteria, whereas 
faster NO-release kinetics were beneficial for killing cariogenic bacteria.  These findings should 
be expanded to include more bacteria from each disease class (i.e., cariogenic versus 
periodontopathogens) to validate these results.  Relevant cariogenic bacteria are Streptococcus 
gordonii, Streptococcus mitis, Streptococcus sobrinus, Lactobacillus acidophilus, Lactobacillus 
casei, and Lactobacillus fermenti.17  Periodontopathogens of interest include Fusobacterium 
nucleatum, Treponema denticola, Actinomyces viscosus, Tannerella forsythia, and Veillonella 
atypica.17  Furthermore, periodontopathogens are typically microaerophilic or anaerobic 
organisms, but bactericidal assays described herein were conducted under aerobic exposure 
conditions.  As the reactive byproducts of NO are produced via reaction with oxygen or 
superoxide,1 killing assays against periodontopathogens under strictly anaerobic environments to 
validate NO’s efficacy against these bacteria in an environment more closely resembling the 
periodontal pocket would be of interest. 
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6.2.3 Alternate nitric oxide-releasing materials for periodontal disease treatment 
 In Chapter 4, extended NO-release kinetics were shown to improve the bactericidal 
efficacy of NO-releasing silica nanoparticles against periodontopathogens.  However, silica 
nanoparticles may not be the ideal scaffold for achieving extended NO release to treat periodontal 
disease.  Although our laboratory has reported on O2-protected NONOate-based silica particles 
with sustained NO release (t1/2 = 23 d),
18 the large size of these particles (>100 nm) limits 
penetration into subgingival periodontal biofilms and thus prevents NO delivery to the desired site 
of action.  Due to their small size (<10 nm) and ability to penetrate tissue/biofilms, dendrimers 
may be a more viable option for the treatment of subgingival plaque biofilms associated with 
periodontal disease.4  With large NO storage (>1 µmol/mg) and extended NO-release capabilities 
(>4.5 h),19 NO-releasing dendrimers may serve as superior antibacterial agents against periodontal 
biofilms.  Results to date suggest that dendrimers may prove cytotoxic against fibroblast cells, 
limiting their utility as periodontal disease therapeutics.4  However, optimization of the chemical 
and physical properties of NO-releasing dendrimers could potentially create potent anti-biofilm 
agents with reduced gingival fibroblast cytotoxicity.       
Although N-diazeniumdiolates store large payloads of NO, they undergo spontaneous 
decomposition in aqueous environments (i.e., the oral cavity).  The rapid NO release from N-
diazeniumdiolate NO donors upon initial application in the mouth may preclude effective NO 
delivery to the subgingival milieu where periodontal biofilms reside.  Therefore, S-nitrosothiols 
may represent a more suitable NO donor, as they primarily undergo light-activated decomposition 
to release NO.  These donors may reach subgingival plaque prior to the light-initiated release of 
their NO payload.20,21  Targeting ligands for specific periodontopathogens may also be used to 
enhance scaffold-bacteria association prior to NO release.  Once associated, S-nitrosothiol NO-
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donor scaffolds can be irradiated with light to initiate NO release and disrupt biofilms.  Suci et al. 
reported on a similar method in which A. actinomycetemcomitans-specific antibodies were used to 
target bacteria and accumulate a photosensitizer within the biofilm.22  Light was then used to 
trigger the release of reactive species, resulting in significantly greater biofilm killing than without 
the targeting antibody.  Similar methodologies using light-triggered S-nitrosothiols may prove 
beneficial for killing periodontal biofilms.        
 As discussed in Chapter 1, periodontal disease involves the host immune response breaking 
down periodontal tissue and bone, which can result in tooth loss.  Therefore, the clearance of 
periodontopathogens is desirable to prevent further breakdown of periodontal structures, but does 
not reverse the damage caused by infection.  The combination of extended NO-release kinetics 
with tissue regenerative strategies should be a primary focus for next generation NO-releasing 
periodontal disease therapeutics.  Nitric oxide-releasing chitosan has been shown to have superior 
anti-biofilm activity against P. aeruginosa biofilms with no significant L929 mouse fibroblast 
toxicity in vitro.23  Chitosan has also been shown to stimulate cell proliferation in gingival 
fibroblasts both independently and synergistically with specific growth factors (e.g., platelet-
derived growth factor).24  Additionally, chitosan is small and biodegradable, making it well-suited 
as a periodontal pocket insert for localized and extended NO delivery.23,24  Chitosan can also be 
electrospun to form fibrous inserts with excellent osteoblast adherence properties that preserve cell 
phenotype and activity.25  Therefore, electrospun chitosan nanofibers have great potential as drug 
release platforms for tissue engineering and remodeling applications, specifically as NO-releasing 
periodontal disease therapeutics. 
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6.2.4 Polymicrobial biofilms 
 As discussed in Chapter 1, dental plaque biofilms are complex, multi-organism 
communities comprised of both aerobic and anaerobic bacteria.26-29  As such, a more accurate 
representation of in vivo biofilms would include polymicrobial biofilms versus the over-simplified 
monomicrobial S. mutans biofilms studied herein.  Streptococci species (e.g., S. mutans) represent 
the initial colonizers,27 but other bacteria can act as co-colonizers (i.e., F. nucleatum) that serve as 
a bridge between early and late colonizers (i.e., anaerobic bacteria).27,30  Therefore, the layered, 
multi-step growth of complex polymicrobial biofilms is essential to more accurately study the 
utility of NO-releasing dental therapeutics.  A possible challenge will be quantifying the individual 
bacteria species present in a polymicrobial biofilm both before and after treatment to accurately 
assess NO-releasing material performance on biofilm disruption and killing.  Fluorescence in situ 
hybridization (FISH), in conjunction with confocal microscopy, can be used to visualize and 
quantify individual bacterial species within a complex, polymicrobial community.  Bacteria 
specific probes are used in conjunction with FISH that can selectively target dental disease-
relevant streptococci species, A. actinomycetemcomitans, T. forsythensis, P. gingivalis, and T. 
denticola.31-33  Fluorescence measurements can then identify and quantify individual bacteria 
strains amongst a consortium of pathogens.  Additionally, specific growth conditions (i.e., aerobic 
versus anaerobic) and selective plating methods could provide accurate bacteria colony counts of 
distinct species within the polymicrobial biofilm.  For example, trypticase soy-serum-bacitractin-
vacomycin (TSVB) and malachite green bacitracin (MGB) agar plates are selective for A. 
actinomycetemcomitans,34,35 whereas P. gingivalis will form black colonies on Brucella agar plates 
supplemented with 5% defibrinated horse blood.36  The polymerase chain reaction (PCR) with 
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strain-specific primers can also be used to isolate, amplify, and selectively detect pathogens within 
a mixed bacterial population (e.g., A. actinomycetemcomitans and P. gingivalis).36,37        
 
6.3 Conclusions 
 The work described herein describes the potential utility of NO-release vehicles for the 
management of oral health diseases (i.e., dental caries and periodontal disease).  Altering the 
physical and chemical properties of the NO-release scaffolds significantly affected the resulting 
bactericidal efficacy, anti-biofilm activity, and cytotoxicity.  Macromolecular NO-release 
scaffolds were more efficient than small molecule NO donors at delivering lethal doses of NO to 
bacteria.  Regardless of NO-release vehicle, Gram-positive cariogenic bacteria were less 
susceptible to NO treatment than Gram-negative periodontopathogens.  Slower NO-release 
kinetics proved to be beneficial for killing periodontopathogens, whereas faster NO-release 
kinetics were beneficial in eradicating cariogenic bacteria.  The low concentrations of slow NO-
releasing silica particles proved relatively non-toxic to HGF-1 cells, supporting further 
investigation into extended NO-release for the treatment of periodontal disease.  Alkyl-modified 
NO-releasing dendrimers were capable of eradicating S. mutans biofilms and bactericidal efficacy 
was increased with longer alkyl chain modifications and at lower pH (6.4).  The NO-releasing long 
alkyl chain (i.e., octyl and dodecyl) dendrimers demonstrated superior anti-biofilm activity and 
reduced cytotoxicity versus non-NO-releasing long alkyl chain dendrimer scaffolds, supporting 
additional studies for their use as dental caries therapeutics.  While this research represents 
preliminary work in the area, the results described herein have implications to guide the future 
development of NO-releasing materials for the treatment of oral infections.          
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